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ABSTRACT
TUMOR SUPPRESSOR FUNCTIONS OF p53 GENE
Kezban Unsal
Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Ozturk 
May 2000
The subject of this Ph D thesis work is the study of the tumor suppressor 
functions of p53 gene. Our first aim is to test whether wild-type p53 can exert its 
growth suppressive activity in the absence of retinoblastoma gene. This hypothesis 
was tested on the model of hepatocellular carcinoma because these tumors display 
both p53 and retinoblastoma gene mutations. Our second aim was to understand the 
mechanism of temperature-dependent activity of p53 protein. A novel experimental 
approach based on the exchange of functional domains of p53 protein from different 
species was developed and applied for comparative study of human and Xenopus p53 
protein domains.
Both p53 and plô '^ ’^'*® are known to inhibit cell growth by modulating 
retinobastoma protein phosphorylation by different mechanisms. In human 
hepatocellular carcinomas, the loss of function of p53 and plb*’^ ^“ as well as 
retinoblastoma genes by different mechanisms has been largely documented, but their 
hepatocellular effects are poorly known. In the first part of this study, we compared 
the growth inhibitory effects of p53 and p i p r o t e i n s  by transfecting the pRb 
protein-deficient hepatocellular carcinoma cells with inducible p i a n d  p53 
expression vectors. Stable clones were analyzed for transgene expression by western 
blotting and immunoperoxidase staining. Effects on cell growth were analyzed by in 
vitro growth assay, thymidine incorporation and flow cytometry. Biochemical effects 
of p53 were tested by northern blotting of p21^''’*, mdm-2, bax, cyclin-dependent 
kinase 2 and cyclin E proteins. Retinoblastoma protein was studied by western 
blotting and immunoprécipitation assays. The induction of p lb ”^ “*® protein 
expression did not affect in vitra growth of cells. In contrast, p53 protein in its wild- 
type conformation provoked a growth arrest accompanied by transactivation of p21
Ml
and BTG-2 genes and accumulation of p21, bax and mdm-2 proteins. p53-induced 
growth arrest was due to a cell cycle arrest at the Gl/S transition, probably mediated 
by p21 protein, which inhibits cyclin-dependent kinase 2/cyclin E complexes. The 
lack of detectable retinoblastoma protein and resistance of cells to strongly
suggest that p53 is able to arrest the growth of hepatoma cells by a mechanism 
independent of “p53-retinoblastoma pathway”.
In the second part of this study, we have originated a novel experimental 
model in order to provide better information about the possible functions of domains 
of p53, and generated hybrid proteins with human and Xenopus p53 gene products. 
We show by an immunological technique that the Xenopus p53 forms specific 
complex with mammalian hsp72/73 only at temperature (37°C) well above the 
optimal growth temperature for Xenopus. It seems that at 37°C this protein is altered 
in conformation, while at 32®C it exhibits wild-type behavior. To investigate this 
thermal sensitivity of p53, we have specifically exchanged the DNA-binding domains 
of Xenopus and human p53 with each other and tested their transcativation ability by 
luciferase assay at permissive and non-permissive temperatures. When the DNA- 
binding domain of Xenopus p53 is substituted by that of human, this hybrid protein 
behaves like a human wild-type p53; it is able to activate a reporter gene at 37®C. 
The effects of temperature-dependent change in the conformation also reflected in the 
growth suppression ability of p53. This is the most compelling evidence to date for 
the involvement of DNA-binding domain of p53 in thermal sensitivity. Our results 
indicate that p53 protein is highly flexible and that its temperature-dependent change 
plays a key role in the regulation of its biological activity.
Key words; p53, p l b ^ “*“, hepatocellular carcinoma, temperature sensitivity, 
DNA-binding domain.
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CHAPTER ONE
GENERAL INTRODUCTION
U  INTRODUCTION
The simplest genetic diseases are caused by inherited mutations in a single 
gene that are necessary and sufficient to determine the phenotype. This phenotype 
generally can be predicted from knowledge of the precise mutation, and modifying 
genes or environmental influences often play a small role. More complex are certain 
diseases in which single defective genes can predispose patients to pathological 
conditions, but the defective gene itself is not sufficient to cause disease. For 
example, certain cancers display an obvious hereditary influence, but the defective 
gene itself is not sufficient for the development of cancer. Cancers only become 
manifest following accumulation of additional, somatic mutations. These occur 
either as a result of the imperfection of the DNA copying apparatus or through DNA 
damage caused by intracellular or environmental mutagens. It is estimated that only 
a small fraction (0.1% to 10%, depending on the cancer type) of the total cancers in 
the Western world occur in patients with a hereditary mutation. But one of the 
cardinal principles of modem cancer research is that the same genes cause both 
inherited and sporadic (noninherited) forms of the same tumor type. This principle, 
first enunciated by Knudson, is well illustrated by retinoblastomas in children, and 
colorectal tumors in adults. For example, approximately, one percent of colorectal 
cancer patients inherits a defective APC gene from one of their parents. This
inherited mutation is not sufficient to initiate tumorigenesis. However, every cell of 
the colon from such patients is "at risk" for acquiring a second mutation, and two 
mutations of the right type are believed to be sufficient for initiation. The great 
majority of colorectal cancer patients (99% of the total) do not inherit a mutant APC 
gene. However, these sporadic cases also require an APC mutation to begin the 
tumorigenic process. In these sporadic cases, the APC mutations occur somatically 
and occur only in isolated colorectal epithelial cells. The number of colorectal 
epithelial cells with APC mutations therefore is several orders of magnitude less in 
the sporadic cases than in the inherited cases, in which every cell has an APC 
mutation. Accordingly, multiple tumors often develop in patients with the hereditary 
mutations, instead of single, isolated tumors, and tumors develop at an early age in 
the familial patients than the sporadic patients.
What is the "second mutation" that initiates clinically apparent neoplasia in 
both the hereditary and sporadic types of tumors? In most known examples, the 
second mutation is believed to result in inactivation of the wild-type allele inherited 
from the unaffected parent. As described in the following, genes that, when 
mutated, lead to cancer predisposition normally suppress tumorigenesis. If one 
allele of such a gene (e.g., APC) is mutated in the germ line, then the cell still has 
the product of the wt allele as a backup. If a somatic mutation of the wt allele occurs, 
however, then the resultant cell will have no functional suppressor gene product 
remaining, and will begin to proliferate abnormally ("clonal expansion"). One of the 
cells in the proliferating clone then is likely to accumulate another mutation, 
resulting in further loss of growth control. Through gradual clonal expansion, a 
tumor will evolve, with each successive mutation providing a further growdh
advantage, allowing its progeny to continue to replicate in microenvironments 
inhibitory to the growth of cells with fewer mutations.
1.2 GENES THAT ARE MUTATED IN CANCERS
Two classes of genes are involved in cancer formation. The first class of 
genes (gatekeepers) comprising oncogenes and tumor suppressor genes, directly 
control cellular proliferation (for review see Vogelstein and Kinzler, 1998). They 
can do this either by controlling the rate of cell birth or the rate of the cell death. 
Although tumorigenesis largely has been thought of as caused by increases in the 
rate of cell birth, it is now recognized that tumor expansion represents an imbalance 
between cell birth and cell death. In normal tissues, the cell birth precisely equals 
cell death, resulting in homeostasis. Defects in either of these processes can result in 
net growth, perceived as tumorigenesis.
Oncogenes result in increased cell birth or decreased cell death when 
expressed. A mutation in an oncogene is tantamount to accelerate the cell 
proliferation: cell proliferation continues even when the cell's surrounding 
environment is giving it clear signals to stop. Mutations in oncogenes include 
subtle mutations that change their structure and make them constitutively active, or 
mutations that increase their expression to levels higher than observed in normal 
cells.
Tumor suppressor genes are normally functioning to inhibit cell growth. 
Each cell type has more than one tumor suppressor gene, each of which can be 
activated under appropriate microenvironmental stimuli. It is only when several of 
the cell's tumor suppressor genes and oncogenes are rendered dysfunctional through 
mutation that the cell entirely 3pins out of control, and cancer ensues.
The second class of genes (caretaker genes) does not directly control cell 
growth, but instead controls the rate of mutation (for review see Vogelstein and 
Kinzler, 1998). Cells with defective mutator genes acquire mutations in all genes, 
including oncogenes and tumor suppressor genes, at an elevated rate. This higher 
rate leads to accelerated tumorigenesis. The fact that patients with defective mutator 
genes are cancer-prone provides one of the most cogent pieces of evidence that 
mutations in DNA lie at the heart of the neoplastic process.
1.3 IS CANCER A SINGLE DISEASE?
Tumors can be defined best as diseases in which a single cell acquires the 
ability to proliferate abnormally, resulting in an accumulation of progeny. 
"Cancers" are those tumors that have acquired the ability to invade through 
surrounding normal tissues. The most advanced form of this invasive process is 
metastasis, a state in which cancer cells escape from their original location, travel by 
hematogenous or lymphogenous channels, and take up residence in distant sites. 
The difference between a malignant tumor (cancer) and a benign tumor is the 
capacity of the former to invade. Both benign and malignant tumors can achieve 
large sizes, but the benign tumors are circumscribed and therefore generally can be 
removed surgically. Malignant tumors often have invaded surrounding or distant 
tissues prior to their detection, precluding surgical excision of the entire tumor cell 
mass. It is the ability of cancers to destroy other tissues through invasion that makes 
them lethal.
There are as many tumor types as there are cell types in the human body. 
Thus, cancers do not represent a single disease but a large group of heterogeneous 
diseases and they share some biological properties such as clonal cell growth and
invasive ability. One can classify cancers in various ways. For example, most 
common cancers of adults are carcinomas, representing cancers derived from 
epithelial cells. Leukemias and lymphomas are derived from blood forming cells 
and lymphoid cells, respectively. Sarcomas are derived from mesenchymal tissues. 
Melanomas are derived from melanocytes, and retinoblastomas, neuroblastomas, 
and gliobastomas are derived from stem cells of retina, neurons, and glia, 
respectively.
It could not have been predicted twenty years ago, whether all these different 
cancers shared common molecular pathogenesis as well as common biological 
properties. Rapidly growing cancer research revealed that they do all result from 
defects in both oncogenes and tumor suppressor genes, and the characteristic 
mutations in these specific genes are the cause of each specific cancer. Although in 
some cases, the same specific gene is involved in many cancers, such as p53, which 
is mutated in cancers of brain, colon, liver, breast, stomach, bladder, and pancreas, 
in other cases a specific mutated gene appear to be involved in a single tumor type, 
such as the WTl gene in childhood kidney cancers (for review see Haber, 1998).
1.4 PROTO-ONCOGENES AND ONCOGENES
More than 20 different viral oncogenes have been identified, each of which 
has a counterpart in normal cells. The majority of oncogenes have been compared at 
the level of their nucleotide or predicted amino acid sequences with the host proto­
oncogene from which they were derived as well as with proto-oncogene homologues 
in other species. The expression of proto-oncogenes in normal cells is tightly 
regulated, and these cells do not give rise to malignancy. The potential for proto­
oncogene products to participate in tumorigenesis relates to their role in the complex
signaling networks that control the growth and differentiation of normal cells 
(Cantley et al., 1993; Aaranson, 1991). In a normal cell, interaction of growth 
factors and cytokines with specific membrane receptors triggers a cascade of 
intracellular biochemical signals that result in the expression and repression of 
various genes. Proto-oncogene products have been shown to function at critical 
steps in these pathways and include proteins such as extracellular cytokines and 
growth factors, transmembrane cytoplasmic proteins that transmit the signal. The 
relaxation of requirements of transformed cells for growth factors can be mediated 
by an alteration through overexpression or mutation of the gene product involved at 
any level of these signal transduction pathways.
The majority of oncogenes were isolated as altered forms of proto-oncogenes 
acquired by RNA tumor viruses (y-onc). An examination of human tumors by a 
variety of methods revealed that some of the v-onc genes also are altered in human 
tumors. The concept that there are genes capable of causing cancer (oncogenes) is 
based largely on studies carried out with transplantable tumors in chickens, miee and 
rats (Rous, 1911). The causative agent for such tumors was found to be an RNA 
virus. Based on the highly efficient manner in which the viruses were able to cause 
tumors, it was proposed that the virus carried genetic information responsible for 
transforming a normal cell into a tumor cell (Temin, 1974). However, there is little 
evidence that such viruses are causative agents for the majority of human cancers.
Retroviruses are RNA-containing animal viruses that replicate through a 
DNA intermediate. They have been isolated from many avian and mammalian 
sources and can be divided into two classes on the basis of the latent period between 
infection and the appearance of a tumor. Acute transforming retroviruses rapidly 
produce tumors in newborn animals and carry genetic information capable of
inducing tumors directly (oncogene) (Weiss, 1984). The slowly transforming 
retroviruses do not carry oncogenes, they induce tumors by integrating themselves 
adjacent to a cellular gene and altering its transcriptional regulation (Hayward et al., 
1981).
The acquisition of cellular genes by acute transforming retroviruses occurs as 
a consequence of their mode of replication. Retroviruses first copy their RNA 
genome into a complementary DNA intermediate that integrates into the host’s 
cellular genome. During transcription and production of viral genomic and 
messenger RNA, mature replication-proficient virus may be packaged and released 
from the cell, or alternatively, viral sequences are lost and replaced with a cellular 
proto-oncogene that is then packaged as an mRNA copy of that gene lacking introns 
into the virus (Stehlin et al., 1976; Bishop, 1982). Once transduced into a virus, the 
proto-oncogene sequence can rapidly undergo numerous mutational events that 
occur during viral replication. Since thé isolation of acute transforming viruses 
involves screening for tumor induction and the ability of virus isolates to transform 
cells in culture, this results in selection for virus isolates containing proto-oncogene 
products (v-onc) that have undergone genetic alterations, such as point mutations 
and deletions, that directly affect protein function. These genetic alterations, in 
conjunction with a high level of expression driven by retroviral transcriptional 
enhancers unleash the transforming potential of the transduced proto-oncogene 
(B laire/a/., 1981).
Retroviruses that produce disease in animals after long latent periods do not 
contain transduced host oncogenes. The long latency period for disease caused by 
these retroviruses is in part a result of the low probability that the retrovirus will 
integrate into or adjacent to host cellular protooncogenes. Integration enhances
proto-oncogene expression in a manner similar to that of the acute transforming 
retroviruses and has been shown to induce the unregulated expression of cellular 
homologues of known oncogenes, resulting in or contributing to neoplastic 
transformation (Hayward e/a/., 1981; Payne ei a/., 1982).
This activation mechanism first was demonstrated with avian leukosis virus- 
induced bursal lymphomas. In these tumors, transcription of the c-myc gene was 
elevated 50- to 100-fold as a result of a provirus insertion upstream from the c-myc 
proto-oncogene locus (Hayward et al., 1981). Several modes of oncogene activation 
by provirus insertion have been documented, showing that integration of proviruses 
can also occur downstream of c-myc or upstream in the opposite orientation (Payne 
et ai, 1982). Retroviruses that lack v-onc sequences can induce many different 
types of tumors, ranging from lymphoproliférative diseases to mammary 
carcinomas. The presence of a provirus integrated in the same region of the cellular 
genome in independently derived tumors of the same histologic type has allowed 
investigators to identify new cellular genes that can be activated in specific tumor 
lineages. With the use of this strategy, many novel oncogenes have been 
discovered.
Homologues of proto-oncogenes have been found in all multicellular animals 
studied thus far, and their widespread distribution in nature indicates that their 
protein products play essential biologic roles. The more highly conserved domains 
of the protein probably are those which have a crucial structural and/or functional 
role, and characterization of their normal biochemical properties will provide insight 
into the contribution an activated oncogene makes to cell transformation. 
Understanding the mechanism of activation of each oncogene requires
characterization of the proto-oncogene, a comparison of the changes that have 
occurred, and systematic testing of changes that influence the transforming potential.
There essentially are only three biochemical mechanisms by which proto­
oncogenes act. One mechanism involves phosphorylation of proteins on serine, 
threonine, or tyrosine residues (Hunter and Cooper 1985). Proteins of this class 
transfer phosphate groups from ATP to the side chain of tyrosine or serine or 
threonine residues. Phosphorylation serves two basic purposes in signal 
transduction. First, in many instances it changes the conformation and activates the 
enzymatic kinase activity of the protein. Second, phosphorylation of tyrosine 
residues generates docking sites that recruit target proteins, which the activated 
kinase may phosphorylate. Thus, phosphorylation acts to potentiate signal 
transmission through the generation of complexes of signal-transducing molecules at 
the specific sites in the cell where they are required to act. For example, activation 
of the catalytic activity of a receptor tyrosine kinase by its ligand leads to the 
formation of a complex of signaling proteins at the plasma membrane where the 
receptor is localized.
The second mechanism by which genes act to transmit signals involves 
GTPases (Bourne, 1987; Bourne et ai, 1990). The prototype for this class of 
proteins is the ras gene family. In a similar manner to the kinase gene family, ras 
proteins function as molecular switches that are turned of and on via a regulated 
GDP/GTP cycle. Ras proteins have been implicated as key intermediates that relay 
the signal from upstream tyrosine kinases to downstream serine threonine kinase 
pathways. Some of the conventional heterotrimeric G proteins can also transform 
cells when altered (Bourne, 1987). The third mechanism involves proteins that are 
localized in the nucleus. A large variety of proteins that control progress through
9
the cell cycle and gene expression are encoded by proto-oncogenes, some of which 
also maybe involved in DNA replication (Ariga et al, 1989; Wasylyk et ai, 1990). 
Thus, the relaxation of the requirements of transformed cells for growth factors 
could be mediated by an activated oncogene at multiple levels of the signal 
transduction pathway.
1.5 TUMOR SUPPRESSOR GENES
Tumor suppressor genes differ from DNA repair genes in critical ways. 
Specifically, although many DNA repair proteins are likely to have a more passive 
role in regulating cell growth, protein products of many tumor suppressor genes are 
likely to be directly involved in growth inhibition or differentiation.
In contrast to the relatively straightforward approaches to the identification 
of oncogenic alleles in cancer, identification of tumor suppressor genes has proven 
far more difficult. Somatic cell genetic studies provided early compelling evidence 
that tumorigenicity was a recessive trait in many cancers. Harris and his colleagues 
were the first to demonstrate that the growth of murine tumor cells in syngeneic 
animals could be suppressed when the malignant cells were fused to non-malignant 
cells (Harris & Klein, 1969; Harris, 1988). However, tumorigenic revertants often 
arose when the hybrid cells were cultured for extended periods, and chromosome 
loses were found in the revertants. Harris and coworkers proposed that malignancy 
was a recessive trait that could be suppressed in somatic cell hybrids, and this 
proposal subsequently was supported by additional studies of rodent somatic cell 
hybrids (Harris, 1988; Klinger, 1982). Interspecies hybrids between rodent tumor 
cells and normal human cells also supported the proposal that tumorigenicity was a 
recessive trait, although the karyotypic instability of the rodent-human hybrids
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complicated the analysis of the human chromosomes mediating suppression. This 
problem was overcome by fusion of various human tumor cell lines to normal, 
diploid human fibroblasts (Stanbridge ei al., 1982). Hybrids retaining both sets of 
parental chromosomes were suppressed for tumorigenic growth in athymie mice. 
Furthermore, it was demonstrated that the loss of specific human chromosomes, and 
not simply chromosome loss in general, correlated with reversion. Tumorigenicity 
could be suppressed even if activated oncogenes, such as mutant ras genes, were 
expressed in the hybrids (Geiser et al., 1986). Because the loss of specific 
chromosomes was associated with tumorigenic reversion, it was suggested that a 
single chromosome and perhaps even a single gene might be sufficient to suppress 
the tumorigenic growth of human cancer cells in nude mice. To directly test this 
hypothesis, using the technique of microcell-mediated chromosome transfer, single 
chromosomes were transferred from normal cells to cancer cells. As predicted, the 
transfer of specific human chromosonies suppressed the tumorigenic growth 
properties of various cell lines (Saxon et al, 1986; Weissman et al, 1987; Shimuzu 
étal,  1990; T rente/a/., 1990; Oshimurae/a/., 1990).
Although the tumorigenic phenotype often can be suppressed following 
single chromosome transfer or cell fusion, other traits of the parental cancer cells, 
such as immortality and anchorage-independent growth, may be retained in the 
hybrids. Considering the notion that most malignant tumors arise from multiple 
genetic alterations, suppression of tumorigenicity might thus represent only the 
correction of one of the alterations. Nevertheless, because the transferred genes 
suppressed at least some of the phenotypic properties seen in cancer cells, all genes 
that suppressed neoplastic growth properties in vitro assays or in vivo tumor models 
often have been referred to collectively as tumor suppressor genes.
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Basically parallel with the somatic cell studies, Knudson undertook 
epidemiologic studies of retinoblastoma (Knudson, 1971). Although most cases of 
retinoblastoma were sporadic, in some families, autosomal dominant inheritance 
was seen. Knudson found that familial cases were much more likely than sporadic 
cases to determine bilateral or multifocal diseases. It has been estimated that about 
60 percent of cases are nonhereditary and unilateral, 15 percent are hereditary and 
unilateral, and 25 percent are hereditary and bilateral. In addition, Knudson found 
that the familial and bilateral/multi-focal cases, in general, had an earlier age of 
onset. Based on largely these observations, Knudson developed a model (Knudson,
1971), in which two “hits”, or mutagenic events, were necessary for retinoblastoma 
development in all cases. In those with the inherited forms of retinoblastoma, he 
proposed the first hit was present in the germline and thus in all cells of the body. 
However, inactivation of one allele of the susceptibility gene was insufficient for 
tumor formation, and a second somatic mutation was needed. Given the high 
likelihood of a somatic mutation occurring in at least one retinal cell during eye 
development, the dominant inheritance pattern of retinoblastoma in some families 
could be explained. In the nonhereditary form of retinoblastoma, both mutations 
were somatic and hypothesized to arise within the same cell. Although each of the 
two hits could have been in different genes, subsequent loss of heterozygosity 
studies led to the conclusion that both hits were at the same genetic locus, 
inactivating both alleles of the retinoblastoma (RBI) susceptibility gene. The 
significance of Knudson’s hypothesis was two-fold. First, it served to illustrate the 
mechanisms through which inherited and somatic genetic changes might collaborate 
in tumorigenesis. Second, it linked the notion of recessive genetic determinants for 
human cancer to the somatic cell genetic studies.
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More than dozen tumor suppressor genes have been localized and identified 
through several experimental approaches that are often employed in concert (Table 
1.1). These approaches include cytogenetic studies of constitutional chromosomal 
alterations in cancer patients, linkage analyses to localize genes that predispose to 
cancer, and loss of heterozygosity (LOH) or allelic loss studies undertaken on 
matched pairs of normal and cancer tissue.
The authenticity of a tumor suppressor gene is most clearly established by 
the identification of inactivating germline mutations that segregate with cancer 
predisposition, coupled with the identification of somatic mutations inactivating the 
wild-type allele in cancers arising in those with a germline mutation. Supportive, 
but less compelling, evidence of a tumor suppressor role for other genes may be 
presented, such as the identification of somatic, inactivating mutations in a gene in 
one or more types of cancer or its decreased or absent expression in cancers. In 
large part because of the difficulties in assigning causal significance to any gene 
solely based on somatic alterations in its sequence and/or expression in cancers, all 
genes not targeted by inactivating germline mutations might be considered most 
appropriately as candidate tumor suppressor genes until additional data are available.
Although, the cellular functions of a number of the tumor suppressor 
proteins, such as pRB, p53 and p i 6, are becoming increasing by well understood, 
others remain largely undefined. It is clear, however, that the tumor suppressor 
proteins will exhibit a variety of functions and act at many sites within the cell. 
Some tumor suppressor proteins have been shown to directly or indirectly 
antagonize the function of proto-oncogenes in growth regulation.
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Tabic 1.1 Selected Tumor Suppressor Gene and Presumptive Tumor Suppressor Gene Alterations
rumor type/Tumor Syndrome Chromosomal Region Evidence*
Retinoblastoma 13ql4 LA, LOH, RB1 mutation
Osteosarcoma 13qI4 LA, LOH, RB 1 mutation
17pl3 LA, LOH, p53 mutation
Wilms’ tumor llpl3 LA, LOH, WTl mutation
llpl5 LA, LOH
16q LOH
Other(s) LA
Rhabdomyosarcoma 17pl3 LA, LOH, p53 mutation
llpl5 LOH
Hepatoblastoma 5q APC mutation
llpl5 LOH
Colorectal ip LOH
' 5q21 LA, LOH, APC mutation
8p LOH
17pl3 LOH, p53 mutation
18q21 LOH, DCC, DPC4 mutation
Others LOH
r^ reast 17pl3 LA, LOH, p53 mutation
!7q21 LA, LOH, BRCAl mutation
16q LOH, E-cadherin mutation
llpl5 LOH
llq LOH
13ql2 LA, BRCA2 mutation
13ql4 LOH, RBI mutation
Others LOH
Lung (small cell) 3p LOH
13pl4 LOH, RBI mutation
17p LOH, p53 mutation
Others LOH
Lung (non-small-cell) 3p LOH
17pl3 LOH, p53 mutation
Others LOH
9p21 LOH, pl6/CDKN2 mutation
Bladder (transitional cell) 9p21 LOH, pl6/CDKN2 mutation
9q LOH
llpl5 LOH
I7pl3 LOH, p53 mutation
Others LOH
Kidney (renal cell) 3p25 LA, LOH, VHL mutation
17pl3 LOH, p53 mutation
Others LOH
Glioblastoma 9p21 LOH, pl6/CDKN2 mutation
lOq LOH
17pl3 LOH, p53 mutation
Others LOH
Melanoma 9p21 LOH, pl6/CDKN2 mutation
17q NFl mutation
Others LOH
Ovarian I6q LOH, E-cadherin mutation
17q LOH, BRCAl mutation
outers LOH
Gastric 5q LOH
16q LOH, E-cadhcrin mutation
17p LOH, p53 mutation
18q LOH
Pancreatic 9p21 LOH,p 16/CDKN2mutation
13ql4 LOH, RBI mutation
I7pl3 LOH, p53 mutation
18q21 LOH, DPC4 mutation
Neurofibromatosis type I 17q LA, LOH, NFl mutation
Neurofibromatosis type 2 22q LA, LOH, NF2 mutation
Menineioma 22q LOH, NF2 mutation
*LA, Linkage analysis and/or germline mutation; LOH, loss of heterozygosity.________ _________________ _________
(This table from Vogelstein and Kinzler, 1998)
14
Many of the tumor suppressor gene products appear to be expressed at 
roughly equivalent levels in virtually all adult tissues. Thus, the basis for the 
restricted tumor spectrum seen in those harboring a germline mutation in a tumor 
suppressor allele is rather puzzling. For example, patients with an RBI germline 
mutation are at elevated risk for the development of only a rather limited number of 
tumor types, including retinoblastoma in childhood, and osteosarcomas, soft tissue 
sarcomas, and melanoma later in life. RBI germline mutations fail to predispose to 
more common cancers, despite the fact that somatic RBI mutations have been 
observed in a sizeable fraction of breast, small cell lung, bladder, and prostate 
cancers (Knudson, 1993). Similarly, somatic mutations in the p53 and p i 6 genes are 
very prevalent in many different types of cancer (Greenblatt et al, 1994; Okamoto et 
ai, 1995). Yet, those with p53 germline mutations are predisposed to a relatively 
limited number of cancers, including breast cancer, sarcomas, brain tumors, and 
lymphomas (Knudson, 1993; Malkin et al., 1990). Similarly, those with germline 
p i 6 mutations are predisposed to á very narrow spectrum of tumors, including 
melanoma and pancreatic cancer (for review see Ruas and Peters, 1998).
Although a detailed molecular explanation for these rather mysterious 
observations has not yet been provided, several new findings have provided clues. 
In some cell types, loss of pl05-RB  function has been shown to lead to increased 
cell death, rather than cell transformation (Howes et al., 1994; Williams et al., 
1994). Hence, inactivation of both RBI alleles may provide a growth advantage in 
only a limited number of cell types, unless other oncogene or tumor suppressor gene 
mutations already have arisen in the cells. Similarly, given that those with germline 
p53 mutations do not appear to be predisposed to most common cancers, loss of p53 
function does not appear to be predisposed to most common cancers, loss of p53
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function does not appear to be critical to the early developmental stages of many 
common epithelial cancers, including lung and colon cancer (Greenblatt et al, 
1994). Rather, mutations that inactivate p53 function may only provide selective 
growth at later stages of tumorigenesis, such as when neoplastic cells confront 
growth arrest or apoptosis signals stemming from environmental stresses to which 
the cells are exposed (Graeber et al, 1996).
1.6 APOPTOSIS AND CANCER
Apoptosis is a descriptive term for the phenotype of cells undergoing 
programmed cell death. Apoptosis is critical component of development and 
homeostasis in multicellular eukaryotic organisms. Apoptotic cell death can be 
distinguished from necrotic cell death by several criteria, including the characteristic 
morphology and the absence of a resulting inflammatory reaction.
The Bcl-2 family of proteins plays a central role in apoptotic control and is 
conserved evolutionarily. The bcl-2 gene (for B-cell lymphoma/leukemia-2) 
initially was identified as the gene on chromosome I8q21 at the breakpoint of the 
t(14;18) chromosomal translocation found in the majority of B-cell follicular 
lymphomas (Tsujimoto et al, 1984; Tsujimoto et al., 1985; Bakhshi et al., 1985; 
Cleary and Sklar, 1985). This genomic rearrangement juxtaposes the bcl-2 gene 
with the immunoglobulin heavy chain gene enhancer, leading to marked up- 
regulation and constitutive expression of the bcl-2 gene in lymphoid cells. The 
coding sequence of Bcl-2 is not altered by translocation.
The first associationjbetween Bcl-2 and inhibition of cell death was made in 
1988 (Vaux et al., 1988). Stable bcl-2 transformants of a cell line dependent on the 
growth factor interleukin-3 (IL-3) were found to survive for prolonged periods after
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withdrawal of IL-3, much longer than the parental cell line lacking the upregulated 
bcl-2 gene. In addition, Bcl-2 was shown to cooperate with a more traditional 
oncoprotein, c-myc, to immortalize pre-B-cells. Bcl-2 subsequently has been found 
to be a potent inhibitor of apoptosis in a wide variety of experimental systems (Yang 
and Korsmeyer, 1996).
The realization that Bcl-2 functions to prevent apoptosis defined a new 
category of oncogene: the antiapoptotic gene (Korsmeyer, 1992). Research on 
oncogenesis had focused largely on the mechanisms regulating cell proliferation: 
Cancer was thought to arise from the products of abnormally expressed genes 
deriving cell replication (oncogenes) or failing to inhibit cell replication (tumor 
suppressor genes). Bcl-2, which is overexpressed by the most common 
chromosomal rearrangements in lymphoid malignancy, was found to have no direct 
effect on replication but caused a failure to die. This realization implied for the first 
time that alteration of either side of the homeostatic balance can contribute not only 
to cell accumulation but also to carcinogenesis. Subsequent work by many groups 
has confirmed the carcinogenic potential of antiapoptotic gene dysrégulation and has 
led to a broader view of the types of genetic alterations that contribute to cancer.
Another group of proteins that has been implicated strongly in the central 
apoptotic pathway is the ICE-related protein family (Chinnaiyan and Dixit, 1996; 
Henkart, 1996). The ICE-related proteins, including Ced-3, are cysteine proteases 
that cleave at aspartate residues in a defined amino acid context. The family has at 
least nine mammalian members, most of which has been shown to trigger apoptosis 
when overexpressed in cell lines. The apoptotic role of this family members in 
mammalian cells has been suggested by studies using specific inhibitors of ICE-
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related proteases, which prevent apoptosis in response to many of the known 
triggers of programmed cell death (Miura et al, 1993; Rabizadeh et al, 1993).
Many cell surface receptors, including the tumor necrosis factor receptor 
(TNFR) family, have been shown to modify the apoptotic sensitivity of cells. 
Different members of the TNFR family can promote or inhibit apoptosis. An 
apoptotic signaling pathway from one of these receptors. Fas, has been traced by 
direct protein-protein interaction from receptor engagement to ICE-related protease 
activation.
Cellular and viral oncogenes that stimulate proliferation are strong inducers 
of apoptosis. The proto-oncogene that has been most clearly associated with 
apoptotic induction is c-myc. The c-myc gene encodes a transcription factor that is 
upregulated in many transformed cells and induces rapid cell proliferation (Evan and 
Littlewood, 1993). However, isolated c-myc overexpression results in apoptosis 
(Vaux et al., 1988). Concomitant overexpression of the bcl-2 gene prevents 
apoptosis, resulting in an immortalized, transformed phenotype (Bissormette et al., 
1992). Overexpression of both c-myc and bcl-2 in lymphocyctes of transgenic mice 
results in synergistic tumorigenesis, generating lymphoid tumors much more rapidly 
than either transgene alone. Two models of c-myc function have been proposed to 
explain these findings (Harrington et al., 1994). In the conflict model, c-myc 
generates a purely growth-promoting signal. Under unfavorable growth conditions, 
the cell produces inhibitory factors to prevent proliferation. This conflict of 
opposing signals affecting cell cycle progression results in an apoptotic response. 
Under favorable growth conditions, no conflict arises, and cell proliferates. In the 
dual signal model c-myc -generates both proliferative and apoptotic signal.
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Proliferation then requires the suppression of apoptosis by expression of survival 
factors (e.g. Bcl-2).
Tumor suppressor gene function has been found to be linked to apoptosis as 
well. Tumor suppressors, such as p53 and pRB participate in cell cycle regulation 
and can inhibit proliferation by causing stage-specific cell cycle pauses known as 
checkpoints. Cell cycle checkpoints are thought to function to permit the repair of 
DNA damage and to ensure the integrity of the genome before cell cycle 
progression. It is recognized increasingly that in addition to inhibiting the cell cycle 
progression of abnormal cells, checkpoints are involved in triggering apoptosis to 
delete potentially abnormal cells from the body. The apoptotic function of p53 will 
be summarized in section 1.7.6.
1.7 THE TUMOR SUPPRESSOR GENE p53
Discovered in 1979 complexed to the SV40 large T antigen in SV40- 
transformed rodent cells (Lane and Crawford, 1979; Linzer and Levine, 1979), the 
p53 protein was initially classified as a tumor antigen. Transfection of the 
molecularly cloned p53 gene into rodent embryo fibroblasts suggested that p53 was 
an oncogene as it was capable of immortalizing these cells by itself or transforming 
them in conjunction with the ras oncogene (Jenkins et al, 1984; Parada et ai, 1984). 
Only in the last few years has it become clear that wild-type p53 behaves as a 
negative growth regulator or tumor suppressor gene. The earlier transfection studies 
demonstrating oncogenic properties of p53 were misleading because mutant forms 
of p53 were used (Hinds et al., 1989). Many mutant forms of p53 are indeed 
capable of behaving in an oncogenic manner (Levine et al., 1991).
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The evidence for the tumor suppressor activity of wild-type p53 is now 
conclusive. Transfection of wild type p53 into tumor cell lines reduces or terminates 
cell growth and division (Chen et al, 1990). Loss of wild type p53 alleles is 
exceedingly common in human tumors; the first p53 allele may incur a point 
mutation, while the remaining wild type allele is often lost in the progression of the 
tumor (Nigro et al., 1989; Hollstein et al., 1991). While co-transfection of mutated 
p53 and ras causes transformation of rodent embryo fibroblasts in culture (Parada et 
al., 1984), addition of wild type p53 DNA to mutant p53 and ras results in a marked 
decrease in transformed colonies (Eliyahu et al., 1989). Human families with Li- 
Fraumeni syndrome, an inherited predisposition to cancer, have a mutated germ line 
p53 gene (Malkin et al., 1990). Some mice with Friend virus-induced 
erythroleukemia have rearranged or deleted p53 alleles in their tumor cells (Ben- 
David and Bernstein, 1991; Ben-David et al., 1989). Finally it was found that p53- 
deflcient mice generated by gene targeting methods, with two p53 null alleles, 
develop normally, but are susceptible to tumors at a young age (Donehower et al.,
1992) . Thus, it was concluded that p53 is dispensable for normal cell growth and 
development, but somehow is required to prevent the manifestation of malignant 
genetic alterations. At around the same time, an observation made already in 1984 
by Maltzman and Czyzyk (1984), was rediscovered: irradiation of cells expressing 
wild type p53 induced metabolic stabilization of p53, leading to its accumulation 
and to G1 arrest of the irradiated cells. This observation was then extended to other 
genotoxic agents, establishing p53 as a cell cycle check point protein in G1 in 
response to DNA damage (Kastan et al., 1992; Kuerbitz et al., 1992; Fritsche et al.,
1993) . It was noted even in these early studies and subsequently (Stewart et al., 
1995) that in a population of fibroblasts with elevated p53 expression, although the
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majority arrest in G l, a noticeable minority arrest in G2. Furthermore, wild-type 
p53 overexpression in a human ovarian cancer cell line resulted primarily in a 
transient G2 delay (Vikhanskaya et al., 1994). These observations suggested that in 
addition to a role in Gl cell cycle arrest, p53 participates in a G2 cell cycle 
checkpoint. In fact strong support for this conjecture has recently been provided 
(see section 1.7.5).
When wild-type p53 was overexpressed in a murine myeloid leukemic cell 
line that lacks endogenous p53 expression the cells rapidly lost viability, in a manner 
characteristic of programmed cell death (Yonish-Rouach et al., 1991). This was the 
first indication of a role for p53 in apoptosis. In the following years, subsequent 
studies have established that the overexpression of wild-type p53 can elicit apoptosis 
in a wide array of cell types (see section 1.7.6).
The combined activities of p53 as checkpoint mediator and apoptosis- 
inducer result in a protein that can act effectively as ’guardian of the genome’ and 
tumor suppressor.
1.7.1 p53 protein is conserved through evolution
The general organization of the p53 protein is well conserved during 
evolution (Soussi et al., 1990). This conservation was first shown by the 
characterization of p53 from Xenopus laevis (Soussi et al., 1987), and confirmed by 
subsequent identifiication of new p53 proteins from other species. The 
characterization of p53 from other species revealed a number of features common to 
all p53 proteins (Soussi and May 1996). The p53 protein could be divided into three 
main regions (i) the amino-terminal region, which contains a large number of asidic 
residues and a number of proline residues (proline-rich region) (ii) the central region
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of protein which contains three highly hydrophobic regions and very few charged 
amino acid residues (iii) the carboxy-terminal region, which is very hydrophilic and 
contains many charged residues. Sequence analysis of individual various p53 
proteins revealed not any significant characteristic of a particular function, whereas 
comparison of the various proteins shows that their homology is not uniformly 
distributed, leading to the identification of five blocks conserved through evolution. 
These conserved blocks, first defined by Soussi et al. (1987, 1990) via the 
comparison of p53 from X. laevis with human p53, was also shown for other 
characterized p53 proteins. Block I is located in the amino-terminal region, and 
blocks II-V are found in the central region of p53. These data suggested that the 
three regions of the p53 protein might have separate functional roles, with crucial 
importance of the central region containing blocks II to V. Each domain and their 
functional features are described in the following section.
1.7.2 p53 protein: structure and functions
The human p53 ean be divided into different domains (Ко and Prives, 1996): 
at the N terminus, a transactivation domain (residues 1 to 43) and proline-rich 
domain (residues 62 to 91); in the middle core, a DNA-binding domain (residues 
100 to 300); and at the C terminus, a tetramerisation domain (residues 326 to 354) 
and a regulatory region (363 to 393).
p53 binds to several proteins through its activation domain in vitro. Tlie 
amino terminus of p53 interacts with many general transcription factors such as the 
TATA box-binding protein (TBP) component of the general transcription factor 
TFIID (Horikoshi et al., 1995, and references therein), several TBP-associated 
factors (TAFs), including Drosophila TAF-40 and TAF-60 (Thut et al., 1995), the
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human TAF31 (Lu and Levine 1995), and the p62 subunit of the dual 
transcription/repair factor, TFIIH (Xiao et a l, 1994; X. Wang et a i, 1995; 
Leveillard et al., 1996). p53 also recognizes the eukaryotic single-stranded DNA- 
binding protein RP-A (Dutta et al., 1993; He et al., 1993; Li and Botchan 1993). 
Although p53 is able to activate transcription through the binding of specific DNA 
regulatory sequences, it has been demonstrated that wild-type p53 specifically 
represses the activity of promoters whose initiation is dependent on the presence of a 
TATA box. Direct interaction of TBP with two p53 domains appears to be involved 
in this activity. It has been proposed that the p53-TBP interaction could be involved 
in the repressive activity of p53 in transcription promoters containing a TATA box. 
The biological function of such activity remains to be established.
The interaction of mdm2 and p53 has been studied either by using point 
mutations (Lin et al., 1994) or a series of synthetic peptides (Picksley et al., 1994). 
These studies defined a very limited region (amino acid residues 18 to 23 in human 
p53, includes the residues Leu22 and Trp23) to be important for transactivation (Lin 
et al., 1994). Partial deletion of this region led to the loss of mdm2 binding 
therefore explains how mdm2 protein inhibits the transactivational activity of p53 by 
masking the transactivation domain.
The amino terminal region of p53 is the target of phosphorylation by various 
kinases (see section 1.7.3). The possible role of this posttranslational modification 
is discussed in section 1.7.3.
Amino acids 100-300 of p53 have been shown by several groups to be a 
protease-resistant, independently-folded structural domain capable of sequence 
specific DNA binding to p53 consensus oligonucleotides. Tetrameric p53 binds to 
four repeats of a consensus DNA site of the type (5’-PuPuPuC(A/T)-3’) (El-Deiry et
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al, 1992). This repeat is arreinged in two pairs of inverted repeats. The structure by 
Cho et al. (1994) shows that residues K120, C277 and R280 of a single DNA- 
binding domain interact through hydrogen bonds with the DNA bases while residues 
K120, S241, R273, A276 and R283 interact with phosphate groups of the major 
groove formed by a single 5 base-pair repeat. In addition there are four crucial 
interactions with phosphate groups along the narrowed minor groove formed by the 
A/T-rich junction between two inverted repeats. Importantly, all four minor groove 
hydrogen bonds are from Arg248, the amino acid with the highest frequency of 
mutations in human cancers.
The most noteworthy feature of the crystal structure presented by Cho et al. 
(1994) is how the most frequent tumor-related mutations map to residues at or near 
the DNA-binding surface of the protein. Point mutations appear to alter the DNA- 
binding ability of p53 through two mechanisms. First, mutation of residues directly 
involved in DNA-binding will decrease the affinity of p53 for its consensus sites by 
removing critical contacts with DNA. This class of so-called ‘contact’ mutants 
includes the two most frequently mutated residues, Arg248 and Arg273. The 
majority of the other misssense mutations were classified as ‘structural mutants’ 
because they disrupt the structural elements (L2, L3 loop and loop-sheet-helix) 
which help position the residues that interact with DNA. Cho et al. (1994) point out 
that the DNA-binding surface of p53 is particularly susceptible to disruption by 
mutations because this surface has little regular secondary structure and therefore 
relies heavily on specific interactions from amino acid side chains to hold the 
protein backbone of this region in the proper conformation.
Many mutants of p53, are recognized by monoclonal antibody PAb240, but 
not by PAbl620, while wtp53 has the opposite reactivity (PAb240-, PAbl620+).
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Although, it is very unlikely that all mutants have the same alternative conformation, 
one can assume that all mutants have a common ‘mutant conformation’ distinct from 
that of wtp53. A much more likely explanation suggested by Cho et al. (1994) is 
that the mutant conformation is actually an unfolded or partially unfolded form of 
the protein. This proposal is supported by the fact that PAb240 antibody was 
derived from denatured p53 (Gannon et al., 1990) and PAbl620 epitope is not linear 
and requires a native p53 structure (Milner ei al., 1987). In fact, PAb240 epitope 
forms one of the B strands of the B sandwich and is inaccessible to antibody binding 
in native wtp53. Thus, at least partial unfolding is necessary to expose the PAb240 
epitope. This model of unstable mutant p53 is further supported by the fact that (i) 
structural or conformational mutants are more susceptible to proteolysis than wtp53 
(Bargonetti et al., 1993), (ii) some PAb240 mutants have been associated with heat 
shock proteins.
The carboxy terminus can be divided into three regions, a flexible linker 
(residues 300-320) that connects the DNA-binding domain to the tetramerization 
domain, the tetramerization domain itself (residues 323-355), and, at the extreme 
carboxyl terminus, a stretch of 30 amino acids that is rich in basic residues. The wt 
p53 protein is predominantly found in the form of a tetramer (Wang et al., 1994). 
The three groups that have reported the structure of tetrameriztion domain, using 
three-dimensional nuclear magnetic resonance (NMR) (Lee et al., 1994; Clore et al., 
1995) and X-ray crystallography (Jeffrey et al. 1995), agree that the tetramerization 
domain contains a p-sheet-tum-a-helix motif that can homodimerize, and that the 
p53 tetramer contains a painof such dimers.
In contrast to the DNA-binding domain, only a small fraction of the single 
point mutations observed in tumor-derived p53 mutants are found in the
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tetramerization domain. This could be because the structure of the tetramerization 
domain is inherently insensitive to point mutations, or perhaps because tumor cells 
select for an intact tetramerization domain (Arrowsmith and Morin 1996). It is also 
possible that both factors play a role. Since the isolated tetramer is so stable, it is 
able to withstand some level of destabilization due to a single point mutation and 
still function at physiological temperatures.
Although it is known that the minimal region of p53 necessary for cellular 
transformation localizes to the oligomerization domain (Shaulian et al., 1992), the 
normal role of this domain is not entirely clear. Experiments demonstrating the 
requirement for p53 oligomerization for DNA binding (Halazonetis and Kandil 
1993; Shaulian et al., 1993; Pietenpol et al., 1993) are contradicted by several 
groups showing that the central core alone binds to DNA. In some cases, the 
oligomerization domain appears dispensable for sequence-specific transactivation 
(Shaulian et al., 1993; Tarunina and Jenkins 1993), but not in others (Halazonetis 
and Kandil 1993; Pietenpol et al., 1994). It is possible that the presence of this 
domain may be required for binding to some p53 cognate sites but not others. There 
is likely to be complex communication between the different domains of p53, and 
removal or alteration of one domain may affect the function of the others. In fact, 
one recent study showed the influence of the N-terminal region on the 
oligomerization between Human and Xenopus p53 (Chene, 1999).
Although the wt p53 protein is predominantly found in the form of a 
tetramer, there is considerable evidence that an activating structural change is 
needed in order for wt p53 to bind efficiently to its consensus DNA targets. Wt p53 
exists in DNA-binding latent and active conformation which can be detected in vivo 
(Ulrich et al., 1992; Hupp and Lane, 1994). These two forms of the protein have
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differential reactivity with antibodies specific for regions in and near the N- and C- 
terminal domains (Haleizonetis et al., 1993; Hupp and Lane 1994). The latent form 
of the protein appears to be maintained by the C-terminal basic region because 
alterations of this domain such as deletion, phosphorylation or antibody binding can 
constitutively activate p53 for DNA-binding (Hupp et al., 1992; Halazonetis and 
Kandil, 1993). The structure of the tetramerization domain suggests that the C- 
terminal basic region could physically interact with portions of the protein. 
Furthermore, Wang et al., (1994) have shown that the DNA-binding domain itself 
has a propensity to oligomerize. With the finding that small peptides derived from 
this region can activate specific DNA binding, it was suggested that the latent form 
of p53 is one in which the DNA-binding domains are held together (possibly by the 
C-terminal basic region, a negative regulatory domain) in a conformation in which 
they are not free to align themselves along the four pentanucleotide repeats of a 
consensus DNA site.
The carboxy terminus of p53 is the target of several viral and cellular 
proteins (EBV BZLFl, EBV EBNA-5, RPA and HBx) (Zhang et al., 1994; Szekely 
et al., 1993; Dutta et al., 1993; Wang et al., 1994), but the biological significance of 
these interactions remains to be determined. The carboxy terminal region of p53 is 
the target of phosphorylation by various kinases (see section 1.7.3). The possible 
role of this posttranslational modification and acetylation is discussed in section 
1.7.3.
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1.4.3 Biological and Biochemical Properties of p53
(i)Regulation of p53 function
Because p53 is such a critical cellular protein, it is not surprising that 
multiple mechanisms have evolved to regulate its activity, potentially resulting in 
both an increase in the levels of p53 and a conversion of p53 from an inactive to an 
activated form for DNA binding.
The predominant regulation of p53 occurs at the protein level. Mutations in 
p53 that affect its conformation typically increase its half-life, in part by inhibiting 
degradation by the ubiquitin complex (Maki et al., 1996; Haupt et al., 1997; 
Kubbutat et al., 1997; Midgley and Lane, 1997), and the majority of human tumor 
mutations decrease the sequence-specific DNA binding and transcriptional activity 
of p53 protein (Cho et al. 1994). In unstressed cells, p53 appears to be present at 
low levels and exists in a latent, inactive form that requires modification to become 
active. The types of modification that p53 is subjected seem to be stress-, species- 
and cell-type specific.
p53 is a short-lived nuclear protein with a half-life of 5-20 min in most cell 
types studied. Following exposure to DNA damage, the half-life of p53 protein 
increases by several fold (Maltzman and Czyzyk 1984; Price and Calderwood 1993; 
Maki and Howley 1997). Two years ago studies made in several laboratories 
implicated that the Mdm2 protein as a major intracellular regulator of ubiquitin- 
mediated degradation of p53 protein (Haupt et al., 1997; Honda et al., 1997; 
Kubbutat et al., 1997; Midgley and Lane, 1997). For several years it had been 
known that the Mdm2 protein could inhibit p53 function by binding to and 
inhibiting transactivation by p53 (Momand et al., 1992; Oliner et al., 1993; Thut et 
al., 1997), but with these recent studies it only became clear that Mdm2 binding also
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targets p53 for rapid proteosomal degradation. If Mdm2 fails to bind to p53, the 
intracellular levels of p53 protein increase, thus potentially contributing to the 
initiation of p53-dependent processes such as cell cycle arrest or apoptosis. The 
physiological significance of this process of p53 regulation has subsequently been 
supported by the observations that activation of p53 either DNA damage (Shieh et 
al., 1997) or by oncogenes via p i9'^ *^*^ (de Stanchina et al, 1998; Zindy et al, 1998) 
are both associated with decreased binding of Mdm2 protein to p53 (Shieh et ai, 
1997; Kamijo et al., 1998; Pomerantz et al., 1998; Zhang et al., 1998). It has 
recently been suggested that hypoxia can increase p53 protein levels through 
induction of HIF-ip, which can bind to and stabilize p53 (An et al., 1998). 
However, E6 protein decreases p53 protein level by enhancing its ubiquitin- 
mediated degradation (Scheffner et al., 1990; Wemess et al., 1990).
Changes in the level of p53 protein is not the sole story in the modulation of 
p53 activity. Both post-translational modifications and alterations in p53-binding 
proteins also affect the regulation of p53 function. This observation initially was 
documented by Hupp et al.; the recombinant p53 protein produced in bacterial cells 
can bind to sequence-specific DNA with a very high efficiency only when the 
carboxy-terminal of protein is phosphorylated, or incubated with a carboxy-terminal 
binding anti-p53 antibody (Hupp et al., 1993). These observations with subsequent 
studies showed that the carboxy-terminal domain of p53 is a regulatory region of the 
protein (Hupp et al., 1995; Jayaraman and Prives 1995; Lee et al., 1995; Selivanova 
et al., 1997). Other functional domains of p53 include sequences required for 
transactivation in the amino terminus, sequences required for specific DNA binding 
in the central portion of the protein, and sequences involved in oligomerization in 
the carboxyl tail. A proline-rich region exists between the amino-terminal
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transactivation domain and the central DNA-binding domain, which has been 
implicated in both p53-mediated growth arrest (Walker and Levine, 1996) and 
apoptosis (Venor et al, 1998). Although the mechanisms remain to be elucidated, it 
has recently been suggested that this region cooperates with carboxy-terminal 
domain in negatively regulating p53 activity and maintaining p53 in latent form 
(Muller-Tiemann et al., 1998).
The existence of these various regions of p53 that can modulate its activity 
sets up a situation in which a primary p53 regulatory mechanism could be by 
specific post-translational modifications of one or more of these domains, or 
modulation of proteins that bind to these domains (Figure 1.1). In fact, the data 
accumulating from recent studies suggest that a series of post-translational 
modifications occurs in p53 that can affect its levels, its function, its homo- and 
hetero-oligomerization, and its DNA-binding capabilities. Increasing the 
complexity of such data is the likelihood that some of these modifications in turn 
affect p53 functions by altering its abilities to bind to other proteins.
Phosphorylation
p53 is multiphosphorylated at serines in both the amino- and carboxy- 
terminal regions in vivo and in vitro (Figure 1.1). Protein kinases that have been 
shown to phosphorylate p53 in vitro include casein kinase I (serines 6 and 9; Milne 
et al., 1992), DNA-PK (serines 15 and 37; Lees-Miller et al., 1990; Shieh et al., 
1997), ATM and ATR (serine 15; Banin et al., 1998; Canman et al., 1998), CDK- 
activating kinase (CAK) (serine 33; Ко et al., 1997), cdk2 and cdc2 (serine 315; 
Bischoff et al., 1990; Price et al., 1995), protein kinase C (serine 378; Baudier et al., 
1992), and casein kinase II (serine 392; Hall et al., 1996). These modifications
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likely represent the balances between phosphorylation and phosphatase events. 
Supporting such a concept was the observation that activation of latent recombinant 
p53 by protein kinase C was reversible by treatment with protein phosphotases 1 or 
2a (Takenaka et al., 1995). Many of these sites are also phosphorylated in vivo. 
What is unknown is which of these sites are modified in the basal state and which 
are altered in response to specific physiologic stimuli. For example, IR appears to 
result in both de novo phosphorylation of serine 15 (Shieh et al, 1997; Silicano et 
al, 1997) and déphosphorylation of serine 376 (Waterman e/a/., 1998).
Acetylation
Sequence-specific DNA binding is only one component of the ability of p53 
to function as a transcription activator. p53 must also be able to interact with 
transcriptional machinery to influence transcription of its target genes. In addition 
to interacting with components of TAF (Lu and Levine et al, 1995; Thut et al, 
1995), members of the histone acetylase family, p300/CBP, have recently been 
shovra to bind to p53 and enhance p53-mediated transcription (Avantaggiati et al, 
1997; Gu et al, 1997; LUI et al, 1997a; Scolnick et al, 1997). The functional 
importance of binding of p300/CBP to p53 was consistent with the previous 
observations that both adenovirus El A and SV40 large T antigen bind to members 
of p300/CBP family (Eckner et al, 1994, 1996; Lill et al, 1997b) and disrupt p53 
functions (Steegenga et al, 1996). However, due to the binding ability of p300/CBP 
to p53 in the absence of these viral oncoproteins implicated a more direct 
mechanism of action. Moreover, subsequent studies (Gu and Roeder 1997) showed 
that p300 can directly acetylate p53 in the regulatory region of its carboxy-terminal 
domain and that this acetylation activates the latent sequence-specific DNA-binding
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activity of p53. Furthermore, Sakaguchi et al, (1998) recently demonstrated that the 
acetyltransferases p300 and PCAF acetylate p53 in vitro at lysines 383 and 320, 
respectively, that these acetylation events enhance sequence-specific binding of p53, 
and that lysine 382 becomes acetylated in response to DNA damage in cells. 
Interestingly, recombinant p53 protein that was phosphorylated by DNA-PK 
appeared to be a better substrate for the acetyltransferase than unphosphorylated 
p53. This observation suggests that p53 is modified by a series of posttranslational 
event that work independently, both in terms of occurrence and their functional 
consequences.
Alterations in p53 intracellular localization
p53 must be located in the nucleus to bind to DNA and activate transcription. 
Significant amount of p53 was found in the cytoplasm of cell lines derived from 
certain tumors, such as germ cells and neoroblastomas. This observation suggested 
that this is a potential mechanism of inactivating p53 function even in the presence 
of wild-type gene sequences (Moll et al., 1992, 1995). Even the cytoplasmic p53 
protein in these cells is almost certainly inactive, DNA damage does appear to 
induce p53 levels and function in the nucleus (Goldman et al., 1996). Nevertheless, 
intracellular transport of p53 seems to be a potential important mechanism of 
functional regulation and it has recently been suggested that part of the influence of 
mdm2 on p53 proteolysis is its ability to enhance transport of p53 protein out of the 
nucleus and into the cytoplasm where it targeted for degradation (Roth et al., 1998).
A final mechanism of regulating p53 activities is via the binding of other 
intracellular proteins. Numerous viral and cellular proteins interact with p53 and, 
can work by a number of different mechanisms, including altering the rate of p53
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degradation, influencing the DNA-binding or transcriptional capabilities of p53, or 
affecting the intracellular localization of p53. Some proteins, such as mdm2, 
appears to have effects on p53 protein localization, half life, and transcriptional 
activity by multiple mechanisms. Alternatively, a variety of different proteins may 
affect the same function. For example, the interaction of Ref-1 with p53 (Jayaraman 
et ai, 1997) was initially identified because of its ability to enhance the sequence- 
specific DNA binding of p53. A novel protein that binds to p53, p33"^°’, was 
cloned recently using a screen for genetic suppressor elements (Garkavtsev et ai, 
1998). It was suggested that the growth suppressive effects of both proteins are 
interrelated and require the activity of both gene products. p53 has also been 
reported to bind to replication protein A (Dutta et al, 1993; Abramova et al, 1997). 
However, the physiologic effect of this binding remains to be elucidated. Taken 
together all these data, one can emphasize that these different mechanisms of 
modulating p53 function appear to be interactive with each other, many of these 
binding proteins will work by altering one or more of the processes, such as directly 
or indirectly affecting p53 half-life. Furthermore, phosphorylation will likely affect 
some of these interactions or these interactions could affect a post-translational 
modifications, such as acetylation. A final complexity to consider is that post- 
translational modifications of these p53-binding proteins may affect their ability to 
interact with p53. For example DNA-damage induced phosphorylation of 
replication protein A (RPA) inhibits its ability to bind p53 (Abramova et al, 1997). 
Similarly, it was demonstrated that phosphorylation of mdm2 by DNA-PK will 
inhibit its ability to bind to p53 (Mayo et al., 1997).
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(ii)Different mechanisms involved in speciflc signaling pathways of p53
Although a numerous genotoxic and nongenotoxic stimuli induce p53 protein 
and its activity in cells, it is very likely that there will be some shared mechanisms 
of p53 induction and activation with these various stimuli and some unique 
mechanisms (Figure 1.2). For example the ATM kinase seems to be important for 
p53 induction after IR, but not following UV radiation (Khanna and Lavin 1993; 
Canman et al, 1994; Siliciano et al, 1997). HIF-ip may play an important role in 
p53 induction during hypoxia, but is probably not involved with the other stimuli. 
Mdm2 interactions with p53 are altered after both DNA damage and oncogenic 
activation, apparently by different mechanisms (Shieh et al., 1997; de Stanchina et 
ai, 1998;Zindye/n/., 1998).
Ionizing Radiation
Ionizing radiation (IR) is a potent inducer of p53 protein and it has been 
known for some time that induction of p53 by IR is suboptimal in cells that lack the 
expression of the ATM kinase (Kastan et al, 1992; Khanna and Lavin 1993). This 
concept was extended by the demonstration that IR induces phosphorylation of 
serine 15 (Shieh et al, 1997; Siliciano et al, 1997) and that this post-translational 
modification is decreased markedly after IR in cells lacking ATM (Siliciano et al, 
1997). However, since ATM-null cells exhibit some serine 15 phosphorylation after 
IR, it suggests the presence of a ‘back-up’ kinase or intermediate (Siliciano et al, 
1997; Canman et a l ,  1998). It was also demonstrated that, whereas 
unphosphorylated p53 had a DNA binding capacity similar to the phosphorylated 
p53 induced by DNA damage, p53 transcriptional activity was correlated with serine
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15 phosphorylation by only being evident in the damaged eells (Silieiano et al, 
1997).
The importanee of the ATM kinase in this IR-induced signaling pathway was 
further established by the recent demonstration that ATM kinase is eapable of 
phosphorylating p53 in vitro on serine 15 and that the ATM kinase activity is 
enhanced following IR (Canman et al, 1998; Banin et al, 1998). These results 
suggested that ATM was directly phosphorylating p53 on this site in response to IR. 
Interestingly, ATM was also implicated in a radiation-induced dephosphorylation 
event. IR causes a loss of phosphate group from serine 376 in the carboxyl terminus 
of p53 in an ATM-dependent manner and this dephosphorylation event results in 
creation of a binding site for 14-3-3 proteins and enliancement of sequence specific 
DNA binding (Waterman et al, 1998). Finally, it has been suggested that DNA-PK 
activity is necessary but not sufficient for induction of p53 DNA-binding and 
transcriptional activity, but does not participate in the damage-induced increase in 
p53 protein levels (Woo et al, 1998). Although it remains to be determined how 
DNA-PK influences this activity and whether it is a direct or indirect effect, these 
observations support the concept that there is more to p53 activation after DNA 
damage than the simple increase in p53 protein levels.
In addition to the induction of serine 15 phosphorylation and serine 376 
dephosphorylation, the other ppsttranslational modification shown to occur in vivo 
in response to the exposure of cell to IR is the acetylation of lysine 382 (Sakaguchi 
et a l, 1998). Because this acetylation event appears to be influenced by 
phosphorylation of certain serines, it is suggested that such post-translational 
modifications are working in a coordinate manner.
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UV radiation
Similar to IR, UV radiation also induce p53 protein, though UV radiation 
seems to have some steps in common and some steps that are distinct from those 
involved in signaling to p53 after IR. The initial signal leading to p53 induction 
after UV treatment is dependent on the generation of DNA strand breaks, and the 
signal does not seem to be the damaged DNA bases themselves (Nelson and Kastan 
1994). The induction of acetylation of lysines 320 and 382 appears to also be shared 
by IR and UV radiation (Sakaguchi ei al, 1998).
However, there is a distinct difference in p53 induction following UV 
radiation versus IR. For example ATM kinase is not required for induction of p53 
after UV radiation (Khanna and Lavin 1993; Canman et al., 1994) and serine 15 
phosphorylation occur in ataxia-telangiectasia (AT) cells after UV irradiation. 
Although, UV-induced kinase appear to phosphorylate the same site, it was 
suggested that this kinase is different from ATM. Moreover, UV irradiation does 
not increase ATM kinase activity in the cells (Canman et al, 1998). Additionally, in 
contrast to IR, UV radiation induce serine 392 phosphorylation, which is associated 
with increased sequence-specific DNA-binding (Kapoo and Lozano 1998; Lu et al, 
1998) and also has been suggested to stabilize tetramer formation of p53 (Skakguchi 
et al, 1997). Due to the lack of this phosphorylation event after IR, it was suggested 
that some other events after IR must compensate this important modification such 
that IR can also lead to enhanced tetramer formation, DNA binding, and 
transcriptional activation.
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Oncogenic stimuli
pl9ARF addresses p53 through a pathway that is distinct from those 
activated by DNA damage. Over expression of Мус, El A or E2F-1 in primary 
MEFs rapidly induces ARF gene expression and leads to p53-dependent apoptosis. 
Мус and ElA can induce p53 through both ARF-dependent and ARF-independent 
pathways, but much higher levels of oncoprotein expression are required to activate 
p53 when ARF is absent. Under the latter conditions, the p53 response is attenuated 
and cells resistant to oncogene-induced killing rapidly emerge. Réintroduction of 
pl9ARF into surviving ARF-null cells expressing either Мус or ElA resensitizes 
them to apoptosis, indicating that the attenuation of death is a direct consequence of 
ARF loss and does not result from other cryptic mutations. Therefore, Мус, ElA, 
and E2F-1 trigger a p53-dependent oncogene checkpoint gated by ARF. Although 
the ARF-p53 pathway is not essential for normal proliferation, the checkpoint could 
provide a fail-safe function during embryonic development. For example, in a 
model of the developing murine lens, Rb deficiency triggers apoptosis in a p53- 
dependent manner (Morgenbesser et al., 1994), but the process is attenuated in 
lenses from animals lacking INK4a/ARF (Pomerantz et al, 1998).
Another oncogene has recently been reported to activate p53 in a pl9ARF 
dependent manner. It was demonstrated that oncogenic Ras elicits an anti- 
tumorigenic response mediated by the upregulation of pl9ARF, which in turn 
activate the tumor suppressor p53. In particular, expression of the Ras oncogene in 
normal primary cells causes a cell-cycle arrest that involves the activation of the 
tumor-suppressor protein p53. In contrast, p53 levels in ARF-/- MEFs remained 
unchanged in the presence of oncogenic form of the Ras protein (Palmero et al, 
1998). Furthermore, ARF-/- cells do not undergo proliferation arrest in response to
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oncogenic Ras. It means that the loss of pl9ARF renders cells unprotected against 
the action of oncogenes.
(iii)Transcriptional Activation by p53
Although the mechanism by which p53 elicits its effect upon cells is not yet 
fully understood, it is clear that the transcriptional activating function of p53 is a 
major component of its biological effects (Crook et al, 1994; Pietenpol et ai, 1994). 
The first mammalian gene that showed regulation by p53 was the muscle-specific 
creatine kinase (CKMM) gene (Weintraub et al., 1991). Cotransfection of a p53 
expression vector with a plasmid containing the CKMM promoter upstream of a 
reporter gene resulted in a high level of reporter activation. Since that time and after 
the elucidation of the consensus DNA-binding site of p53, the human genome has 
been estimated to contain several hundred p53 binding sites (Tokino et al., 1994) 
and a growing number of p53 target genes have been identified. The diverse_nature 
of these targets suggests that p53 may be involved in pathways of cell-cycle control, 
angiogenesis and apoptosis.
Downstream mediators of p53-dependent cell cycle arrest
There appears to be variable pattern concerning the mechanism of p53 gene 
action through specific target gene activation. For example with respect to cell cycle 
arrest in G1 the single target p21 (WAFl) CDK inhibitor appears to be critical 
component, whereas for G2 arrest or apoptosis induction of multiple effector target 
genes may be required. The better-understood p53-regulated genes are discussed 
below.
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1. p21(WAFl)
p53 regulates cell cycle checkpoints in response to DNA damage, hypoxia or 
oncogene activation. Expression of the p21 CDK inhibitor appears to be directly 
controlled by p53 through two specific p53 DNA-binding response elements located 
within the p21 promoter (El-Deiry et al, 1993; El-Deiry et al, 1995). Recent 
studies have suggested the possible existence of distinct signaling pathways that 
may preferentially utilize one or the other p53-binding elements within the p21 
promoter (Resnick-Silverman et al., 1998). Once activated, p21 protein binds to 
cyclin-CDK complexes and inhibits their kinase activity (see El-Deiry, 1998, for 
recent review). Because CDK kinase activity is required for various cell cycle 
transitions, p21 is a potent cell cycle inhibitor. p21 binds with its greatest affinity to 
G1 cyclin-CDK complexes, and binds poorly to cyclin B/cdc2. p21 also binds to the 
proliferating cell nuclear antigen (PCNA) and can inhibit the processivity of DNA 
replication. The expression of p21 in a variety of tissues from p53 null mice 
suggests that it is also regulated by p53-independent mechanisms (Macleod et al., 
1995; Parker et al., 1995). p21 expression is also subject to regulation by other 
candidate tumor suppressors, such as IRFl, p73, WTl, and BRCAl. BRCAl can 
regulate p21 expression through p53-independent and p53-dependent mechanism 
(Zhang et al., 1998).
2. 14-3-3a
While it is clear that p53-deficiency leads to defective cell cycle arrest in Gl, 
the role of p53 in G2 arrest is less clear. Although wild-type p53-deficient cells can 
arrest in G2 following exposure to ionizing radiation, it appears that p53 may 
contribute to G2 arrest when it is present and not mutated. In this regard, the three
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p53-target genes 14-3-3a (Hermeking et al, 1997), GADD45 (Zhan et ai, 1999), 
and B99 (Utrera et al, 1998) have emerged as potential mediators of p53 dependent 
G2 arrest. In the case of 14-3-3a, it has been suggested that following exposure to 
y-radiation phosphorylated cdc25c becomes bound by cytoplasmic 14-3-3a and its 
phosphatase activity becomes sequestered from activation of nuclear cyclin B/cdc2.
3. GADD45
GADD45 was originally identified in Chinese hamster ovary cells in 
increased amount when cells exposed to ultraviolet radiation. In the case of 
GADD45, recent evidence has suggested that cyclin B/cdc2 may be bound and 
inlribited by GADD45 thereby leading to G2 arrest (Zhan et al., 1999). Both 14-3-3 
and GADD45 contain p53 DNA-binding response elements in their regulatory 
regions. In the case of GADD45, there is evidence for modulation of expression by 
p53 through non-p53 response elements (Zhan et al., 1998).
Downstream mediators of p53-dependent apoptosis
Although it is known that apoptosis induction requires multiple effector 
genes, no one target of p53 will be sufficient to recapitulate the p53-dependent 
apoptosis phenotype under all physiological circumstances. The earliest mediators of 
p53-dependent apoptosis to be identified were bax (Miyashita et al., 1994) and 
Fas/APOl (Owen-Scaub et al., 1995). More recently identified targets include 
KILLER/DR5 (Wu et al., 1997), the PIG genes (Polyak et al., 1997), IGF-BP3 
(Buckbinder et al., 1995), and PAG608 (Israeli et al., 1997). The better-understood 
p53-regulated genes are discussed below.
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1. Bax
The bax-gene, which is upregulated in response to expression of p53 encodes 
a 21-kD protein and a proapoptotic member of the Bcl-2 family (Oltvai et ai, 1993). 
The ratio of Bax:Bcl-2 has been likened to a rheostat that determines whether cells 
live or die. Bcl-2 and Bax appear to control apoptosis: Bcl-2 enhances cell survival 
while Bax promotes cell death. The bax knockout mice do not display the same 
spectrum of tumors as p53-knockout mice (Knudson et al, 1995), although certain 
Bax-deficient transgenic mice appear to be predisposed to tumor development (Yin 
et al., 1997). Bax knockout thymocytes, unlike p53-knockout tymocytes, are not 
deficient in y-irradiation-induced apoptosis (Knudson et al., 1995). However, Bax- 
knockout fibroblasts appear to be compromised in DNA-damage-induced apoptosis 
(McCurrach et al., 1997). Thus, there is evidence that under certain conditions 
p21 (Bax) may be an important target mediator of p53-dependent apoptosis. -
2. PIGs (p53-induced genes)
A group of PIG’S has been recently identified through SAGE (Serial 
Analysis of Gene Expression) screening for p53 target genes (Polyak et al., 1997). 
PIG genes are involved in the generation of toxic reactive oxygen species. At least 
one PIG gene, PIG3, appears to be directly regulated by p53 through a p53 DNA- 
binding response element located in the PIG3 gene promoter. The coordinated 
control of PIG3 gene expression under apoptotic signaling as well as their precise 
role and mechanism in p53-dependent apoptosis is not yet clear. However, it is clear 
that toxic reactive oxygen species are generated with kinetics which follow the p53- 
dependent induction of PIGs in cells undergoing p53-dependent apoptotic death.
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3. IGF-Bp3 (insulin growth factor-binding protein #3)
IGF-BP3 binds IGFl and inhibits growth factor signaling. IGF-BP3 appears 
to be directly regulated by wild-type p53 through sequence-specific DNA-binding 
and transactivation (Buckbinder et al., 1995). There is some evidence that 
overexpression of 1GF-BP3 may have pro-apoptotic effects independent of its ability 
to bind IGFl.
Feedback regulation by Mdm2, a p53-target gene
Some targets of p53 appear to negatively regulate its function through 
regulation of the half-life of p53. The Mdm2 gene encodes a p53-binding protein 
that conceals its transactivation domain thereby inhibiting its function as a 
transcriptional activator. In some tumor cells, expression of Mdm2 is increased 
which as a consequence inactivate p53 function in cell cycle arrest and apoptosis. 
Mdm2 appears to play a role in targeting p53 for degradation through a mechanism 
that may involve p300 (Grossman et al., 1998) and which seems to be inhibited by 
the ARF protein (Pomerantz et al., 1998; Stott et al., 1998; Zindy et al., 1998; de 
Stanchina et al., 1998; Bates et al., 1998; Palmero et al., 1998) or phosphorylation 
of p53 at its amino-terminal end (Shieh et al., 1997; Siliciano et al., 1997). Mdm2 is 
a gene whose expression is transcriptionally upregulated by p53. Therefore 
induction of Mdm2 is believed to feedback regulate p53 function in cell cycle arrest 
and apoptosis induction. In another negative feedback loop, p53 appears to repress 
ARF expression thereby indirectly regulating p53 protein stability (Stott et al., 
1998).
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The relatively large number of genes that were found to be induced by p53 is 
not surprising. The heterogeneity in induction, however, was unexpected (Yu et al., 
1999). Vogelstein and coworkers identified a number of potential transcriptional 
targets and found marked heterogeneity in the extent, timing, and p53 dependence of 
both previously identified and unidentified targets (Yu et a l, 1999). This 
heterogeneity suggests that, even in tumor cells derived from the same stem cell 
type, the response to p53 expression varies considerably. The particular genes 
induced likely depend on the cell’s normal tissue derivation as well as on the genetic 
alterations that have occurred during the tumorigenic process.
(iv) Transcriptional Repression by p53
p53 repress transcription of a number of genes with promoters lacking p53- 
binding sites, including among others, c-fos (Ginsberg et al., 1991; Kley. et al., 
1992), IL6 (Santhanam et al., 1991), c-myc (Moberg et al., 1992), and insulin-like 
growth factor II (Zhang et al., 1996), bcl-2 (Miyashita et al., 1994). It is possible 
that p53 mediates its specific repression effects through another DNA-binding 
protein. The first evidence for repression through transcription factor binding was 
provided by a study in which it was shown that wild-type (but not mutant) p53 
inhibited transcription from promoters containing the TATA sequence (Seto et al.,
1992) . Wild-type p53 also binds TBP, again suggesting that this particular protein- 
protein interaction plays a key role in repressing transcription from a large array of 
cellular genes. In a second study, it was demonstrated that p53 could repress 
transcription from the human heat shock protein 70 (HSP70) gene (Agoff et al.,
1993) . In addition, p53 interacted with CCAAT-binding factor (CBF), suggesting 
that p53 may downregulate transcription of the HSP70 gene through protein-protein
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interactions with CBF. Recently, p53 has been shown to bind to TAFs, which 
suggests that these transcription factors may also be necessary for p53-mediated 
repression (Sabbatini et al, 1995a).
The C-terminal domain of p53 may be involved in mediating repression 
(Shaulian et al., 1995). The potency of p53 as a broad-range repressor may be an 
important component of its tumor suppressor function, and the contribution of 
repression to the biological effects of p53 is still under investigation.
1.4.4 The p53 homologues; same response, different signals
Two mammalian proteins, p73 and p63, with significant sequence homology 
to p53 have recently been identified. The first relative of p53, called p73, was 
identified by Caput and co-workers (Kaghad et al., 1997) serendipitously during a 
search for novel interleukins. The second relative, called p63 (it is also known as 
KET, p51, p40, chronic ulcerative stomatitis protein (CSUP) and p73L), was 
identified independently by several groups (Yang et al., 1998; Trink et al., 1998; 
Osada et al., 1998; Augustin et al., 1998; Senoo et al., 1998; Lee et al., 1999).
Alternative splicing of intron 9 in human p53 leads to production of a protein 
truncated at the C-terminus. The significance of this human truncated protein in 
tumor suppression remains to be elucidated. For human p73, at least four 
alternatively spliced form has been identified; p73a, p73p, p73y, p73a (Kaghad et 
al. 1997; De Laurenzi et al., 1998). The p73 gene contains 14 exons and is located at 
chromosome lp36.33. The p63 gene is located at chromosome 3q27-29 and 
contains 15 exons (Yang et al., 1998; Osada et al., 1998) and can be transcribed 
from two different promoters, which are located upstream of exon 1 and within 
intron 3 (Yang et al., 1998). Upstream promoter leads to the production of three
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spliced forms of p63; p63a, p63p, p63y, and cry tic promoter in intron 3 leads to the 
production of three N-terminal truncated proteins, Np63a, Np63p, Np63y.
The genomic organization of p53, p73 and p63 are highly similar, suggesting 
that they are ancestrally related. Importantly, the region of highest similarity 
between p53, p73 and p63 corresponds to the p53 core DNA-binding domain (63% 
for p73 and 60% for p63). The vast majority of missense mutations found in human 
tumors are clustered in the sequence specific DNA-binding domain. In addition, 
p73 and p63 are 29% and 22% identical to the region corresponding to the N 
terminal transactivation domain of p53, respectively. Residues in the C-terminal 
region of p73 and p63 are 38% and 37% identical to the corresponding C-terminal 
oligomerization domain of p53. Therefore, the homology between p53 and the other 
family members is extensive within the most conseiwed p53 functional domains.
The apparent similarity of p73 with p53, together with the fact that p73 maps 
to chromosome lp36.33, a region frequently deleted in human cancers, and it has 
been found to be monoallelically expressed, led to the hypothesis that it can be a 
possible tumor suppressor gene. However the status of p73 as a tumor suppressor 
gene has been challenged by recent observations. Notably, p73 can be biallelically 
expressed in both normal and tumor tissues or cell lines; and mutation of the p73 
gene occurs infrequently in human cancers (Icliimiya et al, 1999; Han et al, 1999).
It is also not certain whether p63 is a tumor suppressor gene. p63 is located 
at chromosome 3q7-29, a region that is hot a common site of loss of heterozygosity 
in human cancers. p63 gene was found to be mutated, albeit infrequently, in both 
human tumor tissues and cancer cell lines (Osada et al., 1998). Although p63 might 
have functions similar to those of p53 in cell-cycle arrest and apoptosis, Np63, 
which lacks an activation domain, inhibits the activity of both p53 and p63, thereby
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exhibiting oncogenic functions (Yang et al, 1998). In addition, p63 is highly 
expressed in the basal region of many epithelial tissues (Yang et al., 1998) and is 
essential for limp, cranifacial and epidermal morphogenesis (Mills et al., 1999; 
Yang etal., 1999).
p53 was originally identified as a T-antigen binding protein (Lane and 
Crawford 1979). It is known that the physical interaction with and inactivation of 
p53 by viral oncoproteins, such as the SV40 large T antigen, adenovirus ElB 55- 
kDa protein and human papillomavirus (HPV) E6 protein, plays a central role in 
viral tumorigenesis (Ko and Prives 1996). However, adenovirus EIB protein and 
human papillomavirus (HBV) E6 protein and SV40 large T antigen do not bind to 
p73 both in vitro and in vivo (Marin et al., 1998; Higashino et al., 1998; Roth et al., 
1998). Given the high degree of similarity between p53 and p73, it is surprising 
that none of the viral oncoproteins described above interact with p73. Only one 
viral oncoprotein, adenovirus E4orf6, was capable of associating with p73 and 
inhibiting the activity of p73 in one experimental protocol (Hogashino et al., 1998; 
Steegenga et al., 1999), but not in another (Roth et al., 1998). Thus, further studies 
are required to address this issue. Whether these viral oncoproteins that discriminate 
between p53 and p73, can regulate p63 remains to be elucidated.
p73 and p63 can also induce cell-cycle arrest and apoptosis like p53 (Kaghad 
et al., 1997; Yang et al., 1998; Osada et al., 1998; lost et al., 1997; Zhu et al., 
1998). Loss of p73 transcriptional activity abrogates its activity in cell-cycle arrest 
and apoptosis (Kaghad et al., 1997; lost et al., 1997; Zhu et al., 1998). It is well 
known that upregulation of p21 by p53 is primarily responsible for p53-dependent 
arrest in G1 phase. Consistent with their ability to induce cell-cycle arrest, both p73 
and p63 can induce p21 synthesis. Although the level of p21 induced by p73 is
several times lower than that induced by p53. If the level of p21 induced by p73 is 
not sufficient to cause cell-cycle arrest, other cellular genes might also be involved 
in p73-dependent cell-cycle arrest.
As described before, p53-dependent G2-M arrest is mediated, at least by 
upregulation of 14-3-3a (Hermeking et al, 1997). Consistent with the ability of p73 
to induce G2-M arrest, p73 is capable of inducing 14-3-3 a(Zhu et al., 1998). 
Interestingly, p73 induces several fold higher levels of the 14-3-3 ogene product 
than does p53. It remains to be determined whether p63 can induce 14-3-3 a  and 
cell cycle arrest in G2-M.
Although both p53 and p73 can induce apoptosis (lost et al., 1997; Zhu et 
al., 1998), the signaling pathways used might differ. Bax and several redox-related 
genes (PIG2, PIG3, PIG6 and PIGl 1) are possibly involved in mediating p53- 
dependent apoptosis (Miyashita et al., 1994; Polyak et al., 1997), were not 
significantly induced by p73 (Zhu et al., 1998). Because p73 transcriptional activity 
is required for inducing apoptosis (lost et al., 1997; Zhu et al., 1998), it is possible 
that p73 can activate a distinct group of cellular genes for mediating apoptosis. The 
signaling pathway for p63 induction of apoptosis remains to be determined.
Mdm2, an oncogene that negatively regulates p53, and is also induced by 
p53 (Wu et al., 1993), is weakly induced by p73p but not by p73a (Zhu et al., 
1998). Mdm2 binds to p53, enhancing the degradation of p53 through the 
ubiquitination pathway. Interestingly, Mdm2 binds to and suppresses p73 function 
without promoting p73 degradation (Zeng et al., 1999; Dobbelstein et al., 1999). 
For the case of p63, the Mdm2 binding domain is present in the activation domain of 
p63, but whether p63 can regulate Mdm2 or be regulated by Mdm2 remains to be 
determined.
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1.4.5 p53 and Cell-Cycle Arrest
Eight years ago Kastan’s group suggested a role for p53 in cell cycle control 
after DNA damage. Exposure to DNA damaging agents caused a temporary arrest 
in G1 phase of the cycle in cells with wild-type p53 but not with mutant p53 (Kastan 
et a l, 1991). Since then, this initial observation was confirmed in many adult 
tissues. Several groups have shown that in early pluri-potent embryonic cells, the 
regulation of the Gl/S checkpoint and DNA-repair are p53-independent (Aladjem et 
al, 1998; Schmidt-Kästner et a l, 1998). This may be connected to the p53 
homologue, p73, which was shown to mediate G1 arrest (.Tost et al, 1997). The p53- 
mediated arrest at the late Gl, was shown to be a result of p53 transactivation of the 
p21 cyclin inhibitor gene (El-Deiry et al, 1993; El-Deiry et al, 1994). This protein 
was shown to bind various cyclin-cdk complexes (cyclin E/cdk2 and cyclin A/cdk2), 
that regulate both Gl-S and G2-M transitions, and to inhibit their action (Nieulescu 
et al, 1998). The p21 protein is not the sole mediator of p53-dependent Gl 
checkpoint, since p21 knockout mice exhibit only a partial annihilation of the Gl 
checkpoint. The fact that p21 knockout mice do not exhibit any susceptibility to 
tumorigenesis, raises doubts about the significance of p53-mediated Gl checkpoint 
in preventing carcinogenesis (Deng et al, 1997). Moreover, double atm(-/-)/p2!(-/-) 
mice exhibit reduced lymphomagenesis compared to atm(-/-) phenotype only. This 
result is intriguing, since it suggests that the p21-mediated checkpoint activation 
may induce lymphoma genesis, due to reduced apoptosis of the arrested cells (Wang 
et al, 1997).
Deregulation of the G2 checkpoint is one of the hallmarks of malignant 
transformation (Kaufmann et al, 1995). This checkpoint is very important for the
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maintenance of genomic stability, since it is the last barrier before the perpetuation 
of mutations or an unstable genome following the actual mitotic divisions. The cdc2 
kinase-cyclin B1 complex, termed Mitosis Promoting Factor (MPF), is the target of 
the G2 checkpoint inhibitory signal because it serves as the primary mediator of tlie 
signal for G2-mitosis transition. The activated MPF is responsible for the 
phosphorylation of the major components of chromatin structure and G2/M 
transition machinery. Several cellular pathways have shown to be involved in 
modulating MPF activity. Recently, it was shown that several members of the 14-3- 
3 family are able to induce G2 arrest, by binding to the non-functional 
phosphorylated form of the cdc25c phosphatase (Conklin et al, 1995), which in 
turn, prevents the inliibitory dephosphorylation of the cdc2 kinase, thus resulting in 
non-iunctional MPF.
Initially it was thought that p53 plays no role at the G2 checkpoint, since p53 
knockout cells seem to arrest at the G2 following DNA damage. Moreover, it 
appears that the onset of G2 delay is p53-independent and involves rapid inhibitory 
phosphorylation of the MPF complexes. Nevertheless, now it has been accepted that 
p53 plays a role as a secondary regulator of the G2 delay (Stewart et al, 1994). p53 
was shown to be efficiently in vitro phosphorylated by S and G2-regulating cyclin- 
cdk complexes (Wang and Prives, 1995). This phosphorylation alters the specificity 
of p53 binding to various target DNA sequences. In several p53-null non-lymphoid 
cell lines, reconstitution of wild-type p53 conformation, or transcriptional induction 
of wild-type p53 without any DNA damage (Agarwal et al, 1995) resulted in a G2 
as well as a G1 arrest. The role of p53 as a second barrier at the G2 checkpoint is 
further supported by the finding that annihilation of the phosphorylation-dependent 
G2-delay by caffeine, is reduced in wild-type p53 expressing cells (Powell et al.
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1995). Recently, it was shown that p53 can modulate cdc2 activity to prolong 
radiation-induced G2 arrest independently of the inhibitory phosphorylation of MPF.
The molecular mechanism of p53 regulation of G2 checkpoint is still a 
matter of controversy. Elevated expression of p21 in cell lines causes G2 as well as 
G1 arrest (Medema et al, 1998; Cayrol et al, 1998; Bunz et al, 1998) in a manner 
similar to p53 up-regulation. Cyclin G, another p53 effector gene (Zauberman et al., 
1995) is believed to regulate G2 arrest as well (Shimizu et al., 1998). Last, but not 
least, it was shown that p53 up-regulates the 14-3-3 a  gene (Hermeking et al., 
1997), which belongs to a family of proteins shown to regulate the G2 delay (see 
Figure 1.2)
1.4.6 p53 and Apoptosis
Early evidence that p53 may modulate apoptosis came from studies in which 
p53 function was restored to a p53-deficient myeloid leukemia cell line (Yonish- 
Rouach et al., 1991). Tliese results were confimied in vivo with p53 knockout mice. 
Tymocytes from p53 -/- mice subjected to ionizing radiation were resistant to 
apoptosis, whereas tymocytes with wild-type p53 were not (Clarke et al., 1993; 
Lowe et al., 1993a). Mice that were heterozygous for wild-type p53 showed a slight 
resistance to thymocyte apoptosis under identical conditions, suggesting that precise 
expression levels of p53 may be important in p53-mediated apoptosis.
Studies using human cancer cell lines further illustrated the complexity of the 
p53 story. Studies with lymphoma cell line (Fan et al., 1994), ovarian cancer cell 
lines (McIIwrath et al., 1994), and breast cancer cell lines (Fan et al., 1995), all 
demonstrated an increased sensitivity to radiation or specific chemotherapetic agents 
in the presence of wild-type p53. In contrast, studies with colorectal carcinoma cell
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Figure 1.2 Cellular response to DNA damage.
The cell-division cycle is blocked after DNA damage, alloviring time for repair. After 
damage, cdc2 is maintained in an active state by phosphorylation on threonine 14 (T14) and 
tyrosine 15 (Y15). This is done by weel, a nuclear kinase that phosphorylâtes cdc2 on Y15, 
and by Mytl, which is cytoplasmic and phosphorylâtes cdc2 on both T14 and Y15. 
Cdc2/cyclin B1 complexes continually shuttle between the nucleus and the C3doplasm, and a 
nuclear-export sequence (NES) in cyclin B1 prevents nuclear accumulation of cdc2/cyclin B1 
complexes. Cdc25C, which activates cdc2/cyclin B1 complexes by dephosphoiylating cdc2, 
also shuttles between the nucleus and the cytoplasm, and 14-3-3-binding proteins (although 
not 14-3-3o) contribute to the nuclear exclusion of cdc25C. DNA damage activates the 
nuclear Chkl and Cdsl kinases, which maintain cdc25C in a 14-3-3-bound form. DNA 
damage stabilizes p53, leading to transcriptional activation of the 14-3-3a gene that 
contributes to the nuclear exclusion of cdc2/cyclin B1 complexes.
(This figure is from Kwnica-Worms, 1999)
lines (Brachman et a l, 1993) containing or lacking functional p53 failed to 
demonstrate any significant differences in sensitivity to radiation. Thus, the effect 
of functional disruption of p53 may vary between cell lines. One potential reason for 
such variation may lie in differences in the regulatory signals for apoptosis lying 
upstream or downstream from p53.
Several stimuli including DNA damage (Clarke et al., 1993; Lowe et al., 
1993a), adenovirus El A expression (Lowe and Ruley, 1993), myc expression 
(Hermeking and Eick, 1994), or withdrawal of growth factors (Gottlieb et al., 1994) 
can cause p53 dependent apoptosis. However, apoptosis can also occur by pathways 
independent of p53; one example is glucocorticoid induction (Clarke et al., 1993; 
Lowe et al., 1993a). Expression of the survival factor bcl-2 can block p53-mediated 
apoptosis (Chiou et al., 1994). Apoptosis in response to p53 expression can also be 
inhibited by exposure of cells to a variety of growth factors such as IL-3 and IL-6 
that act as a survival factors (Canman et al., 1995; Gottlieb et al., 1994).
Although the ability of p53 to function as a transcriptional activator is 
necessary for its function in mediating G1 arrest, some studies have provided 
evidence that p53 may have another transcription-independent function in apoptosis. 
p53-dependent programmed cell death was shown to occur in the presence of either 
the transcriptional inhibitor actinomycin D or the translational inhibitor 
cycloheximide (Gaelics et al., 1994; Wagner et al., 1994). Recent evidence, on the 
other hand, suggests that the transcriptional repression function of p53 may be 
important in mediating apoptosis. The adenovirus ElB protein and the cellular 
protein bcl-2, both of which block p53-dependent apoptosis, were found to suppress 
transcriptional repression but to have no effects on transcriptional activation by p53 
(Sabbatini et al., 1995b; Shen and ¿henk, 1994).
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An important issue which arises from the multifunctional activity of p53 is 
how p53 ’decides’ when to induce cell cycle arrest and when to induce apoptosis. 
Cell type appears to be at least one factor (Haupt et al, 1996; Midgley et al, 1995). 
Several experimental systems have demonstrated that it is possible to manipulate 
cells to undergo either response dependent on (1) viral protein expression, (2) 
growth factor availability, or (3) expression of Rb and/or E2F.
1.4.7 Role of p53 in DNA Replication and Repair
p53 function can block cells in the G1 phase of the cell cycle (allowing time 
for possible DNA damage to be repaired), thereby preventing them for progressing 
to S phase where DNA replication takes place. There are experiments, however, 
suggesting that p53 plays a more direct role in regulating processes such as DNA 
replication and DNA repair. Early studies showed that p53 could inhibit large T 
antigen-mediated SV40 DNA replication (Braithwaite et al., 1987) and could 
apparently compete with DNA polymerase alpha for binding to large T antigen 
(Gannon (?/a/., 1987).
A growing body of experimental evidence today suggests that p53 may have 
a direct impact on the ability of a cell to synthesize DNA through its function as a 
transcriptional activator. After DNA damage p53 induces transcriptional activation 
of the p21 gene, the protein product of which binds and inhibits a subunit of DNA 
polymerase called PCNA directly, thereby blocking DNA replication itself (Li et al., 
1994). p53 also may function to stimulate the DNA repair machinery through its 
transcriptional activation function. The product of the p53 tai'get gene GADD45 has 
been shown to bind PCNA to stimulate excision repair of damaged DNA (Smith et
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al, 1994). The mechanism by which the interaction between GADD45 and PCNA 
stimulate repair is under active investigation.
The possibility also exists that p53 directly regulates DNA replication and 
repair in a transcription-independent manner. p53 forms protein-protein complexes 
with cellular proteins involved in DNA synthesis, for instance the replicating protein 
antigen RPA (Dutta ei al., 1993). It also interacts with proteins involved in DNA 
repair. p53 binds ERCC3, an excision repair molecule that recognizes and removes 
damaged DNA segments (Wang et al., 1994).
Other workers, however, argue that p53 has no role in DNA replication and 
repair based on observations like the following; (1) p53 -/- mouse fibroblasts display 
normal rates of repair as do wild-type p53-containing cells (Sands e( al., 1995) and 
(2) p53 does not influence DNA repair in vitro (Leveillard et al., 1996; 
Sancar,1995). Thus, there are good arguments for either side of the question 
whether p53 directly affects DNA replication or repair, and further experiments are 
needed to clarify this issue.
1.4.8 Role of p53 in Development
A p53 null allele has been generated in mice by several groups and the 
conclusions are similar (Donehower et al., 1992; Clarke et al., 1993; Jacks et al., 
1994; Tsukada et al., 1993). The complete loss of p53 results in the development of 
multiple tumor types and a sharp decline in survival of the mice, but it was 
dispensable for growth, differentiation, and embryonic development. Subsequent 
studies, however, have shown that while most p53 null mice are viable and fertile, 
some developmental abnormalities were visible upon closer inspection (Sah et al., 
1995). In crosses between male and female mice heterozygous for the p53 null
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allele, 25% of the progeny should be null for p53. However, a decrease in the 
number of null mice born was observed. Detailed analysis indicated loss of some 
female mice due to exencephaly, an outgrowth of neural tissue. Depending on the 
strain of mice 10-16% of female p53 null mice died during embryogenesis.
Wliile the absence of p53 appears to have a minor defect on development in 
some mice, the presence of too much p53 results in major developmental defects. 
This discovery came from the in vivo analysis of a negative regulator of p53, the 
product of the mdm2 gene (Momand et al, 1992). Mdm2 binds the transcriptional 
activation domain of p53 rendering it non-functional as a transcriptional activator 
(Levine, 1997). Mice null for mdm2 are not viable and in fact die shortly after 
implantation at 5.5 days of development (Montes de Oca Luna et al., 1995; Jones ei 
al., 1995). However, this lethality can be rescued in the absence of p53; whereas 
mdm2 -/-p53+/+, and mdm2 -/-p53 +/- embryos die in utero, mdm2 -/-p53 -/- mice 
are viable. These data support two important concepts: (1) the dividing cells of the 
early mouse embryo make functional p53 and; (2) p53 must be down regulated by 
Mdm2 for cell division to proceed.
1.4.9 p53 in Tumorigenesis
(i) p53 As a Tumor Suppressor
During the past few years, a substantial amount of evidence has accumulated 
suggesting that p53 is an important tumor suppressor gene in normal cells and a 
central target in human carcinogenesis (Hollstein et al., 1991; Levine et al., 1994): 
(1) The wild-type p53 suppresses or inhibits cell transformation mediated by either 
viral or cellular oncogenes; (2) Missense mutations or allelic losses occur frequently 
in diversee human cancers; (3) Germline mutations of the p53 gene are associated
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with the Li-Fraumeni familial cancer syndrome. Members of these families are 
heterozygous for p53 mutations in nonneoplastic tissues but carry mutations in both 
p53 alleles in the neoplastic cells; (4) Transgenic mice deficient for p53 carrying 
altered p53 gene are significantly more prone to spontaneous development of a 
variety of neoplasms; (5) Functional inactivation due to formation of protein 
complexes between the wild-type p53 and oncoproteins of several tumor viruses, is 
linked to virus mediated oncogenesis; (6) Restoration of wild-type p53 into 
neoplastic cell lines with defects in the p53 gene suppressor cellular growth and/or 
tumorigenicity in vitro and in vivo.
(ii) p53 Inactivation
Loss of normal p53 function can occur in a variety of ways. The most 
common change of p53 in human cancers is a point mutation within the coding 
sequences of the p53 gene (especially within the highly conserved regions'II-V), 
which gives rise to an altered protein product (Hollstein et al, 1991; Levine et al. 
1991; Levine et al., 1994; Soussi ei al., 1994). This pathway is currently regarded 
as the most frequent genetic change in a variety of human cancers. Approximately 
half of the major forms of cancer contain p53 missense mutations, 40% of which 
localize at hot spots. Small or large deletions, structural rearrangements and genetic 
insertions also affect p53 but with a lower frequency.
A second mechanism of loss of normal p53 function is the formation of 
protein complexes with viral oncoproteins, which are highly pertinent to tumor 
virus-mediated oncogenesis (Levine, 1990). It has been demonstrated that SV40 
large T antigen (Tan et al., 1986), adenovirus ElB protein (Sarnow et al, 1982), 
human papillomavirus (HPV) E6 protein (Scheffner et al., 1993), and HbxAg of
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Hepatitis B virus (Feitelson et al., 1993) are capable of binding with p53. While the 
formation of protein complexes generally stabilizes the p53 protein, the binding to 
HPV E6 protein results in accelerated p53 degradation through the ubiquitin 
proteolytic pathway (Levine, 1990; Scheffner et al., 1993).
A third way to inactivate p53 is via mdm2 gene amplification and 
overproduction of the protein (Momand et al., 1992). As discussed earlier, high 
levels of mdm2 gene and the consequent overexpression of the mdm2 protein, like 
viral proteins, inactivate p53 by binding to it (Oliner et al., 1993). The fourth 
mechanism that leads to inactivation of p53 is its dissociation between the cell 
compartments (Moll et al., 1992). In some human breast cancers with wild-type 
p53, the protein is localized in the cytoplasm (Moll et al., 1992). In colorectal 
adenocarcinomas cytoplasmic accumulation was reported without evidence of the 
p53 status (Bosari et al., 1994). Nuclear exclusion of wild-type p53 was also 
detected in immortalized retinoblastoma cells (Schlamp et al., 1997). This nuclear 
exclusion is probably naturally occurring translocation defect abrogating p53- 
mediated G1 arrest (Moll et al., 1996). It is nevertheless possible that some 
cytoplasmic proteins like bcl-2 (Beham et al. 1997) or the HBx protein in liver 
cancer (Elmore et al., 1997), may be involved in the cytoplamic retention of p53. 
Because p53 is a transcription factor, only the p53 protein that is transferred to the 
nucleus can act as a negative regulator of cell growth. The sequestering of the p53 
protein into the cell cytoplasm therefore prevents its acting as a tumor suppressor.
(iii) Properties of Mutant p53
Biochemical and immunological comparisons of mutant and wild-type p53 
proteins strongly suggest That the different mutations have similar effect on the
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protein structure. First, the mutant proteins have a much longer half-life than the 
wild-type protein. Typically, the half-life is extended from 6-20 min for normal up 
to 6 hours for mutants (Levine et al, 1991). As discussed earlier, degradation of 
p53 may involve ubiquitin-dependent proteolysis, and regulated changes in p53 
degradation may increase p53 protein levels rapidly and massively in response to 
specific stimuli. Interestingly, most mutations in p53 disrupt the degradation 
pathway, resulting in high levels of the mutant protein. Thus, p53 overexpression 
frequently indicates the presence of a mutation. Second, many of the mutant 
proteins complex to the HSP70 family of heat shock proteins (Finlay et al., 1988), 
whereas wild-type p53 does not have such an ability. Third, mutant p53 proteins 
have a common ‘mutant’ conformation distinct from that of the wild-type protein. 
The observation that p53 was capable of altering its conformation was made 
possible by the development of a series of p53 monoclonal antibodies which 
recognize different conformational states of the protein (Gannon et al., 1990; 
Yewdell et al., 1986). For instance, the monoclonal antibody PAb246 recognizes 
wild-type murine p53 protein, while many mutated versions of the protein do not 
react with it (Yewdell et al., 1986). In contrast, PAb240 is reactive with mutant 
forms of murine and human p53, but not wild-type p53 (Gamion et al., 1990). This 
recognition of different conformations of mutant and wild-type versions of p53 is 
not a fixed property of the mutant and wild-type proteins. The discovery of a 
temperature sensitive mutant (p53Vall35) of p53 (Michalovitz et al., 1990) was 
followed by the observation that this same protein could switch conformation 
between wild-type (PAb246-reactive, PAb240-non-reactive) at low temperature, and 
mutant (PAb246-non-reactive, PAb240-reactive) at high temperature (Milner and 
Medcalf, 1990). The change in the temperature sensitive p53 from a wild-type
59
conformation to a mutant conformation is accompanied by change in activity from 
that of a growth suppressor protein to that of a growth promoter (Michalovitz et al, 
1990). However, given the broad spectrum of residues that are mutated within p53, 
it is highly unlikely that all mutants have the same stable alternative conformation. 
A much more likely explanation is that the mutant conformation is actually an 
unfolded or partially unfolded form of the protein (Clio et al., 1994). This proposal 
is supported by the fact that the PAb240 antibody was derived from denatured p53 
(Gannon et al., 1990) and the PAbl620 (another wild-type p53 specific antibody) 
epitope is not linear and requires a native p53 structure (Milner et al., 1987).
Several studies suggest that all p53 mutants are not equal in their 
transforming activities. Mutants can be divided into three major classes: (1) ‘loss of 
function’ mutants which have merely lost their ability to suppress transformation 
and are weakly transforming or non-transforming (Halevy et al., 1990); (2) ‘jjain of 
function’ mutants, which in addition to losing their tumor suppressor function, can 
actively participate in the transformation of cells (Dittmer et al., 1993); and (3) 
‘dominant-negative’ mutants, which oligomerize with wild-type p53 thereby 
compromising the wild-type allele’s function. This dominant negative phenotype 
may lead to a growth advantage due to less growth suppression or due to an 
increased frequency of additional tumorigenic mutations because of compromised 
cell cycle checkpoint activity.
(iv) p53 and Tumor Development
Examination of tumor spectrum and incidence in p53-deficient mice has led 
to several observations (Donehower et al., 1992; Jacks et al., 1994). p53 -/- mice 
are highly prone to spontaneous tumor formation and predominantly develop
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lymphomas. The particular genetic background of the mice, however, affects tumor 
incidence and spectrum. Mice heterozygous for the inactivated p53 allele also show 
increased incidence of spontaneous malignancies as compared to p53 +/+ mice. In 
this case, the heterozygous mice develop predominantly osteosarcomas and soft 
tissue sarcomas. In addition to susceptibility to spontaneous tumors, p53 deficiency 
also results in increased sensitivity to induced tumorigenesis, both by the carcinogen 
dimethylnitrosamine, or y-irradiation (Harvey et al. 1993a; Kemp et al, 1994).
Mouse embryo fibroblast derived from p53-/- mice have several altered 
growth characteristics relative to wild-type fibroblasts, such as a significantly 
shorter doubling time, an increased ability to grow under conditions of low cell 
density, and lack senescence even at high passage (Harvey et al., 1993b), consistent 
with previous data correlating loss of p53 with indefinite cell proliferation 
(immortalization).
Mice subjected to a wide variety of genetic manipulations, such as those with 
targeted inactivation of particular genes, are now being crossed and analyzed for the 
effects of combination of overexpression and / or lack of expression of several 
interesting genes. Mice deficient in both retinoblastoma (Rb) and p53 show 
cooperative effects of both tumor suppressor genes, with reduced viability and faster 
rate of tumor development than in mice deficient in either one (Harvey et al, 1995). 
Furthermore, mice heterozygous for both Rb and p53 display novel tumor types not 
observed in mice containing either Rb or p53 mutant alleles (Harvey et al, 1995).
(v) p53 and Tumor Progression
Although the loss of p53 function clearly contributes to tumor development, 
recent observations have, elucidated the involvement of mutant p53 in tumor
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progression as well. The efficient growth of tumors is dependent on their ability to 
develop new blood supplies, and angiogenesis, the formation of new blood vessels, 
and is controlled by the balance between stimulatory and inhibitory influences. 
Wild-type p53 expression results in the secretion of inhibitors of angiogenesis 
(Dameron et al, 1994), and this may be an additional mechanism by which the 
presence of wild-type p53 inliibits tumor progression. Hypoxic conditions, such as 
those in a tumor with inadequate blood supply, induce accumulation of the p53 
protein (Graeber et al., 1994) and a subsequent p53-dependent apoptosis (Graeber et 
al., 1996). Thus, low oxygen conditions can provide a selective advantage for cells 
carrying mutations in p53, allowing escape from apoptosis. Indeed, cells lacking 
p53 can overtake wild-type cells after hypoxia treatment. In addition to a resulting 
cellular survival and growth advantage, mutation of p53 selected by hypoxic 
conditions would be expected to favor expansion of the tumor by loss of expression 
of anti-angiogenic factors, allowing growth of new blood vessels to a tumor.
1.4.10 p53 Alterations in Human Cancer
(i) Prevalence of p53 Mutations
p53 is the most frequently mutated gene in human cancer (Chang et al., 
1995; Harris and Hollstein, 1993). Genetic alterations of p53 in human tumors 
include allelic losses, missense and frameshift mutations, intragenic deletions, and 
epigenetic changes. Unlike other tumor suppressor genes, which are frequently 
disrupted by nonsense mutations that result in a truncated protein product, most of 
the mutations involving p53 are substitution changes that render the protein 
incapable of binding to DNA or of activating gene transcription (Harris and 
Hollstein, 1993; Vogelstein and Kinzler, 1992). The mutations cluster in four
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evolutionarily conserved hotspot domains (II-V), between exons 5-8 which 
encompass the DNA-binding function of the wild-type p53 protein (Cho ei ai, 
1994).
A compilation and analysis of screening data from 2567 cancers worldwide 
revealed that 37% contain mutations in the p53 gene including >50% of lung and 
colon cancers. p53 mutations were also common in cancers of the esophagus (45%), 
ovary (44%), pancreas (44%), skin 44%, stomach (41%), head and neck (37%), 
bladder (34%), prostate (30%), liver 29%), brain (25%), adrenal (23%), breast 
(22%), endometrium (22%), kidney (19%), thyroid (13%), parathyroid (8%), and 
cervix (7%), and in melanoma (9%), hematological malignancies (12%), and 
sarcoma (31%). In contrast, p53 mutations were extremely rare in Wilm’s tumor, 
testicular cancer or pituitary tumors.
(ii) Germline p53 Mutations
Germline p53 mutations are associated with the Li-Fraumeni syndrome 
(Malkin, 1993). This syndrome is an autosomal dominant disorder that predispose 
individuals to diverse mesenchymal neoplasms at multiple sites, including breast 
carcinomas, soft tissue sarcoma, brain tumors, osteosarcoma, leukemia, 
adrenocortical carcinoma and possibly other tumors (Malkin, 1993). Tumors 
develop in the family members at unusually early ages, and multiple primary tumors 
are frequent. Recently, germline p53 mutations were also found in some patients 
(out of the Li-Fraumeni families) who had an unusual history of sarcomas (McIntyre 
et al., 1994), second malignant neoplasms (Malkin et a l, 1992), childhood 
leukemias (Felix et al., 1992), and adrenocortical carcinomas (Sameshima et al,
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1992), as well as in subsets of gliomas (Kyritsis et al, 1994) and breast cancers 
(Sidransky et al., 1992a).
Members of these families contain one mutant and one wild-type p53 allele. 
Furthermore, all of the tumor-affected individuals retain the mutant allele and lose 
the wild-type p53 allele in their tumor tissues. It is therefore thought that Li- 
Fraumeni syndrome patients are predisposed to cancer because one p53 allele is 
inactivated in the germline and only the remaining allele needs to be altered by 
somatic mutation. In normal individuals who develop sporadic tumors, both p53 
alleles must be inactivated in the same cell by somatic mutation.
(iii) Endogenously-Induced pS3 Mutations
Mutations can arise by either endogenous mutagenic mechanisms or 
exogenous mutagenic agents and are present in the spectrum of p53 mutations found 
in human cancer (Greenblatt et al., 1994; Hams and Hollstein, 1993; Hollstein et al., 
1991; Levine et al., 1991; Soussi et al., 1994). Errors introduced during DNA 
replication, RNA splicing, DNA repair and DNA deamination are examples of 
endogenous mutagenic mechanisms. The DNA context is an important factor 
determining these events. One fourth of all p53 mutations in tumors are transitions 
at CpG dinucleotides (Hollstein et al., 1994), which are likely to have arisen by 
deamination of 5-metylcytosine. In fact, the three p53 hotspot codons, 175,248, and 
273, contain such a dinucleotide and over 90% of the mutational events in these 
codons are compatible with the occurrence of deamination (Soussi, 1996). 
Deamination of DNA is a spontaneous chemical process, although different factors 
(e.g. DNA methyltransferase) can also affect its rate (Lindahl, 1993). Analysis of 
the mutational events in cancers such as colon cancer, leukemia, lymphoma and
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brain cancer, shows that the mutation rate at the CpG dinucleotide is very high, 
suggesting that most of the mutations that alter the p53 gene in these cancers are due 
to endogenous process related to the deamination of 5-methylcytosine.
(iv) Exogenously-Induccd p53 Mutations
Hepatocellular Carcinoma and Aflatoxin B1
The p53 mutational spectrum in hepatocellular carcinoma is the first example 
of the molecular linkage between carcinogen exposure and cancer. In liver tumors 
from patients living in geographic areas in which aflatoxin B1 (a compound 
produced by fungi that contaminate food) is a cancer risk factor, most p53 mutations 
are at the third nucleotide pair of codon 249 (Bressac et al, 1991; Hsu et ai, 1991). 
A dose-dependent relationship between dietary aflatoxin B1 intake and codon 
249Ser p53 mutations is observed in hepatocellular carcinoma cases from Asia, 
Africa, and North America (Harris, 1996). Exposure of aflatoxin B1 to human liver 
cells in vitro produces 249Ser (AGG to AGT) p53 mutants (Aguilar et al., 1993). 
These results indicate that expression of the 249Ser mutant p53 protein provides a 
specific groNVth and/or survival advantage to liver cells.
Skin Cancer and UV Light
The induction of skin carcinoma by UV light is associated with the 
occurrence of p53 mutations at dipyrimidine sites including CC to GG double base 
changes (Brash et al., 1991; Ziegler et al., 1994). Since patients with xeroderma 
pigmentosum have a severe deficiency in repair of DNA damage induced by UV, 
one would expect a higher frequency of CC to TT transitions in skin carcinomas of 
these individuals. This prediction has proven to be correct (Dumaz et al, 1994).
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Lung Cancer and Tobacco
Numerous studies have consistently reported increased occurrence of lung 
cancer among smokers. Cigarette smoking is currently believed to be responsible 
for 80-90% of lung cancers. p53 mutations are common in lung cancer, occurring in 
33% of adenocarcinomas and 70% of small cell lung cancers (Takahashi et al, 
1989; Takahashi et el., 1991). These mutations are mostly G:C to T:A 
transversions. There is a strong correlation between the frequency of these 
mutations and cigarette smoking. Experiments in bacteria and mammalian cells 
have demonstrated that an important preniutagenic component of cigarette smoke, 
benzo-pyrene, reacts preferentially with guanine bases, generating primarily G to T 
transversions (Eisenstadt et al., 1982).
(v) p53 Deletions and Insertions
The DNA sequences is an important factor determining endogenous 
mutagenic events. Almost all short deletions and insertions occur at monotonic runs 
of two or more identical bases or at repeats of 2- to 8- base pair DNA motifs, either 
in tandem or separated by a short intervening sequence. Several mechanisms are 
probably involved (Ripley et al., 1990). The mechanism that has been most studied 
is called slipped mispairing, a misalignment of the template DNA strands during 
replication that leads to either deletion, if the nucleotides excluded from pairing are 
on the template strand, or insertion, if they are on the primer strand. When direct 
repeat sequences mispair with a complementary motif nearby, the intervening 
oligonucleotide sequence may form a loop between the two repeat motifs and be 
deleted (Jego et al., 1993; Krawczak and Cooper, 1991). More lengthy runs and 
sequence repeats are more likely to generate frameshift mutations. The detection of
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en ors in replication of reporter genes has helped quantify this phenomenon (Kunkel 
et ai, 1993). The deletions and insertions in the p53 gene found in human tumors 
may be biologically selected from the broad array of such mutations occurring in 
human cells. When compared with the distribution of missense mutations, these 
types of mutations occur more frequently in exons 2-4 (54%) and 9-11 (77%) than in 
exons 5-8 (20%). The N-terminus of the p53 protein (encoded by exons 2-4) is 
involved in transcriptional function of p53 (Liu el al, 1993; Seto et al, 1992). The 
carboxy-terminus (encoded by exons 9-11) of the p53 protein is important in the 
oligomerization, nuclear localization, and recognition of DNA damage (Lee et al., 
1995; Milner and Medcalf, 1991; Shaulsky et al, 1990). Multiple point mutations 
are infrequently found in the p53 gene. Therefore, deletions and insertions would be 
a more efficient mutagenic mechanism than single-point mutations in disrupting 
these N- and C-terminal functional domains.
1.4.11 Clinical Implications of p53
(i) p53 in Cancer Diagnosis
The high prevalence of p53 mutations in human cancer suggest that p53 
could be used as a marker in malignancy. p53 mutations can occur as early or late 
events in tumor progression, depending on tissue type. p53 mutations have been 
found in late or advanced stages of various tumor types, including colon cancer 
(Fearon and Vogelstein, 1990), prostate cancer (Navone et al., 1993), ovarian cancer 
(Kohler et al., 1993a), bladder cancer (Fujimoto et al., 1992), uterine cancer (Tsuda 
and Hirohashi, 1992), and liver cancer (Murakami et al., 1993). On the other hand, 
p53 mutations occur in early stages of lung cancer (Chiba et al., 1990), head and 
neck cancer (Boyle et a/., 1993), and breast cancer (Thor et al., 1992). p53
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alterations have been associated with evolution of the clironic phase to blast crisis in 
chronic myelocytic leukemia (Foti et a l, 1991), and with the progression of 
Barrett’s epithelium to invasive esophageal cancer (Casson et al., 1994).
Nuclear staining of the majority of tumor cells with the absence of reactivity 
in surrounding uninvolved tissue is the most commonly observed pattern 
characteristic of the presence of a missense p53 mutation. Uniform nuclear 
immunostaining has been observed in mild dysplasias of the esophagus, breast, 
bronchus, and larynx, and in some instances the protein-stabilizing missense 
mutation was subsequently identified by microdissection of the lesion and direct 
sequencing of the gene (Bennett et al., 1992; Sozzi et al., 1992). In a study, where 
preinvasive squamous cell lesions of the esophagous were classified into basal 
hyperplasia, dysplasia, and carcinoma in situ, no p53 immunoreactivity was found in 
the normal epithelium of resected speciments, but 78% to 92% of the precancer 
lesions were p53-immunoreactive (Wang et al., 1993).
Alterations in the p53 status, assessed by molecular diagnostic strategies or 
immunohistochemical analysis of tissue-biopsy samples, sputum cytologic 
specimens, or cells collected from breast-nipple aspirates could be an early indicator 
of disease in screening programs that use cytologic specimens.
(ii) p53 in Cancer Prognosis
The presence of p53 mutation has been associated with poorest prognosis in 
some tumor types, in part through the loss of wild-type p53 tumor suppressor 
function. On theoretical grounds one might expect the loss of p53 function to be 
associated with more rapidly advancing disease, since such a loss might prevent 
arrest of the cell cycle at the G1 phase during which DNA repair can proceed before
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DNA is replicated. This would result in an increase in the frequency of mutations, 
particularly in the presence of exposure to mutagenic substances. Other hallmarks 
of genetic instability, such as gene amplification, have been shown to increase 
dramatically in cells lacking normal p53 (Yin el al, 1992). The unfavorable 
prognosis associated with p53 mutations can also be explained in part through the 
acquisition of oncogenic properties that have been observed with certain p53 
mutants, and in part through the ratio- or chemoresistance exhibited by cells lacking 
functional p53, due to the loss of the p53-dependent apoptotic pathway.
p53 mutations have been associated with aggressive behavior of various 
tumor types, including brain tumors (Sidransky el al., 1992b), bladder cancer 
(Fujimoto et al., 1992), breast cancer (Faille el al. 1994; Mazars el al., 1992), gastric 
cancer (Kakeji et al., 1993), head and neck cancer (Boyle et al., 1993), melanoma 
(Strech et al., 1991), ovarian cancer (Teneriello et al., 1993), prostate cancer 
(Navone e/a/., 1993), and thyroid carcinomas (Donghi et a/., 1993)
A consistent picture is now emerging correlating the loss of p53 function 
with shortened survival in patients with various types of cancer. In breast cancer, 
accumulation of p53 protein is correlated with both p53 mutation and shortened 
survival (Friedrichs et al., 1993; Thor et al., 1992), and has predicted increased 
overall survival in node-negative patients (Silverstrini et al., 1993). In colorectal 
cancer, p53 correlated with high risk for disease recurrence and decreased survival 
(Bosari et al., 1994). p53 accumulation in node-positive colon cancer is a useful 
independent prognostic factor (Zeng et al., 1994), and accumulation in soft tissue 
sarcomas is correlated with decreased patient survival (Drobnjak et al., 1994). p53 
mutation predicted shortened survival in gastric cancer (Martin et al., 1992), chronic 
myelocytic leukemia blast crisis (Nakai et al., 1994), non-small-cell lung cancer
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(Mitsudomi et al;, 1994), endometrial cancer (Soong et al, 1996), colorectal cancer 
(Goh et al., 1995), prostate cancer (Bauer et al., 1995), and renal cell carcinoma 
(Uhlman i?/a/., 1994).
These observation suggest that p53 might be one of the most promising 
molecular markers with regard to both our understanding of the mechanisms of 
carcinogenesis and linkage to clinical and biologic behavior of cancers. The 
detection of p53 alterations in these tumors may provide additional and independent 
prognostic information and serve as an indicator of high-risk patients for whom 
more aggressive adjuvant therapy is required.
(Hi) p53 in Cancer Treatment
Strategies to screen potential drugs to mimic the tumor suppressor function 
of p53 and to target other components of the p53 pathways are suggested by the 
development of assays that reflect biologic functions of the p53 protein: its binding 
to specific DNA sequences, its function as an inducer of apoptosis, and its ability to 
form complexes with cellular or viral oncoproteins. Since certain p53 missense 
mutants demonstrate an increase in potential oncogenic function (Dittmer et al.,
1993), the identification of drugs inhibiting this acquired activity is a second and 
complementary strategy to those focusing on the restoration of its tumor suppressor 
function.
Tumors With Wild-Type p53
The status of p53 in the tumor is an important prognostic and therapeutic 
response indicator. p53 mutation is generally associated with poorer prognosis in 
the most common types of human cancer (Harris and Hollstein, 1993). In addition
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Wilm’s tumor, retinoblastoma, testicular cancer, neuroblastoma, and acute 
lymphoblastic leukemia, which are some of the most curable cancers, rarely contain 
p53 mutations. Ionizing radiation or drugs such as doxorubicin, etoposide, or 
cisplatin produce DNA damage and p53-dependent apoptotic tumor cell response in 
laboratory studies (Clarke et ai, 1993; Perego et al, 1996). Clinical studies 
(Righetti et al., 1996; Rusch et al. 1995) testing the hypothesis that these anticancer 
therapies mediate their apoptotic response by a p53-dependent mechanism have so 
far provided equivocal results; these may be due to cell type differences or may 
indicate that anticancer therapies can also activate a p53-independent apoptotic 
pathway (Bracey er a/., 1995).
Other inducers of apoptosis are dependent on p53 and could be used in novel 
anticancer strategies. For instance, certain growth factors may act as survival factors 
of cancer cells so that their depletion or reduced activity would produce apoptosis. 
p53 may down-regulate the expression of survival factors including IL-6 (Camnan et 
al. 1995), or it may inhibit the cellular response to survival factors, such as insulin­
like growth factor (IGF), by upregulating IGF-BP3 (Buckbinder et al., 1995). 
Apoptosis activated by tumor necrosis factor (TNF) can be dependent on wild-type 
p53 (Gotlieb et al., 1994), a fact that suggests that cancers with wild-type p53 would 
be more sensitive to TNF therapy.
Tumors With Inactivated Wild-Type p53
As discussed earlier certain DNA viruses have oncoproteins that bind to p53 
and inactivate its function. Drugs that inhibit either the formation of these protein 
complexes or the degradation of p53 might have therapeutic benefit in tumors 
associated with human papilloma virus infections, such as cervical carcinoma. p53
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can also be inactivated by cellular proteins like mdm2. One approach would be to 
target the mdni2 gene directly by antisense or triple DNA helix therapy (Fox ei al, 
1995; Scanlon el al., 1995). A second strategy could involve drugs specifically 
inhibit mdm2 from binding to p53.
Tumors with Mutant p53
Since p53 constitutes an integral component of the apoptotic pathway 
induced by chemotherapeutic drugs or ionizing radiation, inactivation of the normal 
p53 function by genetic mutations might result in increased resistance to apoptosis 
and thus reduced sensitivity to chemotherapy or radiation. This has been 
demonstrated to be true by studies which showed that thymocytes with homozygous 
deletion of the p53 gene are more resistant to radiation and etoposide administration 
and do not undergo the norrnal apoptotic response to these agents (Clarke et al., 
1993; Lowe e/a/., 1993a; Lowe c/a/. 1993b). Consistent with these observations, 
mutant p53 has been shown to induce transcription from the promoter of the 
multidrug-resistance gene (MDRl), a gene that confers resistance to cytotoxic drugs 
(Chin et al., 1992). Thus, in tumors bearing mutairt p53, therapeutic agents such as 
Taxol, that mediate apoptosis by p53-independent pathways should be used.
The human adenovirus ElB gene encodes a 55-kilodalton protein that 
inactivates the cellular tumor suppressor protein p53. Three years ago, it was shown 
that a mutant adenovirus that does not express this viral protein (ONYX-015) could 
replicate in and lyse p53-deficient human tumor cells but not cells with functional 
p53. Ectopic expression of the 55-kilodalton EIB protein in the latter cells rendered 
them sensitive to infection with the mutant virus. Injection of the mutant virus into 
p53-deficient human cervical carcinomas grown in nude mice caused a significant
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reduction in tumor size and caused complete regression of 60 percent of the tumors 
(Bischoff et al., 1996). These data raised the possibility that mutant adenoviruses 
can be used to treat certain human tumors. In contrast, last year it was reported that 
ONYX-015 replicates independently of the p53 status in various tumor cell lines 
(Rothmann et al., 1998). In addition, the inliibition of p53-mediated transcriptional 
activation in wild-type p53 containing U20S cells, by overexpression of a 
transdominant negative p53 mutant, did not render the cells permissive for ONYX- 
015 replication. Finally, it was reported that, depending on the multiplicity of 
infection, the deleted virus is able to replicate in and to kill primary human cells. 
Thus, the molecular basis for the growth differences of ONYX-015 within different 
cell types remains to be determined.
1.4.12 Serum p53 Autoantibodies
In 1979, Dell et al., showed that the humoral response of mice to some 
metylcholanthrene-induced tumor cells was directed to the p53 protein (Dell et al.,
1979) . It was found later that animals bearing several types of tumors elicited a p53- 
specific immune response (Kress et al., 1979; Melero et al., 1979; Rotter et al.,
1980) . Based on this observation, Crawford et al., hypothesized that p53 could also 
be immunogenic in humans and they looked for p53 antibodies in sera of breast 
cancer patients (Crawford et al., 1982). Antibodies reacting with p53 were detected 
in 14 of 155 serum samples analyzed (9%), with no positives found among 164 
control sera from normal women. It as therefore suggested for the first time that p53 
might be altered in amount, type or presentation in breast tumors, and thus might 
become immunogenic. This hypothesis was later enhanced by the findings of 
another study, which showed that p53 antibodies were present in sera of children
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with a wide variety of tumors. The average frequency was 12% but this figure 
increased to 21% in children suffering from B-cell lymphomas (Caron de Fromentel 
eta l, 1987).
These studies, performed in the early eighties when p53 research was still at 
its infancy, did not draw considerable attention for many years. The discovery that 
the p53 gene is the most common target for molecular alteration in almost every 
type of human cancer and that p53 gene mutations can lead to p53 protein 
accumulation in tumor cells, revived the issue of p53 immunogenicity, and the 
phenomenon of p53 autoantibody generation attracted interest. Analysis of a large 
number of sera from patients with various types of cancer, revealed that the most 
immunogenic tumors are those of the lung (Guinee et al., 1995; Schlichtholz et al, 
1994; Wild el al., 1995; Winter et al., 1992), ovaries (Green et al., 1995), colon 
(Houbiers et al., 1995), breast (Mudenda et al. 1994; Peyrat et al., 1995; 
Schlichtholz et al., 1992), bladder (Lubin et al., 1993), head and neck (Bourhis et 
al., 1996) and esophagus (Von Brevero ei a/., 1996). Complete absence or very low 
frequency of p53 antibodies has been reported for some types of cancer, including 
malignant glioma (Rainov et al., 1995), myelodysplastic syndromes (Preudhomme 
et al., 1994), and myeloid leukemia (Preudhomme et al. 1994). The positive rates 
for autoantibodies correlate with the frequency of p53 mutations in these tumors 
(Lubin et al., 1995a).
The clinical significance of p53 autoantibodies in variety of cancer patients 
has been studied. In breast cancer the positivity rates vary between different groups, 
from 9-26% (Crawford et al., 1982; Mudenda et al., 1994; Peyrat et al., 1995; 
Schlichtholz et al., 1992). However, there is agreement that the presence of p53 
autoantibodies indicates disease aggressiveness and poor outcome in this type of
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cancer (Mudenda ei a/., 1994; Peyrat er a/., 1995; Schlichtholz c/o/., 1992). Recent 
work reports absence of p53 antibodies in breast cancer patients, claiming that the 
antibodies described in previous studies are most likely specific for another 53 kDa 
protein which is unrelated to p53 (Vojtesek et al, 1995). In colon (Houbiers et ai, 
1995) as well as in head and neck cancer (Bourhis et al., 1996), serum p53 
autoantibodies are also associated with unfavorable prognosis.
Some studies have investigated whether serum p53 autoantibodies could be 
used as tumor markers for early diagnosis. p53 autoantibodies were detected in sera 
of 4 of 36 non-affected individuals with a family history of breast cancer (Green el 
al., 1994). Recently, it was suggested that p53 antibodies may represent a new and 
sensitive tool for detection of preneoplastic and microinvasive bronchial lesions in 
patients with high risk for developing lung cancer, e.g, heavy smokers (Lubin et al., 
1995b). p53 antibodies were detected in serum samples of two heavy smokers 
without demonstrated cancer, who developed lung cancer 5 and 15 months later 
(Lubin et al, 1995b). Anotlier study sought to determine the prevalence and time of 
appearance of serum p53 antibodies during the pathogenesis of angiosarcoma of the 
liver (ASL) associated with occupational exposure to vinyl chloride (Trivers et al., 
1995). Of 92 workers occupationally exposed to vinyl chloride, p53 antibodies were 
detected in the serum of 5 of 15 workers with ASL (33%) and in 4 of 77 workers 
without clinically evident cancer (5%). In two ASL patients p53 antibodies were 
detected from 4 months and 11 years, respectively, prior to cancer diagnosis. More 
recently, a 5-year prospective study was conducted seeking to abate the clinical 
progression of chronic obstructive pulmonary disease (Trivers et al., 1996). During 
the course of this study 23 subjects developed cancer. p53 antibodies were detected
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in five of the cancer patients, four of whom had detectable p53 antibodies before 
diagnosis.
The mechanisms leading to p53 immunogenicity still remain unclear. In 
1992, Davidoff and his coworkers suggested that a 70 kDa heat shock protein 
(HSP70) was responsible for the antigenic presentation of mutant p53 to the immune 
system (Davidoff et al, 1992). Another study demonstrated that the development of 
such antibodies was dependent on the type of the mutation in the p53 gene; all p53 
antibody positive patients had p53 missense mutations, while no antibodies were 
detected in sera from patients whose tumor had stop, splice, splice/stop, or 
frameshift mutations (Winter et al., 1992). Soussi’s group has repeatedly shown 
that these autoantibodies are specific for the amino and carboxy terminus of the p53 
protein, two regions which are devoid of mutations (Lubin et al., 1993; Schlichtholz 
et al., 1992; Schlichtholz et al., 1994). This finding is in agreement with the 
observation that p53 antibodies recognize both wild-type and mutant p53 proteins in 
a similar way (Labrecque et al., 1993; Schlichtholz et al., 1992). The epitope 
localization was found to be similar in animals hyperimmunized with human p53 
(Legros et al, 1994). Given the similarities between the immune response against 
p53 in patients and hyperimmunized animals, it was suggested that p53 
accumulation is a major trigger for the development of the immune response in 
cancer patients. Lately, however, many studies have reported the presence of p53 
antibodies in sera of patients with undetectable levels of p53 in their tumor, as well 
as the presence of these antibodies in patients bearing wild-type p53 gene (Guinee et 
al., 1995; Von Brevern et al., 1996; Wild et al. 1995). Thus the issue of p53 
immunogenicity needs ifurther investigation.
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CHAPTER TWO
OBJECTIVES AND RATIONALE
Mammalian cells respond to DNA damaging agents by activating cell cycle 
checkpoints. These control mechanisms determine temporary arrest at a specific 
stage of the cell cycle to allow the cell to correct possible defects. At least two 
checkpoints monitor DNA damage: one at the Gl/S transition and the other at the 
G2/M transition. The G1 checkpoint prevents replication of damaged DNA, 
whereas G2/M transition is triggered by damaged and/or incompletely replicated 
DNA. Several findings have demonstrated that the product of the p53 tumor 
suppressor gene is responsible for the G1 checkpoint, and recent observations 
suggest that it may also play a role in regulating G2/M transition. In response to 
genotoxic stress, the levels of p53 protein increase and this increase either determine 
a transient arrest of cell cycle progression in the Gl/S or G2/M phase or triggers 
apoptosis.
Although, all p53 functions are legitimate cellular responses to genotoxic 
stress in mammalian cells, the choice of fate in each instance will depend on cell 
type, location, environment, and extend of damage. Therefore, every aspect of this 
molecule, including its biological and biochemical functions, its mutational status 
and levels of expression in human cancers, as well as its prognostic role, has been 
extensively studied in different mammalian cell lines. Although, the loss of function
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of p53 gene by different mechanisms has been largely documented in human 
hepatocellular carcinoma, its hepatocellular effects are poorly known, and 
observations from different laboratories are sometimes contradictory.
In this study, first we have examined the negative regulatory effects of p53 in 
Rb-negative HCC cell lines and compared its phenotypic effects with another tumor 
suppressor gene, p i6, both of which are known to be the upstream regulators of 
“retinoblastoma growth control pathway”.
In order to comprehend how the biochemical and genetic determinants 
activate p53 protein, a numerous studies have been performed concerning the 
structure-function relationship of the protein by different groups. All of which 
focused on the functions of individual domains of p53. These studies illustrated 
conclusively that p53 is composed of five functionally distinct domains.
Second, we have originated a novel experimental model to have a better 
understanding in structure-function alliance of p53 by dissecting the protein in 
functional units, namely domains, and generated human and Xenopus p53 hybrid 
proteins to further investigate the implications of the thermosensitive phenotype of 
p53 regarding its biological function.
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CHAPTER THREE
MATERIALS AND METHODS
3.1 GROWTH AND STORAGE OF BACTERIAL CELLS
5 ml of SOB medium in 15 ml screw capped tubes were inoculated with 
either a single bacterial colony picked from an agar plate or a loopful of bacterial 
freezer stock. The tubes were placed on a shaker (approximately 250 rotation per 
minute) in a 37°C incubator for overnight.
Bacterial cultures were stored at 4°C for up to 1 week. For long term storage 
of bacterial cultures 0.5 ml of overnight culture were mixed with 0.5 ml of sterile 
50% glycerol in a 1.8 ml sterile screw top blood vials and stored at -80°C.
The genotype of the bacterial strain (Tgl) used in this study is the following; 
supE hsdlS.5 thi A {lac -pro AB)F'[/raD36 pro AB^lacI^ lac Z  AM 15]. The genotype 
of the bacterial strain (DH5a) used in this study is the following: supEAA A/acU169 
(080 lacZEM.15) hsdRM recAX gyrA96 thi-\ relAX.
3.2 GROWTH AND STORAGE OF PLASMIDS IN TANSFORMED 
BACTERIA
Double stranded DNA was manipulated by the introduction of plasmid 
vectors into bacterial host cells (section 3.8). The existence of the ampicillin 
resistance gene in each of these vectors was exploited to select the transformed 
bacterial cells during growth of bacterial cultures. Bacterial cells transformed with
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plasmid vectors were streaked onto LBagar plates supplemented with 50 mg/ml 
ampicillin and grown overnight at 37°C in the inverted position. A single bacterial 
colony was transferred into 5 ml of LB broth containing 50 mg/ml ampicillin by 
using a sterile loop, and rotated at 37°C overnight. Cultures were stored at -80°C in 
25% glycerol (v/v) as a freezer stocks.
3.3 PREPARATION OF DOUBLE-STRANDED DNA
(i) Miniprep of plasmid DNA using QIAprep
The QIAprep miniprep procedure is based on alkaline lysis of bacterial cells 
followed by adsorption of DNA onto silica in the presence of high salt. The QIAprep 
miniprep procedure uses the modified alkaline lysis method of Birnboim and Doly 
(1979). Bacteria are lysed under alkaline conditions, and the lysate is subsequently 
neutralized and adjusted to high-salt binding conditions in one step, ready for 
purification on the QIAprep silica-gel membrane. For more details on alkaline lysis, 
please refer to QIAprep Miniprep Handbook.
This procedure typically yields 5 pg plasmid DNA.
(ii) Purification of supercoilcd plasmid DNA by equilibrium
centrifugation in caesium chloride/ethidium bromide gradients
Plasmids were first purified by QIAGEN Kit, which is based on a modified 
alkaline lysis procedure, followed by binding of plasmid DNA to QIAGEN Anion- 
Exchange Resin under appropriate salt and pH conditions. RNA, proteins , dyes, and 
low-molecular-weight impurities were removed by a medium-salt wash. Plasmid 
DNA is eluted in a high-salt buffer and then concentrated and desalted by 
isopropanol precipitation. DNA pellet was dissolved in 3.6 ml of TE buffer.
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To this supernatant which was transferred to a 6.5 ml ultracentrifuge tube, 
Ig/ml caesium chloride plus 180 |xl 10 mg/nil ethidium bromide were added, this 
gave a final concentration of ethidium bromide of approximately 300 pg/ ml. The 
tube was centrifuged at 60,000 rpm for 17 hours in a vertical ultracentrifuge rotor. 
The occupation of the supercoiled plasmid DNA of interest was observed in the 
central position of caesium chloride gradients. This DNA was removed from the 
gradients by using 21-gaugexl.5 inch hypodermic needle. Other bands were formed 
by host chromosomal DNA with nicked circular plasmid DNA and RNA at the top 
and bottom of the tube, respectively. After the recovery of plasmid DNA from the 
gradients, ethidium bromide was removed by the addition of an equal volume of 
butanol saturated TE buffer and through mixing. The upper layer which had 
absorbed some of the ethidium bromide was then removed. After repeating this step 
at least 5 times the DNA was dialysed in the cold room in 2 litres of TE buffer for 
overnight and then precipitated with two volumes of ethanol and resuspended in 500 
pi of TE buffer.
3.4 GEL ELECTROPHORESIS
(i) Horizontal agarose gels
The percentage and the type of agarose gels can differ according to the size of 
the fragment and the type of work required. DNA fragments of less than 1 kb were 
generally separated on 1.5% agarose gels, ,those of greater than 1 kb (up to 6 kb) 
were separated on 0.8% agarose gels. SeaKem LE was routinely used for analytical 
electrophoresis of nucleic,acids. Low melting temperature agarose was used for 
preparative electrophoresis of DNA fragments. For the recovery of DNA fragments 
from low melting gel. Gene Clean Kit supplied by Biorad was used.
81
(ii) Vertical SDS-polyacrylamide gels
The glass plates were assembled according to the manufacturer’s instructions 
(Bio-Rad). For most of the experiment 10% acrylamide gel was used unless 
otherwise is indicated. The polymerization reaction of the gel mixture was catalyzed 
by the addition of ammonium persulphate and TEMED.
p S ] labelled proteins were visualized by autoradiography after fixation of 
the gel for 1 hour in 40% methanol, 10% glacial acetic acid, and dryed at 80°C for 1 
hour.
3.5 AUTORADIOGRAPHY 
Exposure of polyacrylamide gels
[^ ^S] gels were fixed and dried as described above. These were exposed to X- 
ray film by allowing the gel contact directly with film is a low energy B-jemitter 
and its B particles carmot penetrate efficiently barriers such as Saranwrap). These 
were placed in a light proof cassette and exposed overnight or several days at -80°C.
[^ ^P] acrylamide gels were transferred to a plastic backing and wrapped in 
Saranwrap. [^ P^] emitters do not need to be fixed before autoradiography as their 
radioactive emissions can penetrate plastic or water. The wrapped material was then 
placed in a light proof cassettes containing a sheet of X ray film. To produce 5-fold 
enliancement of the image, pairs of intensifying screens were used.
3.6 IN VITRO MANIPULATION OF DNA 
(i) Restriction endonuclease digestion
Restriction enzyme digestions were routinely done in 20 pi volumes with 
typically 0.1-10 pg DNA obtained by the miniprep procedure (section 3.3 (i) or from
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Qiagen (section (3.3 (ii)) or Caesium chloride (section 3.3(ii)) preparations. AH the 
enzymes and buffers were obtained from NewEngland BioLabs. Digestion reactions 
were performed with excess of enzyme (up to 5 fold) for 2 hours at 37°C unless 
stated.
In cases where more than one enzyme was used DNA was digested with first 
enzyme and verified on the gel, and then the second enzyme was added into the same 
reaction tube if they had the same buffer requirements. If the buffer requirements for 
the enzyme were different, the DNA first incubated with an enzyme requiring the 
lowest ionic strength buffer, then the salt concentration of the reaction mixture was 
adjusted according to the requirements of the next enzyme. If the incubation 
temperature was different, the DNA was incubated first with a high temperature, and 
then with a low temperature.
In cases of high amount of DNA, DNA was digested with approximately a 3- 
5-fold excess of restriction enzymes, for overnight.
(ii) Dephosphorylation of vector DNA
To prevent the religation of digested vector, DNA was routinely 
dephosphorylated by shrimp alkaline phosphatase (SAP). After heat inactivation of 
an enzyme, 1 pg vector DNA was incubated with lOx dephosphorylation buffer and 
1 unit of phosphatase alkaline shrimp at 37°C for 10 minutes, and then SAP was 
inactivated at 65°C for 15 minutes. For ligation 50 ng of dephosphorylated vector 
DNA was used. SAP is the product of Boehringer Mannheim.
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(iii) Ligation of DNA fragments
DNA fragments either cut from low melting temperature agarose or recovered 
from standard agarose gel by using Gen Clean Kit, or directly used after digestion to 
perform the ligation of DNA. For forced cloning (where the termini of the insert 
DNA carried two different protruding end), approximately 3 fold of insert was mixed 
with vector DNA and reaction was carried at 16°C for overnight with the presence of 
T4 DNA ligase Buffer and T4 Ligase. In cases of Rapid Ligation, the Rapid Ligation 
Kit (from Boehringer Mannheim) was used, and the reaction was completed after 30 
minutes of incubation at room temperature. The ligation reaction was stopped by 
heating at 65°C for 10 minutes. The ligation reaction was purified with the High Pure 
PCR Product Purification Kit from Boehringer Mannheim. 1/10 volume of the 
ligation reaction was used for electroporation. The products from the DNA ligation 
reaction was analyzed by agarose gel electrophoresis (1/4 of the ligation reaction), by 
the addition of 1/10 volume of gel loading buffer.
(iv) Mung Bean Nuclease Treatment
This single strand specific DN.^ or RNA endonuclease which degrades 
single-stranded extensions from the ends of DNA or RNA molecules, leaving blunt, 
ligatable ends was used for the treatment of p53 Human Cassettes which yielded two 
protein products instead of one, coming from the promoter region of the vector pClO.
Mung Bean Nuclease is the product of New England Biolabs.
DNA was digested with Notl and Nhel enzmes and 1.0 unit of Mung Bean 
Nuclease per pg of DNA was added into the reaction tube. It was incubated at 30°C 
for 30 minutes. Enymes were inactivated by addition of SDS to 0.01%. DNA was 
recovered by ethanol precipitation. Recovered DNA was religated by Rapid Ligation
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Kit and transformed into TGI compotent cells by electrophoration method. After the 
selection of transformed bacteria on agar plates, mini preps were made from putative 
transformant and digested with both restriction enzymes that would produce 
diagnostic DNA fragments. DNAs which were not digested with both enzymes were 
used directly for transfection into Saos2 cells and Western Blot was performed to see 
if really these Mung Bean Neclease treated plasmid DNAs can only produce one 
single protein product. This mini prep DNA was also used for sequencing reaction 
for the verification of the removal of both enzyme sites from vector, which should 
normally break the frame that comes from the vector.
3.7 TRANSFORMATION OF BACTERIAL CELLS
(i) Preparation of competent cells
Two methods were used to prepare competent E.coli strain TGI for 
transformation.
Calcium chloride treatment method: 2 ml culture was grown in LB medium 
overnight at 37°C with vigorous shaking. The following day 100 pi overnight 
culture was inoculated into 1ml LB medium and grown at 37°C for 2 h, till the 
density of cells rich to the ODeoo^O.b. Cells were harvested by centrifugation at 
5000 rpm for 5 minutes at 4°C and gently resuspended in 10 ml ice-cold O.IM CaCL. 
After 1 hour incubation on ice, cells were centrifuged at 5000 rpm for 5 min and the 
pellet was resuspended in 2 ml ice-cold 0.1 M CaCb.
Since I have often found that transformation rates were much lower with 
frozen competent cells, feesh competent cells were prepared routinely and kept at 
4°C up to 24 hours after preparation.
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Electro-competent cells : 2 ml culture was grown in SOB-Mg+2 medium 
overnight at 37°C. The following day 100 ml of SOB-Mg+2 medium was inoculated 
with 100 fxl of overnight culture and grown at 37°C with vigorous shaking until the 
OD6oo=0.6-0.8. Cells were centrifuged at 4000xg for 15 minutes at 4°C and the 
pellet was washed with 100 ml of ice-cold 10% glycerol. After centrifugation for 15 
minutes at 4000xg at 4°C, the pellet was washed with 50 ml of ice-cold 10% 
glycerol. Following washing was carried out in 25 ml of ice-cold 10% glycerol. The 
final pellet was dissolved in 400 fxl of ice-cold 10% glycerol. Cell suspension was 
divided into 40 [xl aliquots and used immediately.
(ii) Transformation
2 fxl ligation reaction (approximately 20 ng) containing the insert and vector 
DNA was mixed with competent cells and incubated on ice for 30 min. The cells 
were heat shocked at 42°C for 90 seconds, then transferred to ice immediately for 2 
minutes. The cells were diluted with 1 ml SOC medium and incubated at 37°C for 
Ih, shaking at 225 rpm. After incubation 100 [xl of each transformation was plated 
onto LB agar plates containing 100 |xg/ml ampicillin.
Alternatively, E.coli pulser Transformation apparatus (Bio-Rad) was used for 
electro-transformation of cells according to the manufacturer’s instructions with the 
pulse of 2.5 kV. The cells were diluted with 1 ml of SOC medium and incubated at 
37°C for 1 hour, shaking at 225 rpm. After incubation 100 p,l of each transformation 
was plated onto appropriate antibiotic agar plate and incubated at 37°C for overnight 
for the selection of antibiotic resistance transformants.
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(Hi) Confirmation of the transformed cells containing the correct 
recombinants
In order to confirm that transformants with the desired plasmid constmct had 
occurred plasmid minipreps were made from putative transformants (section 3.3 (i)) 
and digested with restriction enzymes that would produce diagnostic DNA 
fragments. These were electrophoresed on an agarose gel. Positively transformed 
bacterial strains were stored as -80°C glycerol freezer stocks.
3.8 SEQUENCING OF DOUBLE STRANDED DNA
The primers used for DNA sequencing, and their positions on the p53 
Cassettes are shown at Table 3.1. The sequencing reactions were performed using 
the Kit PRISM™ BigDye® Ready Reaction Temiinator (PE Biosystem). For this 1 
pg of plasmid DNA or 90 ng PCR product was used. Plasmid DNA was heated 
during 30 minutes at 55-60°C before adding to the mix; 4 pi Big Dye, 2 pi Dilution 
Buffer (TrisHCl 400 mM, MgCb 20 mM), 3.2 pmol Primer. The mix was completed 
to 20 pi with H2O. For cycling condition, each reaction was initiated with a 
dénaturation step at 95°C for 5 min. The cycling consisted of dénaturation at 95°C 
for 30 seconds, annealing at 50°C for 20 seconds, extension at 60°C for 4 minutes, 
and it was repeated for 35 times. DNA was subsequently precipitated with Ethanol 
precipitation and DNA pellet was dissolved in TSR (Template Suppression Reagent). 
Heat denatured DNA was chilled on ice for 2-3 minutes and then transferred to the 
sequencer tubes. The samples were loaded in the sequencer. For Capillary 
electrophorese ABI PRISM 310 Genetic Analyzer was used.
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3.9 OLIGONUCLEOTIDES
Oligonucleotides used in this study are listed in Table 3.1. All the 
oligonucleotides were synthesized by Genset Corp.
3.10 POLYMERASE CHAIN REACTION
Polymerase chain reaction had been used during this work for the generation 
of second strand of cDNA of both human and Xenopus p53. A standard 50 p.1 
reaction set up in a 0.5 ml microfuge tube. 2-5 pi DNA out of 33 pi of first-strand 
cDNA product was used as a template DNA. 20 pM each of upstream and 
downstream primers were included (see Table 3.1) with 20 mM dNTP into a reaction 
tube. For each reaction 5 units of Pfu polymerase was used with appropriate 5 pi of 
lOx buffer. For positive control 100 pg DNA template was used. No DNA included 
into the negative control reaction tube. Cycling conditions are the following;
1 cycle; 94°C for 2 minutes
30 cycles; 94°C for 30 seconds 
55°C for 30 seconds 
72°C for 2 minutes
1 cycle; 72®C for 10 minutes
3.11 CELL CULTURE
All cell lines used in this study were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% FCS and ImM glutamine. The 
antibiotics penicillin and streptomycin (50 pg/ml) were used to supplement the 
medium when necessary. The cells were passaged before reaching confluence. The 
growth medium was aspirated and the cells were washed once with FCS free
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medium. The monolayer cells were removed from the surface using trypsin solution. 
Fresh medium was added and the suspension was pipetted gently to disperse the 
cells. The cells were transferred to fresh flasks using different dilutions (from 1 : 20 
to 1 :5) depending on the requirements and incubated at 37°C in an incubator with an 
atmosphere of 5% CO2 in air.
All media and solutions used for tissue culture were kept at 4°C (except stock 
solutions) and warmed to 37°C before use.
3.12 IN VITRO TRANSLATION
Plasmids were in vitro translated with [^^S]-methionine using the TNT T7 
Quick Coupled Transcription/Translation System (Promega). This system combines 
the RNA Polymerase, nucleotides, salts, and Rnasin Ribonucléase Inhibitor with the 
reticulocyte lysate solution to form a single TNT Quick Master Mix. 1 i^g of plasmid 
DNA template was added into 40 p.1 TNT Quick Master Mix in the presence of [^^S]- 
methionine. The reaction was incubated at 30°C for 2 hours. The percentage of 
[^ ^S] incorporation was determined by TCA precipitation as described in Technical 
Manual Handbook. The translation product was verified on SDS-polyacrylamide 
mini-gels. For immunoprécipitation 20000 cpm of in vitro translation product was 
used.
For more details please refer to TNT Quick Coupled Technical Manual 
Handbook.
3.13 mRNA PURIFICATION AND GENERATION OF cDNA
For the extraction and purification of mRNA from cell lines QuickPrep Micro 
mRNA purification Kit (Amersliam Pharmacia Biotech) was used. This Kit
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combines guanidinium thiocyanate (GTC) and oIigo(dT)-cellulose chromotograpy in 
a spun-column.
First-strand cDNA was prepared using Ready-To-Go You-Prime First-Strand 
Beads which utilize Moloney Murine Leukemia Virus (Amersliam Pharmacia 
Biotech). The first-strand reaction was primed with random hexanier primer pd(N)6. 
In this procedure, the double stranded RNA :cDNA heteroduplex made during the 
first-strand synthesis is heat denatured to allow the cDNA strand to be used as a 
template for polymerization. For the PCR amplification 2-5 pi of first-strand cDNA 
product was used.
3.14 TOTAL RNA EXTRACTION
For total RNA extraction from cultured cells, QuickPrep™ Total RNA 
extraction Kit was used (Amersham Pharmacia Biotech).
This Kit is based on procedure that combines the disruptive and protective 
properties of guanidium thiocyanate (GTC) with selective precipitation and 
centrifugation using lithium chloride and cesium trifluoroacetate (CsTFA). The 
RNA isolated with QuickPrep Total RNA Extraction Kit was quantified by 
spectrophotometry, and visualized under native conditions using a phosphate gel and 
ethidium bromide, and then used for Northern blot analysis .
For more details please refer to QuickPrep Total RNA Extraction Kit 
Instructions Book.
3.15 TRANSIENT TRANSFECTION ASSAY
Cell transfection was done either by using the calcium phosphate 
precipitation method (for Western blotting and Immunoprécipitation) or with
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DMRIE-C Reagent (for Luciferase assay). 5x10^ cells for 6 cm PD, 3x10^ cells for 
10 cm PD, 2x10^ cells for 24 well plates were prepared 24 hours before transfection. 
For 6 cm dishes 5 pig of plasmid, for 10 cm dishes 10 pg of plasmid was transfected. 
Most of the DNA used for transfection was prepared by equilibrium centrifugation in 
caesium chloride/ethidium bromide gradients. DNA was mixed with 2.5 M CaCl2. 
2XHEPES (10 g HEPES, 16 g NaCl, 0.74g KCl, 0.25 g Na2HPO4,2H20,2 g Dextrose 
for 1 liter, pH 7.15) was added to the above solution through bubbling technique with 
pipetting. This mixture was allowed to incubate for 20-30 min at room temperature. 
The precipitate was added to the culture drop by drop and the plate was swirled 
gently to distribute the precipitate evenly. Cells were washed twice with DMEM 
minus serum 6-8 hours after addition of the DNA precipitate and then refed with 
DMEM plus 10% fetal bovine serum. Cell extracts were prepared 30-36 h later.
3.16 GENERATION OF STABLE CELL LINES
Cells were transfected with 10 pg of DNA with calcium phosphate 
precipitation method when the cells reach 50% confluency. After 6-8 hours, cells 
were washed with DMEM serum free medium and then refed with DMEM plus 10% 
fetal bovine serum. Next day selection was initiated by addition of 400 pg/ml 
neomycin into cells. Cells were allowed to die until the colony formation was 
observed. Single clones were selected and grown initially at 96 well plates in the 
presence of both neeomycin and tetracyclin, and then transferred to 24 well plates, 
and then 6 well plates, and then 10 cm petri dishes.
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3.17 LUCIFERASE ASSAY
For Luciferase assay cells were routinely cotransfected with DMRJE-C 
(Gibco BRL Life Science) in 24 well plates. 1 pg reporter plarnid with 50 ng various 
plasmids of interest were mixed with OPTIMEM medium (Gibco BRL Life 
Science). 2 pg DMRIE-C was added into DNA mixture and kept at room 
temperature for 30 minutes. Cells were washed twice with OPTIMEM and DMRIE- 
C/DNA mixture was added into cells. After 5 hours of transfection, cells were 
washed twice with incomplete medium and following the addition of 2 ml of 
complete medium, cells were kept either at 37°C or 32°C for overnight. After 24 
hours of transfection, cells were washed twice with IxPBS and extracted with 
(250pl/well) lysis buffer (10 mM Tris FICl, pH 7.8; 150 mM NaCl; 1,5 mM MgCL; 
0.6% NP40; ImM DTT; ImM PMSF). Reaction buffer was prepared (lysis buffer; 
ImM ATP; ImM Luciferine (Promega)) and kept at room temperature for 30 
minutes before the reaction started. 100 pi of protein extract was transferred into 5 
ml SARSTEDT tube and placed into luminometre for reading. For each reaction, 
100 pi of reaction buffer was injected. Recombinant luciferase (Promega) was 
routinely used as a positive control.
3.18 WESTERN BLOT ANALYSIS
Adherent cells transfected either transiently or stably were washed by 
removing the culture supernatant and adding precooled PBS twice to remove any 
remaining serum proteins from the culture medium. Upon removal of the PBS, 500 
pi or 1 ml of lysis buffer was added to 6 cm or 10 cm PDs, respectively. Cells were 
scrapped to one side of the dish with a suitable device (e.g. a rubber policeman). 
Lysates were kept on ice for 30 minutes, and then centrifuged for 30 minutes at 4°C
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at ISOOOxg. The Bio-Rad Protein Assay was used to dose the protein lysates. 50 pg 
of protein lysate was mixed with loading buffer, denatured by heating at 100°C for 
10 min and loaded onto 10% polyaciylamide gels. After electrophoresis at 220V/40 
mA for 4 hours the proteins were transferred to a nitrocellulose membrane by 
electroblotting at 12V for 1 hour. Protein transfer was verified by PonceauS 
coloration for 5 minutes. Membrane was washed 3 times with 0.3% TCA for 2 min. 
The membrane was immediately treated for 1 hour in blocking solution and probed 
for 2 hours at room temperature with primary antibody. After washing 5 min 5 times 
with wash solution, the membrane was incubated for 1 hour with the secondary 
antibody. The membrane was washed 5 times at room temperature with wash 
solution for 5 minutes. After the final washing the blot was incubated for 5 min with 
Super Signal Kit (Pierce). The chemiluminescence emitted was captured on X-ray 
film (1 min-1 hour).
3.19 IMMUNOPRECIPITATION ANALYSIS
Cells were washed twice with serum free medium 36 hours after calcium 
phosphatase precipitation. Before metaboiically labeling, cells were starved in 
methionine free medium for 1 hour. Cells were metabolically labeled for 2 hours in 
the following solution : 200 pCi/PD [^ ^S] methionine, 10% fetal calf serum and 1% 
glutamine in methionine-free Dulbecco’s modified Eagle’s medium, and kept at 
32°C or 37°C in a 5% CO2 incubator. Labeling of 6 cm PDs were done in 2 ml total 
volume of solution.
The cells then were washed twice with ice-cold IxPBS, lysed in 500 pi of 
RIPA buffer (150 mM NaGl, 1 mM EDTA, 10 mM Tris, pH 8.00, 1% NP40, 1% Na 
Deoxycholate) with protease inhibitors. To reduce background caused by
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nonspecific adsorption of irrelevant cellular proteins to Protein G Agarose, a 
precleraing step was done, by addition of non-immunized rabbit serum and protein G 
agarose suspension to the sample and incubated at 4°C for overnight on a rocking 
platform. Following day, precleaned supernatant was recleared for an additional 3 
hours in the presence of Protein G Agarose suspension at 4°C on a rocking platform 
and beads were pelleted by centrifugation for 10 minutes at 12000xg in a microfuge, 
and then immunoprecipitated with an appropriate volume of specific antibody for 2 
hours on ice. This was followed by the addition of homogeneous Protein G Agarose 
suspension to the mixture and incubation at 4°C for 1 hour on a rocking platform. 
Samples were collected by centrifugation for 5 minutes at 12000xg in a microfuge. 
Supernatant was removed carefully, and resuspended in 1 ml of washing buffer 
(RIPA), and beads were pelleted by centrifugation for 5 minutes. This washing step 
was repeated 3 times. After the final wash, 50 pi of Laemnli buffer (62.5 inM Tris- 
HCl, pH 6.8, 5% P-Mercaptoethanol, 2% SDS, 15% Glycerol, 0.001% Bromophenol 
blue) was added to the agarose pellet. Proteins were denatured by heating to 100°C 
for 10 minutes. Protein G Agarose was removed by centrifugation for 5 minutes at 
12000xg at room temperature in a microfuge. Supernatant was transferred to a fresh 
tube. Analyzed by SDS-polyacrylamide gel electrophoresis.
3.20 COLONY FORMING ASSAY AND IMMUNOHISTOCHEMISTRY
Saos2 cells were transfected with neomycin resistant appropriate DNA by 
calcium phosphate precipitation method. After 8-10 hours cells were splitted into 
3x25 cm flasks with medium containing 800 pg/ml G418. Cells were kept 
approximately 4 weeks, until only the neomycin resistant colony formation occurred.
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Cells were washed 3 times with 5 ml IXPBS, and then fixed in 50% acetone, 
50% Methanol at room temperature. After washing the cells again 3 times with 5 ml 
IXPBS, saturation took place with 3%BSA for 15 min at room temperature. 
Incubation with primary antibody diluted in PBS with 0.5% BSA was carried out at 
4°C for overnight. Following day, cells were washed with IXPBS 3 times. 2 drops 
of Blocking serum (Vector laboratories) was mixed with 5 ml of PBS and then two 
drops of biotinylated antibody was added. During the incubation of cells with 
secondary antibody at room temperature for 30 minutes, Avidin streptavidin complex 
was prepared (VECTASTAIN ABC R eagent). Incubation with 
Avidine/streptavidine-peroxidase conjugate followed another 3 washings with PBS. 
The biotinylated antibody, avidin-HRP and substrate were components of the 
VectastainR ABC kit commerciaally available from Vector laboratories (Burlingame, 
CA). Cells were incubated at room temperature for 4 min with diaminobenzidine 
(DAB) solution. After washing with water, cells were counterstained with 
hematoxylin for 2 minutes, dehydrated, cleared and counted.
3.21 NORTHERN BLOTTING
Total RNA were extracted by guanidium isothiocyanate method. RNA 
samples were separated by electrophoresis through denaturing formaldehyde agarose 
gel and transferred to nylon membrane (Hybond-N; Amersham). Prehybridization 
was performed at 42°C for ON with at least 200 pi of prehybridization solution per 
cm^ of membrane. The prehybridization buffer was replaced with a small volume of
• “I?fresh hybridization buffer (the same as prehybridization buffer) containing [ P]- 
labeled p21^"’' cDNA as described (Rouault et al., 1996). DNA probes were 
denatured by heating at 100°C for 10 minutes before transferred to the hybridization
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solution. This was incubated at 42°C in the Hybaid oven. The membrane was 
washed twice in 2xSSC, 0.5%SDS for 30 minutes at 65°C. The membrane was 
placed in Saranwrap and subjected to autoradiography.
3.22 ANTIBODIES
Antibodies to pRb (clone IF8 from Santa-Cruz, clones Ab-5 and Ab-6 from 
Calbiochem), p53 (clone Ab-1 from Calbiochem and HR231; from T. Soussi, Paris, 
France), p21 (Ab-1 to wafl from Calbiochem), mdni2 (2A10; a gift from
B.Vasylyk, Strasbourg, France), bax (N-20 from Santa Cruz), p i ( A b - 1  from 
Calbiochem) and cyclin E (Ab-1 from Calbiochem) were used for the first study 
(Chapter 4). The antibodies used for the second study (Chapter 5) are listed below.
Name Epitope
location
Antigen used 
For immunization
Isotype Other species 
recognition
Recognition of
Cassettes
D07 21-25 Fluman p53 IgG2b ? HCassl
HR231 371-380 Human p53 IgG2b Yes HCass5
H015.4 86-95 Human p53 IgG2a No HCass3
PAb240 213-217 Mouse p53 IgGl Yes HCass3
X77 16-25 Xenopus p53 IgGl Yes HCassl,XCassl
X36 349-360 Xenopus p53 IgGl No XCass5
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3.23 COMPUTING
For the design of the mini-gene constructs a variety of programs were used 
from the Internet. BCM Gene Finder, Gen Scan, The Sanger Genomic Anaysis Web 
Tools were the most routinely used ones for the findings of the perfect exon-intron 
boundaries of the both human mdXenopus p53 mini-genes.
3.24 MEDIA FOR BACTEWAL CELLS
LB medium
Bactotryptone 
Yeast extract 
NaCl
lOg
5g
lOg for 1 liter (pH 7.5)
Top Agar LB+agar 0.7% final
SOB
Bactotryptone 
Yeast extract 
MgS04,7H2O 
NaCl
soc
SOB+glucose 20 mM final
20g
5g
5g
0.5 g for 1 liter (pH 7.0)
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CHAPTER FOUR
COMPARATIVE STUDY OF p53 AND IN GROWTH
CONTROL IN HEPATOCELLULAR CARCINOMA CELLS
4.1 INTRODUCTION
Hepatocellular carcinoma (HCC), which is etiologically associated to 
hepatitis B virus (HB V), hepatitis C virus (HCV) and aflatoxins, is one of the most 
frequent cancers world-wide (Strauss et al, 1995). Genetic studies revealed so far 
that a dozen of genes are altered in these cancers. These genetic alterations (mostly 
somatic) are related to at least four different pathways, including DNA damage 
response (p53 gene), cell cycle regulation (retinoblastoma, plb' '^ '^*“ and cyclin D 
genes), TGF-P (M6P/1GF2R, SMAD2 and SMAD4 genes) and wnt ((3-catenin and 
APC genes) signaling pathways (Ozturk, 1999). ,
The p53 was the first tumor suppressor gene found to be mutated in HCC 
(Bressac et al, 1990). Many reports now indicate that the p53 gene is somatically 
mutated in about 30 % of HCCs worldwide (Ozturk, 1999). Both the frequency and 
the type of p53 mutations are different depending on geographical location and 
suspected etiology of these tumors. An HCC-specific codon 249 mutation (AGG- 
>AGT leading to p53-249Ser), suspected to be induced by aflatoxins, was found in
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most HCCs from geographical areas with high incidence of HCC and a high risk of 
exposure to aflatoxins (Bressac et al, 1991; Hsu et al, 1991). The frequency of all 
p53 mutations in HCC varies between 15 % in Europe and 42 % in China (Ozturk, 
1999). On the other hand, physical and functional interaction between p53 protein 
and Hbx viral antigen has been reported. Based on these experimental evidence, 
viral inactivation of wild-type p53 in HCC has been proposed (Wang et al, 1994; 
Ueda et al, 1995; Elmore et al, 1997).
Most of the p53 mutations in HCC, like in other cancers occur in the central 
DNA binding domain leading to a loss of its transcriptional activity. The p53 protein 
functions to integrate cellular responses to stress such as exposure to DNA damaging 
agents and hypoxia (Levine, 1997). Under normal conditions, p53 is rapidly 
degraded in cells by a mechanism that involves p i4'^'^ and mdm-2 proteins. Upon 
cellular stress, p53 is modified post-transcriptionally, dissociates from mdm-2 
protein, becomes more stable, migrates into nucleus and transactivates its target 
genes (Levine 1997; Prives 1998). One of the outcome of p53 activation is cell 
cycle arrest at G1 phase mediated by p21 protein, which is an inhibitor of 
different cyclin-dependent kinases, including those involved in the phosphorylation 
of the retinoblastoma protein (pRb). The so called "p53-retinoblastoma pathway" 
implicates an important role for pRb and its two related gene products, p i07 and 
p i30 in p53-mediated Gl-S phase regulation (Levine 1997). p53 also plays a role in 
triggering apoptosis under several different physiological conditions. The apoptotic 
role of p53 appears to be limited to certain cell types such as hematopoietic cells. 
There is also experimental evidence that p53-dependent apoptosis can occur as a
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most HCCs from geographical areas with high incidence of HCC and a high risk of 
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Most of the p53 mutations in HCC, like in other cancers occur in the central 
DNA binding domain leading to a loss of its transcriptional activity. The p53 protein 
functions to integrate cellular responses to stress such as exposure to DNA damaging 
agents and hypoxia (Levine, 1997). Under normal conditions, p53 is rapidly 
degraded in cells by a mechanism that involves and mdm-2 proteins. Upon
cellular stress, p53 is modified post-transcriptionally, dissociates from mdm-2 
protein, becomes more stable, migrates into nucleus and transactivates its target 
genes (Levine 1997; Prives 1998). One of the outcome of p53 activation is cell 
cycle arrest at G1 phase mediated by p21^''’* protein, which is an inhibitor of 
different cyclin-dependent kinases, including those involved in the phosphorylation 
of the retinoblastoma protein (pRb). The so called "p53-retinoblastoma pathway" 
implicates an important role for pRb and its two related gene products, p i07 and 
pl30 in p53-mediated Gl-S phase regulation (Levine 1997). p53 also plays a role in 
triggering apoptosis under several different physiological conditions. The apoptotic 
role of p53 appears to be limited to certain cell types such as hematopoietic cells. 
There is also experimental evidence that p53-dependent apoptosis can occur as a
100
response to the expression of a viral or cellular oncogene or the absence of a critical 
tumor suppressor gene product such as pRb (Levine 1997). Studies on the response 
of HCC cells to p53 are limited in number and the observations from different 
laboratories are sometimes contradictory. For example, it was reported that p53 acts 
as a growth suppressor in Hep3B cells (Puisieux et al, 1993) and p53-mediated 
apoptosis was reported in the same cell line in several reports (Zhuang et a l 1995; 
Roemer and Mueller-Lantzsch 1996; Mitry et a l, 1997). However, these 
observations were challenged by Friedman et a l (1997), who reported that Hep3B 
cells were resistant to p53-mediated growth arrest and apoptosis.
The gene, which is located at chromosome 9p, codes for two
alternatively spliced transcripts (Chin et al, 1998). One of the transcripts is for p i6 
protein, an inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6, whereas the other 
is pl4'^^'' protein which regulates p53 stability (Prives 1998; Sherr and Roberts 1999). 
The p i s t a t u s  in FICC has been studied extensively. Both germ-line and somatic 
mutations of pi gene were found in HCC patients. It was also reported that about 
50 % of HCC display de novo méthylation of p lb’’^ ’^ '’'* gene, as observed in many other 
cancers (Ozturk, 1999). As an inliibitor of CDK4 whose main substrate appears to be 
pRb protein, plô'^^“*® protein is an antagonist of cyclin D for CDK4 activation (Sherr 
and Roberts, 1999). Therefore, it is not surprising that retinoblastoma gene mutations 
and cyclin D gene amplifications also occur in HCC, albeit at lower frequencies (Ozturk, 
1999). Thus, the main consequence of p i g e n e  alterations is considered to be a 
loss of CDK4 inhibition. As a result, the phosphorylation of pRb by CDK4 is no longer 
regulated leading to an increase in "free E2F" transcription factors involved in the
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progression of G1 phase of cell cycle and Gl/S transition. The expression of plG'^^'’" 
progressively increases as cells undergo senescence (Sherr and Roberts 1999). This 
suggests that the loss of function in HCC is related to cellular immortalisation.
However, the effects of pl6'^'^‘'‘' protein in hepatoma cells have not been reported yet. It 
is also unknown whether and how p i6' '^ '^’® gene alterations affect the cellular functions 
of p i 4^ *^  ^ protein (the product of alternatively spliced transcripts of the same gene), 
whose main role appeal's to be the activation of p53 protein.
In this study, we compare the effects of p53 and p i6''^ '^ '*'’ proteins on Hep3B and 
its derivative cell lines. Hep3B is a differentiated HCC cell line with integrated HBV 
DNA and deleted p53 gene (Bressac et al., 1990). Its derivative Hep3B-TR is a TGF- p - 
resistant clone due to a homozygous deletion of TGF- p - receptor type II (Inagaki et al., 
1997). The status of retinoblastoma gene in Hep3B cell line is a matter of debate 
(Friedman et al, 1997; Puisieux el al, 1993). Our main goal was to know whether 
plgiNK4a proteins, known to be upstream regulators of “retinoblastoma growth'
control pathway”, differ in their phenotypic effects in these cells. We demonstrate that 
p53, but not p i i s  able to suppress the growth of these HCC cells by cell cycle 
arrest at Gl/S transition. We provide evidence that the resistance of cells to pi 
protein is correlated with the lack of pRb protein. The same observation also 
demonstrates that p53-induced growth arrest in FIep3B-TR cells occurs independently 
from the retinoblastoma growth control pathway.
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4.2 HEP3B HEPATOMA CELLS ARE RESISTANT TO
OVEREXPRESSION
The plasmid pAUCT/CCW was constructed by A. Fattaey (Charlestown, 
MA, USA). This plasmid contains a Tet Repressor-Vpl6 fusion cDNA under the 
conrol of CMV promoter. It also contains a multiple cloning site downstream to a 
promoter sequence composed of a Tet operator and CMV TATA box. The 
pAUCT/CCW also contains a Neo*^  gene allowing the selection of stable clones. A 
pBluescript plasmid containing human p i6 cDNA (a gift from A. Samarut, 
Lyon, France) was used for cloning of pl6 cDNA into pAUCT/CCW plasmid. 
The p i6 cDNA insert was removed from the pBluescript plasmid by EcoRI-XhoI 
restriction enzyme digestion. Purified p i c D N A  fragment was then ligated 
with pAUCT/CCW plasmid, which was previously linearized by digestion with 
EcoRI and Xhol restriction enzymes to obtain pAUCT-plb'^* '^*® plasmid. In the 
presence of tetracycline, the Tet repressor-Vpl6 fusion peptide suppresses the 
expression of p i p r o t e i n .  In the absence of tetracycline, the suppressive 
function is abolished.
Hep3B cells were stably transfected with pAUCT-plb'^'^'’“ plasmid and 
stable clones were selected in the presence of tetracycline (5 pg/ml) and G418 (400 
pg/ml). Randomly selected clones from pAUCT-plb" '^ '^** transfections into Hep3B 
cells were first analyzed for tetracycline-regulated expression of pi 6’*^“** protein by 
western blotting. Saos-2 cell line extracts were used as a positive control. As shovra 
in figure 4.1, five clones (clones 9, 20, 23, 33 and 34) displayed increased expression 
of pi in the absence of tetracycline, as compared to the presence of 5 pg/ml
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tetracycline. Three clones (clones 9, 20 and 34) did not express detectable 
protein in the presence of tetracycline, while clones 23 and 33 displayed weak 
immunoreactivity. In all clones tested, the levels of p i6"^'’® were induced in the 
absence of tetracycline. The induction was strong in clones 20, 23 and 33, moderate 
in clone 9, but weak in clone 34. Clone 20 expressed p i6"^ '^ '** as a doublet.
Next, the effect of plb'^'^'’® overexpression on cell growth was tested using 
clones 9, 20, 23 and 33. For initial experiments, all four clones were grown in 
parallel in the presence or in the absence of tetracycline for 7 days and total number 
of cells were estimated by in situ staining. There was no apparent difference 
between the number of cells (data not shown), suggesting that pi 
overexpression did not affect their growth rate. The lack of growth inhibition by 
pl6iNK4a overexpression was confirmed by comparing growth rates of clones 9, 23 
and 33 for 10 days and manual counting of cell numbers every two days. As shown 
in figure 4. IB, the growth rate of these clones was not affected by overexpression of 
pl6iNK4a absence of tetracycline. These observations indicated that Hep3B 
cells are resistant to growth inhibitory effects of pi 6”^ '^ ''® protein.
4.3 HEP3B-TR CELLS ARE RESPONSIVE TO p53-INDUCED GROWTH
INHIBITION
To study the effects of wild-type p53, we used Hep3B-TR clone rather than 
the parental Hep3B cells, as Hep3B-TR clone is resistant to TGF- P (Nagaki et a l, 
1997). Apoptosis studies with Hep3B cells are complicated by the fact that these 
cells express TGF-P and may undergo apoptosis in the absence of wild-type p53
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(Ponchel et al, 1994). To study p53 effects, we used a well known and widely used 
experimental model based on a mouse temperature-sensitive mutant p53-135val 
protein (Michalovitz et al., 1990). The plasmids pLTRp53cGvall35 and pSVneo 
were a gift from M. Oren (Rehovot, Israel). Hep3B-TR cells were transfected with 
the plasmids pLTRp53cGvall35 and pSVneo at a ratio of 1:20, and eight G418- 
resistant clones were tested for p53 expression. As shown in figure 4.2, only three 
clones (TRl, TR3 and TR8) were positive. Our previous experiments indicated that 
certain cell lines tend to loose the expression of transfected plasmids during long­
term culture (data not shown). Thus, it was important to test that the expression of 
p53 was stable and maintained during the in vitro growth of selected clones. TRl, 
TR3 and TR8 clones were grown for several weeks in the presence of G418 and the 
expression of p53 was checked at different time points by immunoperoxidase 
staining with the anti-p53 monoclonal antibody HR231 (Legros et al., 1994). The 
expression of p53 was maintained at nearly 100 % in TR3 cells. Only 30 % of TR8 
cells maintained its expression, whereas TRl cells have lost p53 expression 
completely (Figure 4.2B). Therefore, we performed the additional studies with TR3 
and when needed with TR8 clone, in comparison to TR4 used as negative control 
(see Figure 4.2). To avoid any experimental error, TR3 and TR8 cells were checked 
regularly for the expression of p53 by immunoperoxidase staining tliroughout all the 
experiments described here.
First, we compared the growth of TR3 and TR4 clones by two different 
techniques after incubation of cell at either 32°C (non-permissive temperature, wild- 
type p53 conformation) or 39°C (permissive temperature, mutant p53 conformation).
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Initially, the effects of wild-type p53 on DNA synthesis was tested by thymidine 
incorporation studies. Radioactive [^H]-thymidine was added into standard culture 
medium at times 0 and 24h following temperature-shift and cells grown for an 
additional 24 hours in the presence of [^H]-thymidine. Almost 100% of p53- 
negative TR4 cells were positive for thymidine incorporation at 24h (Figure 4.3a and 
b) as well as at 48h (Figure 4.3c and d), independent of temperature shift. TR3 cells 
grown at 39°C also incorporated thymidine at a rate of about 100 % at both 24h 
(Figure 4.3e) and 48 h (Figure 4.3g). In contrast to these observations, the 
temperature shift to 32°C caused almost a total block of thymidine incorporation into 
DNA of TR3 cells, as early as 24h (Figure 4.3i). Only a few TR3 cells were positive 
at 48h (Figure 4.3h). These observations demonstrated that, the activation of wild- 
type p53 in FIep3B-TR cells provoked a total loss of DNA synthesis.
To test the long-term effects of wild-type p53 expression, Hep3B-TR clones 
were grown at 32°C and 39°C for seven days at different cell densities. When forced 
to grow at 32°C, the parental Hep3B-TR cells (Figure 4.4a) as well as p53-negative 
TR4 clone (Figure 4.4b) formed large colonies. In contrast, p53-positive TR3 clone 
did not form colonies at 32°C, although single and scattered cells were still 
detectable after 7 days of culture (Figure 4.4c). The grov^h inhibition of TR3 cells 
was due to the expression of wild-type p53 at 32°C in these cells which grew well 
and formed colonies at the permissive 39°C (Figure 4.4d). Taken together, these 
studies showed that p53 activation in TR3 cells induced a total loss of DNA 
synthesis and a permanent growth arrest. These cells did not display any visible 
evidence of p53-dependent apoptotic cell death during these experiments. Additional
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39"C 3 2 X
Mutant p53 Wild type p53
Figure 43 p53 activation inTR3 cells at non-permissive temperature leads to an
arrest of DNA ^ thesis.
The p53-negative TR4 (a, b, c, d) and p53-posMve TR3 (e, f,g , h) cells were plated and 
grown at the permissive tenqrerature (39®C) for 24h. The following day, half of the plates (a, 
c, e, g) were kept at the same temperature and the cells in the other half (b, d, f, h) were 
shifted to the non-permissive temperate (32°C). Cells were labelled with [^ H]-thymidine for 
24 h before the arrest of the experiment at 24h (a, b, e, Q or 48h (c, d, g, h), and studied in 
situ for thymidine incorporatioa Note the loss of thymidine incorporation in TR3 cells at the 
non-permissive temperature (:Ç h), in contrast to TR4 cells (b, d).
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apoptosis experiments using morphological analysis, in situ DNA staining by 
H33258 and DNA ladder tests indicated that the apoptotic cell death was minimal 
(<5 %) in all Hep3B-TR clones, independent of p53 status and growth temperature 
(data not shown). Next, we further explored the effects of wild-type p53 in Hep3B- 
TR clones through the study of several known p53 target gene expression.
4.4 p53-DEPENDENT INDUCTION OF MDM2, and BAX GENES
IN HEP3B-TR CLONES
Among known p53 target genes, mdm-2, bax, and p21^''’‘ were studied. 
Northern blot analysis of p21 '^*’* transcripts showed a strong induction of p21^''’' 
gene expression at 32°C in TR3 cells, but not in TR4 cells (Figure 4.5). The p2 l‘' ‘‘’' 
transcripts were nearly detectable in both clones when grown at 39°C. The induction 
of p21^‘‘’* gene expression was detectable as early as 8h in TR3, but not in TR4 cells 
following temperature shift. This study also provided evidence that the mouse p53- 
135val protein was transcriptionally active at 32°C, but not at 39°C in TR3 cells.
Next, protein levels of mdm-2, p21^'·’' and bax were tested under similar 
conditions. The mdm-2 protein was easily detectable in both parental Hep3B-TR and 
TR3 cells grown at 39°C (Figure 4.6A). At 32°C, mdm-2 levels did not change 
significantly in Hep3B-TR and TR4 cells, although a slight increase at 48h was seen 
with Hep3B-TR (Figure 4.6A, data not shown for TR4). In contrast, there was a
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Figure 4.5 p53 activation in TR3 cells at non-permissive temperature induces
the expression of p21^^ gene.
p53-positive TR3 and p53-negative TR4 cells were grown at either permissive (39°C) cm· 
non-permissive (32®C) temperatures for the indicated times, following ovemi^t culture 
at the permissive temperature. Total RNAs were extracted and tested for p21 ‘^*’* 
transcripts by Northern blot analysis. Ethidium bromide staining of total RNAs (bottom) 
was also shown.
clear cut increase of mdm-2 protein levels in TR3 cells when grown at the same non- 
permissive temperature at both 48h and 72h (Figure 4.6A). p53-dependent increase 
of mdm-2 levels was detectable as early as 24 h in these cells (data not shown).
Accumulation of protein products of two additional p53 target genes, namely 
p2l‘^ ''’’ and bax, was investigated following p53 activation in TR3 cells (Figure 
4.6B). At 39°C, p21^''’* protein was undetectable in both TR3 and TR4 cells. At 
32°C, the expression of p21^''’' was strongly induced in TR3, but not in TR4 (Figure 
4.6B). In contrast to p2l‘^ '’’’, bax protein was present in both TR3 and TR4 clones 
grown at 39°C. At the non permissive temperature (32°C), a weak increase in bax 
levels was observed in TR3, but not in TR4 cells (Figure 4.6B).
Taken together, these studies demonstrated that the basal expression of 
p2 iCipi ggj^g Hep3B-TR-derived clones was weak (low levels of transcripts, but 
no detectable p21^''’* protein). The activation of wild-type p53 provoked an 
immediate and strong accumulation of both p21^‘‘’' mRNA and protein. In contrast, 
basal levels of bax protein in these cells were quite high and the activation of wild- 
type p53 resulted in moderate increase. Thus, we reasoned that the growth arrest 
induced by p53 in TR3 cells was mainly due to the activation of p2I^''’' gene.
4.5 p53-DEPENDENT CELL CYCLE ARREST IN HEP3B-TR CLONES
To further analyze the growth response of TR3 cells to p53 activation, we 
studied their cell cycle profiles over a period of 3 days. Both TR3 and TR4 cells 
were first grown at 39°C for 24h, then half of the plates were kept at the same
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Figure 4.6 pS3 acdvadoo in TR3 cdU «1 aou-iKHniiiive tcnperaturc kidiicc« the acomuladoo of mdn-2, and bax
proteiai.
(A) p53-po«itivc TR3 ocUx were grown at pennissivc (39D) or non-permissivc (3 2 ^ )  temperature and tested for mdm'2 protein by 
western immunc^iotting assay. Paraital Hep3B-TR cdls were used as a negative control fex· p53 expression. (B) p53»positive TR3 (top) 
and p53-n^ative TR4 (bottom) cells were grown as in A for the indicated times and tested for p2l‘^ "’’ and hax proteins by western 
immunoblotting assay
temperature and the other half transferred to 32°C. Cells were then labeled at 24h, 
48h and 72h after temperature-shift. The BrdU-labeling was done for Ih to 2h at 
different time-points tested. Cell cycle distributions at different times are shown in 
Table 4.1. TR3 cells grown at 32°C displayed a drop in S phase cells from 29 % to 4 
% , 23±5 % to 9±4 % and 20±6 % to 11±5 % at 24h, 48h and 72h, respectively. 
Concomitantly, there was a moderate increase in both G1 and G2/M phase cells at all 
time points tested. This effect was dependent on p53 expression. Indeed, p53- 
negative TR4 cells showed an increase, rather than a decrease in S phase cells (from 
18-22 % to 31-34 % at different time points). In addition, the ratio of G1 cells was 
consistently lower at 32°C in these cells, while the ratio of G2/M cells remained 
essentially similar to those observed at 39°C. The apparent increase in S phase cells 
of TR4 at 32°C is probably due to a slow down of DNA synthesis at low 
temperature. Thus, the temperature shift to 32°C had an opposite effect on TR3 cells 
as compared to TR4, causing a strong decrease in the fraction of S phase cells in the 
former. This p53-dependent effect remained effective as long as the TR3 cells are 
kept at 32°C (Table 4.1), but the fraction of S phase cells increased again when the 
cell culture temperature was shifted back to 39°C (data not shown).
In order to confirm the p53-induced growth arrest in another independent 
clone, we tested TR8 clone. As shown in figure 4.2B, only a fraction (about 30%) of 
TR8 cells were positive for p53 expression. When the entire TR8 cell population was 
tested, there was no evidence of cell cycle arrest at 32°C (data not shown). Next, 
TR8 cells were immunostained with an anti-p53 antibody and the flow cytometry 
data of p53-positive cell population were analyzed selectively. TR3 and TR4 cells
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Tabic 4.1: Effect of p53 activation on cell cycle distribution of Hep3B-TR-derived clone 
TR3, as compared to p53-negative control clone TR4
TR3 24h (n=l)* 48h (n=3)* 72h(n=3)*
G1 32°C 52 52 ±6 54 ±7
39°C 43 45 ±3 48 ±3
S 32°C 4 9 ± 4 11 ±5
39°C 29 23 ±5 20 ±6
G2/M 32'>C 44 38 ±10 35 ±6
39°C 29 33 ±3 32 ±2
TR4 24h (n=l)* 48h (n=3) 72h (n=3)
G1 32°C 48 44 ±6 48 ±9
39°C 53 57 ±1 60 ±2
S 32°C 32 34 ±3 31 ±6
39°C 26 22 ±0 18±4
G2/M 32°C 20 21 ±4 22 ±4
39°C 22 22 ±2 22 ±2
*n= number of experiments, % value of each fraction (mean ±SD) was given.
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were used as positive and negative controls, respectively (Figure 4.7A). The 
distribution of p53-positive cells of TR8 clone after 24h of growth at 39°C was as 
follows: G1 phase=29%; S phase=13%; G2/M phase=58%. When cells were grown 
at 32°C, the G1 phase raised to 35% and S phase dropped to 8%. There was no 
change in G2/M phase. Thus, the fraction of p53-positive S phase cells decreased 
about 50% when these cells were grown at 32°C. This loss appeared to be 
accompanied by a rise in G1 phase cells.
4.6 LACK OF RETINOBLASTOMA PROTEIN IN HEP3B AND HEP3B-
TR CELLS
I
Hep3B cell line and its TGF- P -resistant Hep3B-TR clone were tested for 
pRb expression. Mahlavu and Saos-2 cells were used as positive and negative 
controls, respectively. Mahlavu cells express a normal- sized pRb (Puisieux et al. 
1993), whereas Saos-2 cells express an abnormal pRb protein of 95 kDa with a C- 
terminal truncation due to the deletion of exons 21-27 of the retinoblastoma gene 
(Shew et al., 1990). Three anti-pRb monoclonal antibodies directed against distinct 
epitopes (IF8, Ab-5, and Ab-6) were used for Western blot and Immunoprécipitation 
experiments. Western immunoblotting with Ab-5 antibody (Figure 4.8A) detected a 
single 110 kDa polypeptide in Mahlavu cell line, but not in Saos-2 and Hep3B-TR 
cells. The Ab-6 antibody provided a similar result, except that this antibody also 
reacted weekly with a smaller polypeptide in all three cell lines (Figure 4.8B). With 
both antibodies, Hep3B-TR cells did not show any evidence of full length pRb 
protein and reacted similarly to Saos-2. In a third western blot assay using the IF8
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Note the d ^ e a s e  in S phase in cells grown at 3TC*
antibody, we compared Mahlavu, Hep3B-TR and Hep3B cells. As shown in figure 
4.8C, 110 kDa pRb protein was detected only in Mahlavu cell line, but not in 
Hep3B-TR or Hep3B cells. This antibody also reacted strongly with a smaller 
polypeptide in all three cell lines. However, immunoprécipitation experiments with 
Mahlavu and Hep3B-TR allowed to detect a single 110 kDa band in Mahlavu, but 
not in Hep3B-TR cells. The smaller polypeptide was not detected by this technique 
(Figure 4.8D). Thus, it appears that, under denaturing conditions of western blotting 
assays, IF8 antibody reacts with a polypeptide unrelated to pRb protein. Under the 
PAGE conditions used for these experiments (8% gel), pRb protein is not separated 
to its differentially phosphorylated forms. Therefore, it is also highly unlikely that 
the smaller bands observed here represent underphosphorylated forms of pRb 
protein.
These findings obtained with three different anti-pRb monoclonal antibodies, 
together with our previously published studies using a polyclonal anti-pRb antibody 
(Puisieux et ai, 1993), clearly establish that pRb is not detectable in Hep3B and 
Hep3B-TR cells. Obviously, we can not formally exclude the possibility that the 
pRb is present at extremely low levels in Hep3B and Hep3B-TR cells. However, it 
is clear that these cells are not different from Saos-2 cells in terms of normal pRb 
expression. Unlike us, Friedman et ai (1997) were able to detect low levels of pRb 
protein in Hep3B cells. However, these authors reported that the pRb protein in 
Hep3B cells protein was not functional. Thus, despite a discrepancy for the presence 
of pRb, the final conclusion of both studies was that Hep3B (Friedman et ai, 1997 
and our observations), as well as Hep3B-derived Hep3B-TR cells (our observation)
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were pRb-defícient. This conclusion provided a plausible explanation for the 
resistance of Hep3B cells to pló'^ *^ "*“* overexpression.
4.7 ACCUMULATION OF CYCLIN E PROTEIN IN TR3 CELLS
INDICATES A CELL CYCLE ARREST AT THE Gl/S TRANSITION
The G1 growth arrest induced by p53 in TR3 cells was accompanied by an 
accumulation of p21^’’’' protein due to a p53-dependent increases in p21 '^*’' gene 
expression. This protein acts as an inhibitor of CDK2/cyclin E complexes during the 
late stage of the G1 phase (Sherr and Roberts 1999). To test any effect of p21^'’’' 
accumulation to cyclin E and CDK2 protein levels, we analyzed these two proteins 
by western immunoblotting at time zero, 8h, 24h, 48h and 72 h in TR3 and TR4 cells 
grown at either 32°C or 39°C. As shown in figure 4.9, basal levels of CDK2 protein 
were high in TR3 cells, and they remained constant for at least 72h, independent of 
growth temperature. Cyclin E protein was weakly detectable at time zero. At non- 
permissive temperature (32°C), there was no change at 8h, but a strong and 
continued increase was observed at times 24h, 48h and 72h. At permissive 
temperature (39°C), there was also a slight and continued accumulation of cyclin E 
in these cells. However, even at 72h, these levels remained far below the levels 
observed at the non permissive temperature (Figure 4.9). Studies with the negative 
control cell line TR4 were also shown in figure 4.9, for comparison. Basal levels of 
CDK2 were also high in this clone at early times (first 24h), but slightly lower
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CDK2 levels were detected thereafter. Cyclin E levels, low at time zero remained 
essentially the same at 39°C, but there was a slight increase at 32°C. Strong 
accumulation of cyclin E in TR3 cells at non-permissive temperature was a 
consequence of p53 activation, but the delayed accumulation suggested that this 
change was not due to the direct transactivation of cyclin E gene by p53. As 
reported in figure 4.5, the response of direct targets of p53 (p21^''’') was detectable 
as early as 8h, whereas cyclin E accumulation started at 24h.
4.8 DISCUSSION
We compared the effects of p53 and p i p r o t e i n s  in pRb-deficient 
hepatocellular carcinoma cells. The overexpression of p i 6^ '^ '^ ''® did not affect the cell 
groNvth rate. To our knowledge, the effects of pi 6*^ '^ '’® in hepatoma cells have not been 
reported previously. Spillaire et al. (Spillaire et al, 1996) reported that the number of 
colonies of Hep3B cells following a transfection with a p i6'^ *^ ® expression plasmid was 
about 30% lower than those obtained with a control plasmid and 50 % of colonies 
expressed the transfected p i6"^ *^ ''® cDNA. Thus, both the weak effect of p i6 "^ '^ ® 
transfection on colony formation and the in vitro growth of at least 50% of colonies 
despite plb'^ *^ ® overexpression also confirm our hypothesis that Hep3B cells can tolerate 
pl6 *^ '^ ® overexpression. Moreover, studies with other cell types demonstrated that pRb- 
deficient cell lines are resistant to G1 phase growth arrest by p i6'^ '^ '*® protein (Guan et 
al., 1994; Koh ei a/., 1995, Lukas ei a/., 1995; Medemaei a/., 1995). pló'^ *^ "*® indirectly 
blocks cell cycle progression by inhibiting the release of "free E2F" transcription factors 
from the pRb/E2F complexes by CDK4-catalyzed phosphorylation of pRb protein
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(Dyson, 1998). In cells lacking pRb protein, the availability of "free E2F" transcription 
factors (more specifically E2F-1, E2F-2 and E2F-3) is no longer controlled.
In contrast to p i t h e  overexpression of wild-type p53 in pRb-deficient 
hepatoma cells provoked a strong and sustained growth inhibition. This effect was 
consistent with our previous studies showing that the in vitro growth of these cells were 
not compatible with the expression of wild-type p53, in contrast to p53-249Ser mutant 
(Puisieux e/a/., 1993; Ponchel ei a/., 1994). Other studies with Hep3B cell line reported 
that wild-type p53 induce apoptotic cell death (Zhuang et al, 1995; Roemer & Mueller- 
Lantzsch 1996; Mitry et al, 1997), with the exception of one study reporting that these 
cells were resistant to p53-induced apoptosis and growth arrest (Friedman et al., 1997). 
Both the choice of cell line (TGF- P -resistant Hep3B-TR clone in our studies in contrast 
to TGF- p-sensitive parental Hep3B cells used in others) and different experimental 
conditions could effect the outcome of experiments. The use of a mouse mutant p53- 
135val expression vector in this study contrasts with the use of human wild-type p53 in 
previously reported apoptosis studies (Zhuang et al., 1995; Roemer and Mueller- 
Lantzsch 1996; Mitry et al., 1997). Although th^ mouse mutant p53 used here way 
initially used to demonstrate p53-mediated apoptosis (Yonish-Rouach et al., 1991), we 
can not exclude the possibility tlial tliis particular protein is unable to induce apoptosis in 
Hep3B-TR cells.
The p53-mediated growth arrest in Hep3B-TR clones was confirmed by three 
independent tests including thymidine incorporation, flow cytometry and in vitro long 
term growth assays. The mechanism by which p53 induces growth arrest in Hep3B-TR 
cells is not known yet. But, our observations are in favor of the following hypothesis:
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p53 activation in these cells causes an accumulation of p21^''’' protein leading to an 
inhibition of kinase activity of CDK2/cyclin E complexes. Recent studies, as reviewed 
by Sherr and Roberts (Sherr and Roberts 1999), showed that G1 phase cell cycle 
inhibition by p21^’’’* (as well as other members of Cip/Kip family of proteins) is 
concordant with specific inhibition of cyclin E-dependent CDK2 rather than cyclin D- 
dependent CDK4 enzyme. The active CDK2/cyclin E complexes have at least two 
different functions in cell cycle progression: (1) further phosphorylation of pRb allowing 
an amplification of "free E2F" release from pRb/E2F complexes; (2) phosphorylation of 
other proteins (i.e. NPAT) involved in Gl/S transition (Sherr and Roberts 1999; Dyson 
1998; Zhao et ai, 1998). It is expected that, in pRb-negative cells, the first function is 
no longer needed and the second function becomes rate-limiting. Indeed, cyclin E is able 
to induce S phase entry without activation of the retinoblastoma/E2F pathway (Lukas et 
al, 1997), suggesting that CDK2/cyclin E-mediated S phase entry is independent of pRb 
protein. In Hep3B-TR cells, p53-induced growth arrest was accompanied by a 
progressive accumulation of cyclin E, as well as p21^‘‘’* protein. Cyclin E gene is known 
to be activated by E2F factors (Dyson, 1998). Thus, the accumulation of cyclin E may 
be taken as an evidence that, in these pRb-negative cells, pRb-dependent E2F molecules 
(E2F-1, E2F-2 or E2F-3) are "free" (Dyson, 1998). However, this accumulation of 
cyclin E lasted at least 72h (Figure 4.9) and was accompanied by a loss of DNA 
synthesis (Figure 4.3), rather than en entry into S phase. This pattern differs from the 
fluctuating pattern of cyclin E protein levels (and CDK2/cyclin E activity) in 
proliferating cells with peak levels at Gl/S transition followed by a loss at early S phase 
(Dulic et al., 1992). We did not test CDK2/cyclin E enzyme activity in our cells, but 
the pattern of cyclin E accumulation and DNA synthesis inhibition suggest that.
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following p53 activation, cells are able to progress in the early G1 phase of cell cycle 
(no functional pRb), but are maintained at the Gl/S transition because of p21^''’‘- 
mediated inhibition of CDK2/cyclin E enzyme activity. Alternatively, cyclin E 
accumulation could be linked to a direct induction of cyclin E gene expression by p53, 
but cyclin E gene is not a known target of p53. As a first conclusion, our observations 
clearly indicate that the p53 is able to provoke a G1 arrest independent of 
"retinoblastoma pathway" in hepatoma cells and that this "retinoblastoma-independent 
pathway" may involve the inhibition of phosphorylation of non-pRb proteins such as 
NPAT by CDK2/cyclin E complexes
With regard to genetic changes observed in HCC, it appears that, in one group of 
tumors, genetic changes affecting retinoblastoma, cyclin D and p i g e n e s  lead to a 
loss of growth control in early G1 phase of cell proliferation. As demonstrated here with 
a pRb-deficient cell line, in this group of tumors, p53-mediated growth control leading 
to a late G1 phase arrest remains functional. Another group of tumors display alterations 
in p53 gene. In these tumors, a functional retinoblastoma pathway may still protect cells 
against a severe loss of growth control. The worse situation would be with a third group 
of tumors displaying alterations in both p53 and retinoblastoma pathway genes with 
almost a total loss of growth control at G1 phase. HCCs displaying alterations on both 
p53 and retinoblastoma genes have been described (Murakami et a l, 1991). This 
peculiar situation could explain why prognostic value of individual genetic changes in 
HCC was not rewarding. A systematic study of several gene alterations in these tumors 
might provide better information for disease prognosis.
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CHAPTER FIVE
STUDY OF STRUCTURE-FUNCTION RELATIONSHIP OF p53 
USING A NOVEL EXPERIMENTAL APPROACH
5.1 INTRODUCTION
The human p53 gene spans about 20 kb of genomic DNA and contains 11 exons 
and has been localized to the short arm of chromosome 17 (17pl3). The mouse, human, 
and Xenopus laevis p53 genes have similar 11 exon structures and identical exon 
boundaries, although the size of the 10 iiitrons may vary considerably among these three 
species (see Soussi and May, 1996).
The cloning and sequencing of p53 cDNAs from a variety of species has allowed 
researchers to analyze structural and evolutionary features of the p53 protein. Soussi et 
al. (1990) showed that some regions of the p53 protein are highly conserved at the 
amino-acid level throughout vertebrate evolution. These conserved regions fall into five 
widely spaced amino-acid clusters termed domains I to V. In some of these domains the 
sequence conservation among all the species is perfect over stretches of 14 or more 
amino acids, indicating a high degree of fimctional importance.
It has been demonstrated that Xenopus p53 has a very similar behavior compared 
to human p53. Xenopus laevis p53 is able to form tight and specific complexes either in 
vivo or in vitro with SV40 large T antigen (Soussi et al., 1989), which was the basis for
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the discovery of human p53 protein. In the same report it was also demonstrated that 
Xenopus laevis p53 is able to form complexes with 72- and 73-kDa heat shock proteins, 
detectable only at a temperature well above the optimal growth temperature for Xenopus 
laevis. The binding ability of hsp72/73 to human p53 is restricted only to mutant p53 
proteins (Finaly et a l, 1988; Sturzbecher et a l, 1987, 1988). Although the biological 
significance of the interaction between structurally altered p53 and hsp72/73 is
unknown, with the data observed from Xenopus p53, it seems that this phenomenon is
\
not fortuitous and requires a conformational change. These studies also suggest that 
Xenopus p53 behaves like human p53. In fact the optimum temperature between two 
species seems to be the main difference only. The optimum activity of human p53 is 
37°C, whereas Xenopus p53 is only active at 30°C. This is due to the physiology of 
Xenopus that have an optimal temperature at 28°C. Such observation indicates that the 
Xenopus p53 behaves like a thermosensitive mutant in mammalian cells, and explains 
the binding ability oiXenopus p53 to human hsp72/73 only at temperatures well above 
the optimal growth temperature for Xenopus laevis. The “thermosensitive-mutant” 
behavior of Xenopus p53 in mammalian cells, in fact, provides a novel experimental 
system to have a detail look at the functions of various domains of the p53 protein.
In order to examine the contribution of each domain to the various functions of 
the p53 protein, we have decided to construct human and Xenopus p53 mini-genes in a 
fashion that we can easily exchange the domains of interest between two species to 
address specific questions. The behavior of such hybrids could be very informative when 
they are tested at the permissive and nonpermissive temperatures.
Thus, the objectives of this study are: (1) to describe a design of this novel 
system how to look at the structure-function relationship of p53 with our knowledge of
129
this protein; (2) to use this system to address a specific point which will be the detection 
of the p53 domain that contributes to thermosensitivity. From a previous indirect study 
(Hansen et a l, 1996), it is believed that the DNA binding domain is involved in this 
property. The construction of hybrids where the DNA binding domains of p53 have 
been exchanged between two species will provide some more information about this 
topic.
5.2 DESIGN OF HUMAN AND XENOPUS p53 MINI-GENES
The newXenopus p53 and human p53 mini-gene constructs consist of 5 artificial 
exonic sequences, each of which include one domain of the p53 protein that are 
described in Figure 5.1. For example, the first exon of human p53 mini-gene consists of 
39 amino-acids that covers exon 2, 3 and beginning of exon 4 of the human wild-type 
p53 gene, which corresponds to the transactivation domain of p53. Five exons of p53 
mini-genes were interrupted by four different mini-introns, which are similar in 
sequence between human and Xenopus. Within each mini-intronic sequences a unique 
enzyme site was inserted. Each exon of both human p53 and Xenopus p53 mini-gene 
was synthesized by Genosys as one Cassette and cloned into pT7Blue3 vector from the 
unique restriction sites in the intronic sequences. Taken together we have received 10 
different plasmid constructs, 5 of which represents the 5 different functional domains of 
human p53, and the rest of 5 represents the 5 different functional domains oiXenopus 
p53.
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p53 gene (H or X)
4 6 8 9 10 11
■mm isáÉSifc ■■
p53 protein
T ransactiva tion
Dom ain
DNA binding  Negative Regulatory 
Dom ain Dom ain
O ligom erization
Domain
cass. 1 casa. 2 caas. 3 caaa. 4 caaa. 5
■t.
Á mm A A A A
E2 E3 E4 E5 E6
Genetic Organization of Cassettes
Figure 5.1 Organisation of p53 gene and cassettes
Human (H) and Xenopus (X) p53 gene structure from exon 1-11 indicated in yellow 
color, ^ i t e  colored part in exon 1 and 2 indicates the non-transcribed region. The 
p53 protein with defined domains indicated in 5 different colors. Genetic organisation of 
the mini-p53 gene with 5 cassettes (cass.) that corresponds to each domain of p53 were 
indicated in yellow color. Unique restriction en2 yme sites in the intronic sequences were 
indicated as E.
5.3 CONSTRUCTION OF A UNIVERSAL VECTOR FOR THE CLONING
OF THE SYNTHETIC GENE
For the construction of the synthetic genes, we chose restriction sites that cut 
very infrequently in the DNA sucii as we could perform easily the various exchange by 
using these sites within the inserts. As there was no vector with such sites, we have 
constructed a new vector specialized for our purpose. A synthetic oligonucleotide 
containing the 6 restriction sites was cloned in a commercial vector called pcDNA3.1. 
This vector is a well-defined eukaryotic vector with every regulatoiy sequence necessary 
for efficient expression in mammalian cells (Figure 5.2). The new vector obtained after 
the cloning of this new linker has been called pClO. The linker has been sequenced to 
ensure that no mutation was present in the new sequence.
5.4 CONSTRUCTION OF THE SYNTHETIC GENE
Since we received each cassette (five cassettes of human p53 and 5 cassettes of 
Xenopus p53) separately as inserted into pT7Blue vector from Genosys, we had to clone 
five cassettes of both human p53 and Xenopus p53 into one vector, one after the other to 
have the complete mini-p53 gene of both species. The strategy used for these 
constructions is depicted in Figure 5.3. Briefly, the vector pClO is linearized by a 
double digestion with two enzymes (Notl and Pad for Cassette 1). The pT7Blue3 
containing cassette 1 is also digested with these same 2 enzymes and the insert 
containing the cassette 1 is purified. Vector and insert are mixed, ligated and 
transformed in competent bacteria. Once a correct clone is obtained, it is used as a 
substrate in order to clone the second cassette. This iterative procedure has been 
repeated until we obtained the two synthetic genes (Human and Xenopus) with cassette
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BamHI
Noll P ad  Asci Fsel Sgfl Sfil 
CTAGCgcggccgcttaat ta ag g cg cg ccg g ccg g ccg cg a tcg cg g cca t gagggccG
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Cloning of linker into
PCDNA3.1
pC10(5408 bp)
Nhel
Notl
Pad
AscI
'sel
Sgfl
Sfil
BamHI
Figure 5.2 Schematic representation of a universal vector.
Synthetic oligonucleotide containing the 6 restriction enzyme sites were shown as 
sequence in blue color. This oligonucleotide was cloned into a commercial vector 
pcDNAS.l from the Nhe I and Bam HI sites. The resulting plasmid that contains the 
linker sequence called pC 10 is indicated in yellow color.
Ншпап Cassette 1 (HCl) is shown in green colour as inserted into pT7Blue vector (yellow 
colour). Cloning vector, pClO, is indicated by an open red circle. The pT7Blue+HCl 
construct digested with Not I and Рас I to remove Human Cassette I (HCl) from pT7Blue 
vector, and subsequently cloned into pClO vector, from the same linker sequence Not I 
and Рас I. The resulting plasmid is called pClOHCl.
Nlotl (113)
Figure 5.3 Schem atic rep resen ta tion  o f  the strategy used for cloning o f o n e
cassette into pClO vector
Pad (280)
DT7Blue+HC1
(4017 bp)
4
Removal of HCl from pTZBIue 
bv Not I and P a d
349 bp
1,2,3,4 and 5. The resulting mini p53-gene constructs were called, pC10HC12345 and 
pC10XC12345, for human and Xenopus, respectively.
5.5 STRUCTURAL CONTROL OF HUMAN AND XENOPUS SYNTHETIC 
p53 MINI-GENES
In order to verify if the splicing of the p53 mini-genes occurs correctly, mRNAs 
were isolated from Saos-2 cells, transfected with pC10HC12345 and pC10XC12345. 
The cDNA was generated from niRNA by reverse transcriptase, and the PCR products 
were cloned into pcDNA3.1 vector. Four positive human p53, and two iposxXxvQ Xenopus 
p53 clones were chosen for sequencing. After sequencing all the human and Xenopus 
p53 cDNAs, we confirmed that splicing occurs correctly, and there is no mutation in the 
cDNAs of both human (Figure 5.4) and Xenopus cassettes (Figure 5.5 ).
Having constructed all the cassettes in the right order and verified the splicing 
pattern of both human and Xenopus mini-p53 cDNAs, it remained to generate the hybrid 
constructs, by exchanging the Cassette 3 (DNA binding domain) between human and 
Xenopus (Figure 5.6) to see if the DNA binding domain of p53 is involved id 
thermosensitivity.
5.6 BIOLOGICAL CONTROL OF HUMAN AND XENOPUS SYNTHETIC 
p53 MINI-GENES
Having constructed all the cassettes in the right order in the mammalian 
expression vector and verified the splicing pattern of botli human and Xenopus mini-p53 
cDNA, it remained to determine whether these genes could produce the right RNA and 
protein products in cells. -Therefore, a p53-null cell line Saos-2 was transiently
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transfected with different expression plasmids; control human p53 cDNA (pC53SN), 
pC10HC12345 and pC10XC12345. Cell extracts were immunoprecipitated with 
monoclonal antibodies against both human p53 (HR231) and Xenopus p53 (X36 and 
X77). This result demonstrated that what we have constructed as human and Xenopus 
p53 genes are indeed encoding the right protein product at the right size (Figure 5.7), but 
with an unexpected second protein product coming from pClOHC 12345. Since this 
additional protein product could be the result of an aberrant splicing product, we have 
isolated mRNAs from transiently transfected Saos-2 cells and generated cDNAs 
numerous times, and always obtained one expected cDNA product from pC10HC12345.
5.7 XENOPUS p53 BEHAVES LIKE A MUTANT HUMAN p53
To detennine if the hybrid constructs, in which pClOHC 12345 used as a vector, 
produce two protein products as well, we have transiently transfected Saos-2 cells with 
expression plasmids pC10HC12345, pC10XC12345, pC10HC1245XC3, and 
pC10XC1245HC3 and cell exracts were imniunoprecipitated with monoclonal 
antibodies against both human p53 (HR231) and Xenopus p53 (X36 and X77). This 
result demonstrated that pC10HC1245XC3 hybrid construct generates two protein 
products as like pC10HC12345 (Figure 5.8). The fact that only pC10HC12345 plasmid 
and its hybrids that contain this plasmid as a vector appears to have the second larger 
protein product could be explained by the existence of an additional start codon in the 
vector resulting the generation of two protein products, instead of one (see section 5.8).
We show by this immunological data ihdX Xenopus p53 forms specific complexes 
with mammalian hsp72 and hsp73 heat shock proteins only at a temperature well above 
the optimal growth temperature iox Xenopus laevis (Figure 5.8). It seems that at 37°C
139
Transfected DNA Mock pCS3SN p53HCas p53XCas
1 2 3 4 5 6 7 8
HR231 +
X36 
X77
+  -  +  - 
+ - +
97.4
69
56
46
i n  " ■
III
HumfflipiB
Xaaopus p63
Figure 5.7 Electrophoresis showing expression of both human and 
Xenopus p53 mini-genes in Saos-2 cells.
Saos-2 cells were transfected with 5 pg o f the indicated plasmids per 6-cm 
dishes. At 48 hours posttransfection, cells were labelled for 2 hours with 
methionine and proteins were extracted and immunoprecipitated with the 
following antibodies: HR231 anti-human p53-C terminal (lane 1,3, 5, and 7); 
X36 mti-Xenopus p53-C terminal (lane 4 and 6); X77 anü-Xenopus p53-N 
terminal (lane 2 and 8). pS3HCas and p53XCas correspond to human and 
Xenopus p53 Cassettes, respectively; pC53SN is the control human cDNA,
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this protein is altered in conformation, while at 32°C, it exhibits wild-type behavior. 
Interestingly, when the DNA binding domain of human p53 was substituted by the DNA 
binding domain oiXenopus p53, the behavior of human wild-type p53 is changed from 
wild-type to mutant. Since Xenopus optimal temperature is 28°C, and our transfection 
experiments were performed at 37°C, it is plausible that Xenopus p53 could have an 
altered conformation at this temperature. We showed that at a lower temperature 
(32°C), the ability of Xenopus p53 to bind mammalian hsp72 is considerably reduced 
(data not shown). Therefore, we suggest that the temperature efiect reported here might 
be caused by a change in Xenopus p53 confonnation, and tliis effect is directly linked to 
the DNA binding domain of p53 protein.
5.8 ELIMINATION OF THE LARGER PROTEIN PRODUCT FROM
HUMAN MINI-p53 GENE AND ITS HYBRIDS
In order to understand the source of the larger protein products coming from 
pClOHC 12345 and its hybrids, we have searched for a putative start codon derived from 
the vector (pClO) promoter sequence through computer analysis, and found one. In 
order to overcome this problem, the pClOHC 12345 plasmid was digested from either 
one enzyme site, Nhe I, or two enzyme sites, Nhe I-Notl, which were located in the 
upstream of the start codon of the p53 mini-gene and downstream of the putative start 
codon in the vector. The resulted single stranded DNA was removed by Mung Bean 
Nuclease after the linearization of the plasmid. This resulted linear plasmids religated 
from its blunt ends and consequently sequenced to verify the removal of some 
nucleotides which can brake the frame of the larger protein product (Figure 5.9). After 
the verification of the removal of some nucleotides, the Saos-2 cells were transfected
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with mini-prep DNA, and Western Blot analysis was performed to see if the larger 
protein product was eliminated (Figure 5.10) after the Mung Bean Nuclease treatment. 
In fact plasmids that were resistant to Nhel-Notl restriction enzyme sites, but not to 
Nhel, produced only one protein product with the expected size. Next, the effect of 
Mung Bean Nuclease Treatment were tested on plasmids, pC10HC1245XC3, 
pC10HC1234XC5, pC10HC12XC345, after the digestion of these plasmids with Nhel- 
Not I restriction enzymes. After the verification of the removal of 11 nucleotides via 
sequencing, the resulted plasmids were also transferred into Saos-2 cells, and western 
blot analysis was performed to see if we can obtain only one protein product, from these 
hybrid proteins. As shown in Figure 5.11, we were able to see only one protein product, 
from the Nhel-Notl resistant clones. All Nhel-Notl resistant clones in which the second 
protein products were eliminated were indicated as pC10HC123435V, 
pC10HC1245XC3V, pC10HC1234XC5V for further experiments.
When wild-type p53 complementary DNAs were first cloned from normal
-t
human cells, a sequence polymorphism was found in the general population that results 
in either a proline (p53Pro) or arginine (p53 Arg) at residues 72 and affects the migration 
of the protein on SDS-PAGE (Matlashewski et al., 1987). The reason to have a slightly 
smaller protein product at pC10HC12345 compare to the control human wild-type p53 
cDNA (p53SN) is due to the polymorphism at codon 72 (for pClOHC 12345 p53Arg, for 
p53SN p53Pro).
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5.9 IMMUNOLOGICAL CHARACTERIZATION OF BOTH HUMAN AND 
XENOPUS p53 M INI-GENE PROTEIN PRODUCTS AND TH EIR 
HYBMDS BY IMMUNOPRECIPITATION
Having treated all the human cassettes and its hybrids with Mung Bean Nuclease 
and verified the elimination of the second protein product coming from the vector 
sequence by Western blotting (Figure 5.10 and Figure 5.11), it remained to characterize 
the protein products of each cassette by immunoprécipitation teclinique. Therefore, a 
p53-null cell line Saos-2 was transiently transfected with different expression plasmids; 
control human p53 cDNA (p53SN), control Xenopus p53 cDNA (CMV27A), 
pC10HC12345V, pC10HC1245XC3V, pC10XC12345 and pC10XC1245HC3. Cell 
extracts were immunoprecipitated with monoclonal antibodies against both human p53 
(HR231 and D07) and Xenopus p53 (X36 and X77). This result clearly demonstrated 
that what we have obtained after the treatment of human mini-p53 gene and its hybrids 
with Mung Bean Nuclease are indeed encoding the right protein product at the right size 
(Figure 5.12).
5.10 THE DNA-BINDING DOMAIN OF p53 IS RESPONSIBLE FOR THE 
THERMO-SENSITIVE ACTIVITY OF THE p53 PROTEIN
To determine if the temperature-dependent conformational change correlates 
with the loss of transcriptional activity of the p53, we have used a well known 
experimental model, Luciferase assay. This assay employed luciferase reporter 
construct containing an artificial promoter with multimerized p53 binding sites (pG13- 
luc). Saos-2 cells were cotransfected with a luciferase reporter construct and
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a variety of expression vectors containing human and Xenopus p53 mini-genes, 
pC10HC12345V and pC10XC12345, and hybrid constructs, pC10HC1245XC3V and 
pC10XC1245HC3. cDNAs for the human and Xenopus wild-type p53, p53SN and 
CMV27A, respectively, served as positive controls. Tumor derived mutant p53, 
p53175H, and a temperature-sensitive dominant inhibitory mutant p53143Ala were also 
used as negative and positive controls for the comparisons of hybrid proteins. 
p53143Ala assumes a mutant configuration at the nonpermissive temperature of 37°C, 
such that it retains the ability to oligomerize but not to bind DNA (Michalovitz et al., 
1990). After transfection, cells were maintained at 37°C or shifted to 32°C and then 
harvested and processed for analysis 48 h later. Our results from three independent 
experiments show that the control cDNA for the human wild-type p53 (p53SN) and 
human p53 mini-gene pClOHC 12345V transactivates the reporter plasmid at higher 
level at 37°C than at 32°C, whereas control Xenopus wild-type p53 cDNA (CMV27A), 
and Xenopus p53 mini-gene pC10XC12345, demonstrate severe defects in 
transactivation at 37°C, but highly active at 32°C, as it was expected. When the DNA 
binding domain of Xenopus was substituted by that of human, pC10XC1245HC3, this 
hybrid protein behaves like a human wtp53; it is able to activate a reporter gene at 37°C, 
but not at 32°C. Whereas, when tlie DNA binding domain of human was substituted by 
that of Xenopus, pC10HC1245XC3V, this hybrid protein is able to activate a reporter 
gene at 32°C, but not at 37°C ; behaving like a human temperature-sensitive mutant, 
p53143Ala (Figure 5.13). These observations, which have been recaputulated with 
several more Luciferase assays, suggesting, not surprisingly that the temperature- 
sensitive activity of p53 correlates v^ dth the DNA-binding domain of the p53 protein.
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5.11 THE EFFECTS OF TEMPERATURE-DEPENDENT CHANGE IN THE 
CONFORMATION ALSO REFLECTED IN THE GROWTH 
SUPPRESSION ABILITY OF p53.
Based on the prevalent idea that transcriptional activation correlates with p53- 
mediated growth suppression, it became of interest to compare the activity of various 
p53 hybrids in a growth suppression assay. The ability of these cassettes to suppress the 
growth of tumor cells in culture was determined by colony formation assay. This assay 
enables growth suppression in its most general sense to be measured as it scores for 
either p53-dependent growth arrest and/or apoptosis in tumor cells that receive the p53 
protein. Plasmids containing wild-type p53 or various hybrids in cis with a G418 
resistance marker were transfected into the Saos-2 cell line and geneticin-resistant 
colonies were scored ~3 weeks later. Each transfection was performed from a total of 2 
dishes. In the first dishes, G418-resistant colonies were methanol fixed and stained witli 
Giemsa. In the second dishes G418-resistant colonies were methanol fixed and p53- 
resistant colonies were detected by immunohistochemistry.
After Giemsa staining, number of viable cells were counted. Number of viable 
cells in human wild-type p53 mini gene (pClOHC 12345) was higher than that of 
Xenopus p53 mini-gene (pC10XC12345). When the DNA binding domain of human 
p53 was substituted by that oiXenopus (pC10HC1245XC3), the number of viable cells 
become closer to the Xenopus p53 mini-gene (pClOXC 12345), whereas when the DNA 
binding domain of Xenopus p53 was substituted by that of human p53 
(pC10XC1245HC3), compare to \niaci Xenopus p53 mini-gene, the number of viable 
cells was dramatically reduced. In order to see the effects of negative-regulatory domain
151
of p53 on the growth suppression ability of p53, we have used two different hybrids, in 
which the negative regulatory domains of p53 of both species were exchanged. These 
hybrids behaved as wild-type p53, by giving approximately the same number of colonies 
as their wild-type counterparts (Figure 5.14 ).
To further analyze the possible role of DNA binding domain for the growth 
suppression of wild-type p53, G418-resistant colonies were methanol fixed and p53- 
resistant colonies were detected by immunohistochemistry. We observed that none of 
the viable cells was human p53-positive. As a potent suppressor of tumor cell growth in 
culture, the human wild-type p53 plasmid (pClOHC 12345) reduces the number of p53- 
positive drug resistant colonies to 0 (Figure 5.15 ). In contrast, Xenopus wild-type p53 
is defective in this assay, demonstrating no suppression of colony formation at 37°C, 
achieving only a <2-fold decrease in p53-positive colony number compare to the total 
viable colonies. Interestingly, when the DNA binding domain of Xenopus p53 was 
substituted by that of human (pC10XC1245HC3), this hybrid protein reduces the 
number of p53-positive drug resistant colonies to 0. Whereas, when the DNA binding 
domain of human p53 was substituted by that o i Xenopus (pC10HC1245XC3), this 
plasmid demonstrates no defect in growth suppression, achieving a significant increase 
in p53-positive colony number compare to the human wild-type p53 (pClOHC 12345), 
and behaving like o-Xenopus wild-type p53 (pC10XC12345) at 37°C (Figure 5.15).
5.12 DISCUSSION
The p53 protein has been divided into five domains ; (i) a transcriptional 
activation domain that contacts TAF components of TFIID ; (ii) a polyproline rich 
domain crucial for activating cell death ; (iii) a sequence-specific DNA binding
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domain; (iv) a tetramerization domain ; and (v) a negative regulatory domain that 
recognizes and binds to damaged DNA nonspecifically.
The p53 protein is well conserved (Soussi et al., 1990) and, as a consequence, it 
can be assumed that its properties are also preserved during evolution. Upon DNA 
binding, p53 stimulates the transcription of different genes, which are involved in the 
cell-cycle arrest, and the induction of apoptosis. The structural elements responsible for 
these activities are found in all known p53 variants. It has recently been shown that 
Xenopus p53 has a very similar behavior compared to human p53. The optimum activity 
of human p53 is 37°C, whereas the Xenopus p53 is only active at 30°C. This is due to 
the physiology oiXenopus that have an optimal temperature at 28°C. Such observation 
indicates that the Xenopus p53 behaves like a thermosensitive mutant in mammalian 
cells. This finding led us to investigate the possible functions of DNA-binding domain 
of p53 through exchanging this domain between two species.
Exchanging the domains between two different species has only been reported 
recently to our knowledge by Chen (1999), to investigate the tetramerization ability of 
Xenopus and human p53. This work is the second report demonstrating that shifting 
domains between these two species is highly applicable to investigate the functions of 
various domains of p53. The advantage of our system is that since the our mini-gene 
constructs consists of only 5 exonic sequences (corresponds to 5 different domains of 
p53 protein), it is very easy to shift the cassettes of p53 through intronic sequences 
between two species or even between homologous of p53 protein without creating any 
harm to the corresponding domains of p53. This system gave us a unique opportunity to 
have a detail look at the DNA-binding domain of p53 protein by using hybrid proteins.
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The results reported here demonstrate that the two mini-p53 gene obtained 
synthetically behaves like their wild-type counterparts at the structural and functional 
level. On a structural level, the Xenopus p53 might undergo conformational changes 
after incubations at mammalian cells at 37°C by loosing its wild-type conformation, 
behaving like a temperature-sensitive human p53. We show by an immunological 
technique ihaX Xenopus mini-p53 binds to human hsp72-73. At a functional level, 
Xenopus p53 is inactivated for transactivation of its target promoter at 37°C in 
mammalian cells. Whereas human wild-type p53 is more flexible ihsLixXenopus at 32°C, 
activating the reporter gene in mammalian cells. This result indicates that p53 can 
tolerate nonpermissive temperature only if it is lower than its physiological temperature. 
In fact, this thermosensitivity is also seen for human and murine wild-type p53 
expressed in eukaryotic and prokaryotic systems when the temperature was shifted to 
45°C (Lane et al., 1996).
p53 has been shown to be a conformationally dynamic protein in vivo and in 
vitro (Gannon et al., 1990 ; Milner and Medcalf, 1990). Temperature-sensitive p53 
mutants that have been identified in many human tumors display a very different 
phenotype. The conformation of these mutants, for example, human Ala-143 (Zhang et 
al., 1994) and murine Val-135 (Milner and Medcalf, 1990), appear to be flexible and 
very temperature-sensitive. At the permissive temperature (32.5°C), these mutants adopt 
a wild-type conformation and are able to mediate transcription transactivation. At the 
restricted temperature (37.5°C), the conformation is switched to a mutant state, and 
transcriptional activation function is greatly reduced or abolished. These results suggest 
that the conformation of the central core domain of p53 is essential for its biological 
activity. Indeed, we have demonstrated that human p53 mini-gene with the DNA-
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binding domain of Xenopus p53 behaved like a Xenopus p53. It became biologically 
active at 32°C by transactivating the reporter gene, and presumably underwent 
conformational changes by binding to human hsp72-73. Xenopus p53 mini-gene with 
the DNA-binding domain of human p53, became functionally active at 37°C by 
transactivating the reporter gene at 37°C, and lost its conformational change at 37°C, by 
not binding to hsp72-73 protein. These results indicates that conformation of the central 
core domain of p53 is essential for its biological activity and this temperature-dependent 
conformational change correlates with the loss of transcriptional activity of p53.
We have also provided more information by testing the growth suppressor ability 
of these hybrid proteins by colony formation assay. The human p53 mini-gene with the 
DNA-binding domain of Xenopus p53, which behaved like a Xenopus p53 by 
transactivating the reporter gene at 32°C, did not suppress colony formation at 37®C, but 
Xenopus p53 mini-gene with the DNA-binding domain of human p53, which activated 
the reporter gene at 37°C, reduced the number of drug-resistant colonies to 0. This 
means that the effects of temperature dependent change probably in the conformation 
also reflected in the normal biological function of p53, ie. in growth suppression ability.
<
This cause and result phenomenon could be mediated by the thermostability of the 
protein, since the stability of p53 protein is an absolute necessity for its physiological 
function as a tumor suppressor. One very recent study (Xirodimas and Lane 1999) 
investigating the thermal instability of p53 have shown by mutational analysis that 20 
amino acid residues in the core domain of p53 (amino acid 101-120) responsible for the 
thermostable phenotype, interestingly, this is the region where human p53 is very 
different at amino acid level from Xenopus p53. All our findings observed from hybrids 
of p53 protein between human anA Xenopus, support this observation.
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Many of the point mutations identified in the core domain of p53 produce a 
change in the global conformation of the protein, which can be monitored by a set of 
anti-p53 monoclonal antibodies. More specifically, PAbl620 (human and mouse p53- 
specific) (Milner et al., 1987) and PAb246 (mouse p53-specific) (Yewdell et al., 1986) 
recognize the wild-type native conformation of p53, but fail to react with most mutants 
found in tumors. These mutants react with PAb240 (Gannon et al., 1990), which 
recognizes denatured, but not wild-type p53. The definition of distinct p53 conformers 
is simplistic, however, since it appears that p53 is a dynamic protein, adopting different 
conformations in vitro and in vivo. In support of this statement, Milner and Medcalf
(1991) demonstrated that formation of hetero-oligomers of wild-type and mutant p53 
proteins could drive the conformation of the wild-type protein into a mutant state. 
Furthermore, upon binding to DNA, p53 appears to switch from a PAbl620+/PAb240- 
to PAbl620-/PAb240+ conformation (Halazonetis et al., 1993). Since these two 
conformations of p53 dictate the biological status of the p53 protein, one could suggest 
that the balance between these two alternate states might determine the biological 
activity of p53 in cells. Identification of the mechanisms that govern this equilibrium 
could provide new insights into p53 structure/function.
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CHAPTER SIX
MAIN CONCLUSIONS AND FUTURE PERSPECTIVES
This thesis project was on the study of tumor suppressor functions of p53 gene. 
First, we compared the effects of p53 and proteins in pRb protein-deficient
hepatocellular carcinoma (Hep3B) cells. The overexpression of pl6 '^ ’^ ‘*® did not affect 
the cell growth rate, whereas the overexpression of wild-type p53 provoked a strong and 
sustained grov^^h inhibition. Our results with p i w h i c h  show that Hep3B cells can 
tolerate p i o v e r e x p r e s s i o n  support other reports indicating that other pRb-deficient 
cell lines are also resistant to G1 phase growth arrest by plb*' '^ '^’® protein (Medema et al., 
1995; Lukas et al., 1995). plb'^^“*® indirectly blocks cell cycle progression by inhibiting 
the release of free E2F transcription factors from the pRb/E2F complexes by CDK4- 
catalyzed phosphorylation of pRb-protein (Dyson, 1998). In cells lacking pRb protein, 
the availability of free E2F transcription factors (more specifically E2F-1, E2F-2 and 
E2F-3) is no longer controlled.
The exact mechanism by which p53 induce grov^h arrest in Hep3B-TR cells is 
not known yet. However, our findings indicate that activation of p53 in these cells 
causes accumulation of p21^"’‘ protein probably leading to an inhibition of kinase 
activity of CDK2/cyclin E complexes. Under normal conditions, the cyclin E protein is 
periodically synthesized during cell cycle, reaching a peak in abundance in late G1 and
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Gl/S transition followed by a sharp decrease in early S phase (Dulic et a i, 1992; Koff et 
al, 1992). Overall, its level changes approximately 5-fold between early G1 and the 
peak at late G l, and this change in the cyclin E protein correlates with a similar change 
in the level of cyclin E mRNA (Lew et al., 1991). This activation of cyclin E is achieved 
by E2F factors (Dyson, 1998). In Hep3B-TR cells, p53-induced growth arrest was 
accompanied by a progressive accumulation of cyclin E, as well as p21 '^'*‘ protein. 
Therefore, the accumulation of cyclin E may be taken as evidence that, in these pRb- 
negative cells, pRb-dependent E2F molecules are “free”. p53-mediated accumulation of 
p21 presumably results in the inhibition of kinase activity of CDK2/cyclin E complexes. 
This hypothesis may explain how p53 could control cell proliferation in the absence of 
pRb protein and despite to an increase in cyclin E levels in the Gl phase.
In one study, cyclin E was shovm to induce S phase entry without activation of 
the retinoblastoma/E2F pathway (Lukas et al., 1997) implying that CDK2/cyclin E- 
mediated S phase entry appears to be independent of pRb protein. Since the other 
retinoblastoma family protein, p i07, which regulates the Gl/S transition, is known to be 
the major substrate of the complexes of cyclin E/CDK2, one can assume that pi 07 might 
compensate for the loss of pRb in these cells. However, so far there is not any study 
indicating that retinoblastoma family proteins ai’e functionally redundant. Furthermore, 
if the functions of pRb and p i07 overlap, how one can explain that, in the absence of 
retinoblastoma protein, Hep3B cells became resistant to plb'^'^'’®? As a conclusion, 
from our observations we suggest that p53 is able to provoke a Gl arrest independent of 
“retinoblastoma pathway” in hepatoma cells and that this “retinoblastoma-independent 
pathway” may involve the inhibition of phosphorylation of “non-pRb prtoeins” by 
CDK2/cyclin E complexes. Such substrates of CDK2/cyclin E complexes may be
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involved in the initiation of DNA replication at the beginning of the S phase. For 
example, cdc6 which is involved in the activation of origins of replication is known to 
be phosphorylated by CDK2 (Jiang et a l, 1999).
As a future perspective for retinoblastoma-independent growth control by p53, 
we propose to study the levels, cellular localization, kinase activity and/or 
phosphorylation status of E2Fs, CDK2/Cyclin E, CDK2/Cyclin A and cdc2 molecules. 
The TR3 cell line is a good experimental system to study whether p53 activation in these 
cells is accompanied by an inhibition of CDK2/cyclin E and CDK2/Cyclin A activities 
as well as an inhibition of cdc6 phosphorylation. These studies could give new lights for 
a third role of p53 in cell cycle control at the initiation of DNA replication, in addition to 
its blocking role in G1 and G2 phases.
In the second study (Chapter Five) we have shovm that tlie DNA-binding domain 
of p53 is essential for the tempeature-sensitive activity of the protein. To show this, we 
have constructed two p53 mini-genes for human and Xenopus and exchanged the DNA- 
binding domain of human and Xenopus p53 by each other, and their biological^ 
consequences were tested by transactivation assay. In this assay, we have observed that 
the human p53, which is normally active at 37”C, became activated at 32°C by 
transactivating its target genes when the DNA binding domain is substituted with that of 
Xenopus p53. When the DNA-binding domain of Xenopus p53 was substituted by that 
of human p53, this hybrid protein behaves like a human p53, it is able to activate a 
reporter gene at 37”C. Here, we have also demonstrated that the effects of temperature 
dependent change also reflected in the growth suppression ability of p53 by colony 
formation assay. The human p53 mini-gene with the DNA-binding domain oiXenopus
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p53, which behaved like aXenopus p53 by transactivating the reporter gene at 32°C, did 
not suppress colony formation at 37°C, but Xenopus p53 mini-gene with the DNA- 
binding domain of human p53, which activated the reporter gene at 37°C, reduced the 
number of drug-resistant colonies to 0. This means that the effects of temperature 
dependent change probably in the conformation also reflected in the normal biological 
function of p53, ie. in the growth suppression ability. This cause and result phenomenon 
could be mediated by the thermostability of the protein, since the stability of p53 protein 
is an absolute necessity for its physiological function as a tumor suppressor.
Temperature-sensitive p53 mutants that have been identified in many human 
tumors display different phenotypes. The conformation of these mutants, for example, 
human Ala-143 and murine Val-135, appear to be flexible and very temperature- 
sensitive. At the nonpermissive temperature (32°C) these mutants adopt a wild-type 
conformation (PAbl620+/PAb240-) and are able to mediate transcription 
transactivation. At the permissive temperature (37”C), the conformation is switched to a 
mutant state (PAbl620-/PAb240+), and transcriptional activation function is greatly 
reduced or abolished.
It seems that our hybrid proteins at their nonpermissive temperature are altered in 
conformation as well. In fact, our preliminary results by immunological data reported 
here support this phenomenon; the Xenopus p53 forms specific complexes with 
mammalian hsp72/73 heat shock proteins only at a temperature well above the optimal 
growth temperature for Xenopus laevis (37°C). It seems that at 37°C this protein is 
altered in conformation, while at 32°C, it exhibits wild-type behavior. Interestingly, 
when the DNA binding domain of human p53 was substituted by the DNA binding 
domain of Xenopus p53, the behavior of human wild-type p53 is changed from wild-
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type to mutant. Since Xenopus optimal temperature is 28°C, and our transfection 
experiments were performed at 37°C, it is plausible that Xenopus p53 could have an 
altered conformation at this temperature. We showed that at a lower temperature 
(32°C), the ability of Xenopus p53 to bind mammalian hsp72 is considerably reduced 
(data not shown). Therefore, we suggest that the temperature effect reported here might 
be caused by a change in Xenopus p53 conformation, and this effect is directly linked to 
the DNA binding domain of p53 protein.
The biological behavior of these hybrid proteins can be correlated directly with a 
loss or gain of the wild-type conformation at 32°C or 37°C, as it can be detected by the 
loss or gain of reactivity to the monoclonal antibodies specific for human wild-type or 
mutant p53. Such information would directly demonstrate that the loss or gain of 
transcriptional activity of these hybrid p53 proteins are the reflects of the temperature- 
dependent conformational change.
To present in vitro evidence for a rapid temperature dependent change in the 
conformation and tetrameric nature of these hybrid p53 proteins at 32”C and 37°C, the 
DNA binding activity of these hybrids could also be tested. This would demonstrate if 
the effect of temperature is also reflected in the DNA-binding activity of p53 hybrids. 
Because, it is clearly known that activation for DNA binding and stabilization are two 
separate pathways (Hansen et al., 1996). These data would also bring more insights into 
the function of DNA-binding domain of p53.
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